{
  "questions": [
    {
      "answerReady": false,
      "body": "Is CD177 gene associated with paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1527,
          "offsetInEndSection": 1766,
          "text": "ted 402 overlapping genes. As pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic effi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        },
        {
          "offsetInBeginSection": 1558,
          "offsetInEndSection": 2027,
          "text": "ediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic efficacy in the validation set. As indicated by the immune cell infiltration analysis, multiple immune cells may be involved in the development of pediatric sepsis. Additionally, all diagnostic characteristics may correlate with immune cells to varying degrees.CONC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        }
      ],
      "type": "yesno",
      "id": "677eda7e592fa4887300002f",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What is the burden of human trypanosomiases in European hospitals?",
      "documents": [],
      "snippets": [],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-01-20T18:07:11.026Z",
        "round": 9
      },
      "id": "6593de2f06a2ea257c00001e",
      "ideal_answer": [
        "The burden of human trypanosomiases in European hospitals is linked to imported cases from travelers, tourists, migrants, or expatriates who have been in endemic areas. While specific annual case numbers are not provided, Spain has the highest burden of Chagas disease (a form of trypanosomiasis) in Europe. The presence of Trypanosoma species in Europe is typically associated with travel or immigration history or infected animals. Despite progress in reducing human African trypanosomiasis in sub-Saharan Africa, its occurrence in Europe remains a consideration for differential diagnosis among certain patient groups. Additionally, the region faces broader healthcare challenges, such as primary care crises and hospital pressures post-COVID-19, which could impact the management of these diseases.",
        "Human African Trypanosomiasis (HAT), also known as sleeping sickness, poses a significant global threat, affecting approximately 70 million people in 36 African countries. Although not explicitly stated, it can be inferred that the burden of HAT in European hospitals is relatively low or negligible, given that HAT is primarily confined to Africa and there is no mention of significant cases or outbreaks in European regions. However, it\u0027s essential to note that Chagas disease, another form of trypanosomiasis caused by Trypanosoma cruzi, has a substantial presence in Latin America, but its direct burden in European hospitals is not quantified here. Nonetheless, considering the geographical distribution and prevalence of these diseases, it appears that the primary concern regarding trypanosomiases in European hospitals relates to imported cases rather than local transmission, highlighting the importance of vigilance and preparedness among clinicians in diagnosing and managing these conditions in non-endemic settings.",
        "Between 2011-2020, 49 cases of human African trypanosomiasis (HAT) were diagnosed in 16 non-endemic countries across five continents, with a majority caused by Trypanosoma brucei rhodesiense in tourists visiting Africa and T. b. gambiense in African migrants returning from endemic areas. The prevalence of HAT diagnosis in non-endemic countries is rare but significant, emphasizing the need for continued surveillance to support the World Health Organization\u0027s (WHO) elimination goals.",
        "The burden of human trypanosomiases in European hospitals is primarily associated with Chagas disease and human African trypanosomiasis (HAT). Chagas disease, caused by Trypanosoma cruzi, has a prevalence of approximately 4.2% among Latin American migrants in Europe, with significant underdiagnosis and lack of screening programs. The disease can lead to severe complications such as cardiomyopathy and gastrointestinal issues. Human African trypanosomiasis, though less common, poses a risk to travelers and migrants from endemic regions. The increasing incidence of these diseases in Europe is attributed to migration and tourism, highlighting the need for improved awareness, diagnosis, and treatment in healthcare settings.",
        "The burden of human trypanosomiases in European hospitals is relatively low. Between 2011 and 2020, there were 49 cases of Human African Trypanosomiasis (HAT) reported across multiple non-endemic countries, including those in Europe. These cases were primarily among tourists and migrants from Africa, indicating that the disease is mostly imported and not endemic to Europe."
      ],
      "exact_answer": [
        [
          "Spain has the highest burden of Chagas disease in Europe"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What disease can be treated with vorasidenib?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Vorasidenib (VORANIGO®; Servier) is an orally administered, first-in-class, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes being developed for use in IDH-mutant diffuse glioma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39375303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Vorasidenib (VORANIGO®; Servier) is an orally administered, first-in-class, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes being developed for use in IDH-mutant diffuse glioma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39375303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma",
          "beginSection": "title",
          "endSection": "title",
          "document": "37272516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Vorasidenib, an oral dual inhibitor targeting mutant enzymes isocitrate dehydrogenase 1 and 2, is utilized in the management of diffuse low-grade glioma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39215942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma",
          "beginSection": "title",
          "endSection": "title",
          "document": "32071674"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial",
          "beginSection": "title",
          "endSection": "title",
          "document": "36823302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase (IDH) inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 glioma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39737092"
        },
        {
          "offsetInBeginSection": 1853,
          "offsetInEndSection": 2002,
          "text": "ients who received placebo.CONCLUSIONS: In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37272516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tria",
          "beginSection": "title",
          "endSection": "title",
          "document": "34078652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 508,
          "text": "Vorasidenib, an oral dual inhibitor targeting mutant enzymes isocitrate dehydrogenase 1 and 2, is utilized in the management of diffuse low-grade gliomas. Despite limited documentation of its adverse events, we present the case of a 44-year-old male who exhibited trichomegaly and hypertrichosis of body hair, eyebrows, and eyelashes following one month of vorasidenib treatment. Notably, the patient experienced diffuse hair regrowth on the scalp, including in areas affected by severe androgenetic alopecia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39215942"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 611,
          "text": "he recently regulatory-approved vorasidenib, a brain-penetrating oral inhibitor of IDH1/2, has altered the treatment paradigm for recurrent/residual non-enhancing surgically resected CNS WHO grade 2 mIDH gliomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39857783"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-01-22T10:36:34.256Z",
        "round": 9
      },
      "id": "677e8319592fa4887300001e",
      "ideal_answer": [],
      "exact_answer": [
        [
          "IDH-mutant gliomas"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "What is the cause of vestibular migrane?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Vestibular migraine (VM) presents with attacks of spontaneous or positional vertigo lasting seconds to days. Headaches are often absent during acute attacks, but other symptoms of migraine, such as photophobia or auras may be present. Like migraine headaches VM triggers may include stress, sleep deprivation and hormonal changes. During acute attacks there may be central spontaneous or positional nystagmus and, less commonly, unilateral vestibular hypofunction. In the symptom-free interval vestibular testin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "19629427"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 328,
          "text": "Like migraine headaches VM triggers may include stress, sleep deprivation and hormonal change",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "19629427"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-03-04T21:22:27.372Z",
        "round": 12
      },
      "id": "6772bdf0592fa48873000002",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "What biological process is associated with Vitamin K?",
      "documents": [
        "3565295",
        "10806559",
        "38621744",
        "7774512",
        "23631591",
        "15763078",
        "18841274",
        "26413183",
        "32187975",
        "37598356"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Vitamin K is essential for several physiological processes, such as blood coagulation, in which it serves as a cofactor for the conversion of peptide-bound glutamate to γ-carboxyglutamate in vitamin K-dependent proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37337123"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Phylloquinone (vitamin K1) and menaquinones (vitamin K2 family) are essential for post-translational γ-carboxylation of a small number of proteins, including clotting factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36028390"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 235,
          "text": "Vitamin K deficiency, however, primarily affects the blood clotting process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "3565295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Human vitamin K epoxide reductase (hVKOR) is a small integral membrane protein involved in recycling vitamin K. hVKOR produces vitamin K hydroquinone, a crucial cofactor for γ-glutamyl carboxylation of vitamin K dependent proteins, which are necessary for blood coagulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "23631591"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Vitamin K is essential for the formation of at least three proteins involved in blood clotting as well as of other proteins found in plasma, bone, and kidney.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "3565295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "For more than 60 years, vitamin K-dependent proteins have been known to play an important role in regulating blood coagulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "10806559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Vitamin K is a fat-soluble vitamin crucial to the production of many proteins involved with the coagulation process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "7774512"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 515,
          "text": "One of the factors contributing to the development of oxidative stress that has an important effect on the nervous system is vitamin K, which is involved in redox processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38621744"
        },
        {
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1542,
          "text": "Anticoagulant drugs block vitamin K recycling and thereby the availability of reduced vitamin K. Under extreme blockade, vitamin K can bypass the inhibition of Gla synthesis in the liver but not in the bone and the vessel wall.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "18841274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Vitamin K is a cofactor for gamma-glutamyl carboxylase, an enzyme that is important for blood coagulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "15763078"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 134,
          "text": "Vitamin K is known to be important for blood coagulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "26413183"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345,
          "text": "Vitamin K is traditionally connected with blood coagulation, since it is needed for the posttranslational modification of 7 proteins involved in this cascade. However, it is also involved in the maturation of another 11 or 12 proteins that play different roles, encompassing in particular the modulation of the calcification of connective tissue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34472618"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Vitamin K is essential for several physiological processes, such as blood coagulation, in which it serves as a cofactor for the conversion of peptide-bound glutamate to γ-carboxyglutamate in vitamin K-dependent protein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37337123"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Vitamin K (VK) plays many important functions in the body. The most important of them include the contribution in calcium homeostasis and anticoagulatio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35057443"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 450,
          "text": "Vitamin K (VK) is a key nutrient for several biological processes (e.g., blood clotting and bone metabolism). To fulfill VK nutritional requirements, VK action as an activator of pregnane X receptor (Pxr) signaling pathway, and as a co-factor of γ-glutamyl carboxylase enzyme, should be considered. In this regard, VK recycling through vitamin K epoxide reductases (Vkors) is essential and should be better understood. Here, the expression patterns o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32429051"
        },
        {
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1418,
          "text": " to a role of vitamin K in bone metabolism. Vitamin K mediates the \u003c--carboxylation of glutamyl residues on several bone proteins, notably osteocalcin. Epidemiological studies and results from first intervention trials are consistently suggesting that vitamin K may improve bone health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "10389027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Vitamin K is essential for the synthesis of few coagulation factor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32187975"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "Vitamin K2 activates vitamin K-dependent proteins that support many biological functions, such as bone mineralization, the inhibition of vascular stiffness, the improvement of endothelial function, the maintenance of strong teeth, brain development, joint health, and optimal body weigh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35053702"
        },
        {
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1459,
          "text": "d with individual variability of warfarin. The results suggest that an increase in vitamin K concentration can decrease anticoagulation, and gut microbiota may influence warfarin ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37598356"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-02-06T00:06:14.008Z",
        "round": 10
      },
      "id": "6772c765592fa48873000009",
      "ideal_answer": [
        "Vitamin K is associated with several biological processes including blood coagulation, where it acts as a cofactor for the modification of coagulation factors. It is also important for bone metabolism and the inhibition of arterial calcification. Moreover, Vitamin K plays a role in sphingolipid metabolism, which is important for brain function, and has anti-inflammatory effects, contributing to the protection against oxidative stress and potentially supporting cognitive functions.",
        "Vitamin K is primarily associated with the biological processes of blood coagulation and bone metabolism. Additionally, it plays roles in the metabolism of sphingolipids, which are important for brain cell function, and has been linked to anti-inflammatory activity, protection against oxidative stress, and cognition.",
        "Vitamin K plays a vital role in several biological processes, most notably blood coagulation. It serves as a cofactor for the carboxylation of Gla proteins, which is essential for activating proteins involved in blood clotting. Additionally, Vitamin K is involved in bone health by aiding in bone metabolism and helps inhibit arterial calcification, thereby maintaining vascular health.",
        "Vitamin K is crucial for several biological processes. It mainly functions as a cofactor for the gamma-carboxylation of glutamate residues in vitamin K-dependent proteins, which is essential for blood coagulation. Additionally, it plays significant roles in bone metabolism, preventing vascular calcification, and even modulating cell proliferation.",
        "Vitamin K is primarily associated with the biological process of blood coagulation, as it is essential for the posttranslational modification of proteins involved in this process. Specifically, it acts as a cofactor for the conversion of glutamate residues to γ-carboxyglutamate in vitamin K-dependent proteins, which is crucial for their activity in hemostasis. Additionally, vitamin K plays a significant role in the maturation of proteins that regulate calcium metabolism, influencing bone health and vascular calcification. This dual role highlights its importance not only in coagulation but also in maintaining bone density and preventing cardiovascular diseases.",
        "Vitamin K is essential for a variety of biological processes. It plays a critical role in blood coagulation by acting as a cofactor for the gamma-carboxylation of glutamate residues on clotting factors. It is also involved in bone metabolism, prevention of vascular calcification, regulation of inflammation, and modulation of cell proliferation. Additionally, vitamin K influences other physiological functions, including possible roles in the pancreas and central nervous system.",
        "Vitamin K plays a crucial role in the carboxylation of certain proteins involved in blood clotting, including prothrombin and factors VII, IX, and X. It serves as a cofactor for the vitamin K-dependent gamma-glutamyl carboxylase enzyme, facilitating the conversion of glutamate residues to gamma-carboxyglutamate, thereby enabling the attachment of calcium ions and subsequent protein-protein interactions necessary for proper coagulation function. Additionally, it appears to play a role in the metabolism of plasmalogens, specifically through the activity of plasmalogenase enzymes present in neural tissues such as neuronal perikarya, astroglia, and oligodendroglia. However, no direct association between Vitamin K and the described processes involving ethanol distribution, DNA degradation, RNA polymerase activity, or the pharmacological properties of kutkin and its derivatives is evident from the provided abstracts.",
        "Vitamin K plays a crucial role in the gamma-carboxylation of glutamate residues in proteins involved in blood clotting, such as prothrombin and factors VII, IX, and X. This process requires the presence of calcium ions and results in the formation of gamma-carboxyglutamic acid, which facilitates the binding of these clotting factors to phospholipid surfaces during coagulation. Additionally, vitamin K-dependent carboxylase also modifies certain bacterial proteins, including those involved in peptidoglycan synthesis, suggesting a broader functional significance beyond mammalian blood coagulation.",
        "Vitamin K plays a crucial role in the post-translational modification of proteins involved in blood coagulation, specifically in the gamma-carboxylation of glutamate residues to form gamma-carboxyglutamate, facilitating calcium binding and subsequent clot formation. Additionally, vitamin K-dependent carboxylases also appear to play a role in the metabolism of certain amino acids, including the breakdown of delta-aminolevulinate, a precursor in the biosynthesis of porphyrins.",
        "Vitamin K is mainly associated with the regulation of blood coagulation, as it is required for the carboxylation of certain proteins involved in this process. It also contributes to bone metabolism and helps in preventing vascular calcification, making it an essential nutrient for several physiological processes.",
        "Vitamin K is primarily involved in several biological processes, most notably blood coagulation where it acts as a cofactor for specific clotting factors. Additionally, vitamin K is crucial for bone metabolism, the prevention of vascular calcification, gamma-carboxylation of glutamate residues, modulation of cell proliferation, and inhibition of arterial calcification.",
        "Vitamin K is crucial for several biological processes, primarily blood coagulation, where it aids in the activation of clotting factors by facilitating post-translational modifications. It also plays a significant role in bone metabolism, contributing to mineralization and density, which helps reduce fracture risk. Additionally, Vitamin K prevents vascular calcification and arterial stiffness, supporting cardiovascular health. Emerging research suggests its involvement in cell proliferation regulation and other physiological functions, such as endothelial health and brain development. These roles underscore Vitamin K\u0027s importance beyond blood clotting, encompassing bone health and cardiovascular well-being.",
        "Vitamin K is associated with blood coagulation, where it is a crucial cofactor in the gamma-carboxylation of glutamate residues on clotting proteins. It also plays important roles in bone metabolism and the prevention of vascular calcification. This vitamin supports the biological functions of proteins essential for these processes.",
        "Vitamin K is essential for several biological processes including blood coagulation, bone metabolism, prevention of vascular calcification, and modulation of cell proliferation. Its role in blood coagulation is well established as it aids in the activation of proteins necessary for clotting. Additionally, Vitamin K helps maintain bone health and plays a part in preventing the calcification of blood vessels.",
        "Vitamin K is primarily associated with the biological process of blood coagulation. It acts as a cofactor for the carboxylation of specific glutamate residues in proteins, converting them into gamma-carboxyglutamic acid (Gla), which is essential for the activation of several coagulation factors. This posttranslational modification is crucial for the proper functioning of the coagulation cascade, preventing excessive bleeding. Additionally, Vitamin K is involved in bone mineralization and the regulation of vascular calcification, playing a role in maintaining bone health and preventing arterial calcification. It also has roles in cellular processes such as apoptosis and signal transduction. The vitamin K cycle, involving enzymes like vitamin K epoxide reductase, is vital for recycling vitamin K to sustain these processes.",
        "Vitamin K is primarily associated with the biological processes of blood coagulation and bone metabolism. It is crucial in enabling proteins essential for blood clotting and maintaining bone health. Additionally, Vitamin K is involved in the prevention of vascular calcification and modulation of cell proliferation.",
        "Vitamin K is associated with numerous biological processes including blood coagulation, bone metabolism, prevention of vascular calcification, endothelial function, dental health, brain development, joint health, optimal body weight, anti-inflammatory activities, protection against oxidative stress, and possibly influencing cognitive functions, as well as playing a role in cell proliferation and the prevention of ferroptosis.",
        "Vitamin K is associated with numerous biological processes including blood coagulation, bone metabolism, prevention of vascular calcification, improvement of endothelial function, maintenance of strong teeth, brain development, joint health, optimal body weight, anti-inflammatory activity, protection against oxidative stress, and a potential role in cognition, showcasing its multifaceted importance in overall health.",
        "Vitamin K is associated with several biological processes including blood coagulation, where it acts as a cofactor for the modification of coagulation factors, bone metabolism, the inhibition of vascular calcification, reduction of inflammation, protection against oxidative stress, modulation of cell proliferation, regulation of blood pressure, activation of the pregnane X receptor (PXR) signaling pathway, functioning as a co-factor for the γ-glutamyl carboxylase enzyme, and recycling through vitamin K epoxide reductases (VKORs).",
        "Vitamin K is primarily associated with the biological process of blood coagulation. It is essential for the synthesis of several coagulation factors, which are proteins necessary for blood clotting. This process is crucial to prevent excessive bleeding when injuries occur. Vitamin K also plays a significant role in bone mineralization and the regulation of calcium in the body, contributing to bone health and preventing vascular calcification. Additionally, vitamin K-dependent proteins are involved in various physiological functions, including maintaining cardiovascular health and supporting the immune system. Deficiency in vitamin K can lead to bleeding disorders, particularly in newborns, and may contribute to bone and cardiovascular diseases."
      ],
      "exact_answer": [
        [
          "Blood coagulation",
          "Bone metabolism",
          "Bone Health Maintenance",
          "calcium metabolism",
          "Inhibition of arterial calcification",
          "Nervous System Function",
          "anti-inflammatory activity",
          "protection against oxidative stress"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What is the impact of intimate partner violence on maternal mortality?",
      "documents": [
        "10576188"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1459,
          "text": "In three of the five suicide deaths, the obstetric provider was aware of depression.CONCLUSION: Domestic violence and drug and alcohol abuse were common in this series of injury-related maternal deaths.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "10576188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "INTRODUCTION: Intimate partner violence during pregnancy can contribute to maternal mortality and morbidity by limiting women\u0027s ability to receive maternal health services including antenatal care and skilled delivery car",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32497059"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "BACKGROUND: Intimate partner violence is a prevalent public health issue associated with all-cause maternal mortality. This study investigated the relationship between intimate partner violence, severe acute maternal morbidity in the intensive care unit (ICU), and neon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31657489"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 423,
          "text": "BACKGROUND: The high prevalence rates of violence of the intimate partner affects the maternal health of the woman that sometimes ends in maternal mortality as well as the possibility of an adverse effect on the newborn. The purpose of this study was to assess the prevalence and determinants of intimate physical and sexual intimate partner violence (IPV) on mothers and examine the association between IPV and pregnancy c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33679185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "BACKGROUND: Intimate partner violence is a prevalent public health issue associated with all-cause maternal mortality. This study investigated the relationship between intimate partner violence, severe acute maternal morbidity in the intensive care unit (ICU), and neona",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31657489"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 418,
          "text": "OBJECTIVE: Mounting evidence supports the view that intimate partner violence (IPV) is an important cause of maternal mortality. Some, but not all, prior studies suggest that IPV is associated with increased risks of maternal medical conditions such as hypertensive disorders of pregnancy which are leading causes of maternal mortality worldwide. We assessed the relation between IPV and risk of preeclampsia among Per",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "17600610"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-06T11:07:43.298Z",
        "round": 10
      },
      "id": "6777be0b592fa48873000014",
      "ideal_answer": [
        "Intimate partner violence (IPV) significantly impacts maternal mortality by contributing to pregnancy-related complications such as preeclampsia, increased risks of miscarriages, stillbirths, and decreased utilization of essential maternal health services like antenatal care. It can also lead to pregnancy-associated suicides and homicides.",
        "Intimate partner violence (IPV) significantly impacts maternal mortality by increasing the risk of pregnancy-related complications such as preeclampsia and severe acute maternal morbidity. Studies indicate that exposure to IPV during pregnancy elevates the risk of preeclampsia by 2.4-fold, with emotional abuse alone raising this risk by 3.2 times. Additionally, IPV is associated with higher perinatal mortality rates, as evidenced by a 9.3% mortality rate in cases compared to 1.8% in controls. Furthermore, IPV contributes to maternal deaths, including pregnancy-associated homicides and suicides, which account for a substantial proportion of violent deaths during pregnancy. Women experiencing IPV also tend to have lower utilization of essential maternal health services, worsening maternal and fetal outcomes. These findings underscore the critical importance of confidential screening for IPV and timely referral to support services to address its adverse effects on maternal and perinatal health.",
        "Intimate partner violence (IPV) significantly contributes to maternal mortality by increasing the risk of pregnancy-related complications, such as preeclampsia, hypertensive disorders, and poor utilization of maternal health services. It is associated with adverse perinatal outcomes, including miscarriages, stillbirths, and induced abortions, and exacerbates existing health issues like stress, smoking, and substance use, ultimately leading to higher maternal mortality rates. Addressing IPV through early detection and support is crucial to mitigating these risks.",
        "Intimate partner violence (IPV) significantly impacts maternal mortality by increasing the risk of severe health complications and adverse pregnancy outcomes. Studies indicate that IPV is associated with a 1.9-fold increased risk of preeclampsia, higher perinatal mortality rates (9.3% vs. 1.8%), and contributes to maternal deaths. Emotional abuse alone elevates preeclampsia risk by 3.2 times. IPV also leads to fetal deaths at a rate of about 16 per 1000 pregnancies and is linked to pregnancy-associated suicides (54.3%) and homicides (45.3%). Additionally, it deters antenatal care utilization, exacerbating risks like miscarriages, stillbirths, and preterm births. Thus, addressing IPV is crucial for improving maternal and fetal health outcomes.",
        "Intimate partner violence (IPV) significantly contributes to maternal mortality by increasing the risk of pregnancy-related complications, poor maternal health service utilization, and being a primary cause of homicide and suicide during pregnancy. It leads to adverse perinatal outcomes such as preeclampsia, preterm births, low birth weight infants, and elevated rates of miscarriages, stillbirths, and induced abortions. Addressing IPV through early detection and intervention is crucial to prevent these tragic outcomes."
      ]
    },
    {
      "answerReady": true,
      "body": "Which are the most common psychiatric events associated with the consumption of cannabis?",
      "documents": [
        "29480902"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1236,
          "offsetInEndSection": 1646,
          "text": "ally assaulted in the course of their lives. In addition, women are at greater risk of cannabis dependence (OR \u003d 3.87; p \u003c .05) for lower cannabis consumption (grams smoked per week) (OR \u003d 0.96; p \u003c .05).DISCUSSION AND CONCLUSIONS: French women heavy cannabis users are particularly at risk of PTSD and are more likely than men to be dependent despite consuming fewer.SCIENTIFIC SIGNIFICANCE: Further studies a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38092565"
        },
        {
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1385,
          "text": "he participants, p \u003e 0.05.Conclusion: Due to the higher frequency of anxiety and depression disorders in cannabis users in this study compared to the general population, cannabis use is likely to be a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36045802"
        },
        {
          "offsetInBeginSection": 2292,
          "offsetInEndSection": 2510,
          "text": "In conclusion, cannabis-induced anxiety or panic disorders should be considered in patients with no prior psychiatric history presenting with anxiety-like attacks following a period of cannabis dependence or current us",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36843769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Cannabis use is consistently associated with both increased incidence of frank psychotic disorders and acute exacerbations of psychotic symptoms in healthy individuals and people with psychosis spectrum disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37882050"
        },
        {
          "offsetInBeginSection": 225,
          "offsetInEndSection": 588,
          "text": "Marijuana use in this age group is strongly linked to: cannabis dependence and other substance use disorders; the initiation and maintenance of tobacco smoking; an increased presence of mental illness, including depression, anxiety and psychosis; impaired neurological development and cognitive decline; and diminished school performance and lifetime achievement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "29480902"
        },
        {
          "offsetInBeginSection": 506,
          "offsetInEndSection": 1013,
          "text": " cannabis use has been identified. Cannabis can frequently have negative effects in its users, which may be amplified by certain demographic and/or psychosocial factors. Acute adverse effects include hyperemesis syndrome, impaired coordination and performance, anxiety, suicidal ideations/tendencies, and psychotic symptoms. Acute cannabis consumption is also associated with an increased risk of motor vehicle crashes, especially fatal collisions. Evidence indicates that frequent and prolonged use of cann",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24001294"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 1006,
          "text": " cannabidiol has been observed for years, which leads to more serious complications. Evidence indicates that both acute and chronic consumptions of cannabis can be detrimental to both mental and physical health. Effects of cannabis use include mood disorders, exacerbation of psychotic disorders in vulnerable people, cannabis use disorders, withdrawal syndrome, neurocognitive impairments, cardiovascular and respiratory and other diseases. Synthetic cannabinoid has rapidly spread for the last few yea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32877036"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-01-26T15:30:48.755Z",
        "round": 6
      },
      "id": "63ac44c2c6c7d4d31b000011",
      "ideal_answer": [
        "The most common psychiatric events associated with the consumption of cannabis include anxiety disorders, depressive disorders, psychotic disorders, psychosis, paranoia, cognitive impairment, mood disorders, exacerbation of existing psychiatric disorders, withdrawal syndrome, and increased risk of developing chronic psychosis. These events can range from acute adverse mental effects to long-term negative psychiatric outcomes, especially in vulnerable individuals. Cannabis use has been consistently linked to a higher prevalence of comorbid psychiatric conditions, learning and memory impairments, and a range of mental health issues that can have significant impacts on an individual\u0027s well-being and quality of life.",
        "The most common psychiatric events associated with the consumption of cannabis include anxiety disorders, depressive disorders, psychosis, and exacerbation of psychotic disorders -- particularly in vulnerable individuals. Cannabis use can lead to acute adverse effects such as anxiety, paranoia, and psychosis. Chronic use of cannabis may result in mood disorders, an increase in depressive or manic episodes, and the development of cannabis use disorders. Additionally, there is an association between cannabis use and the onset of first mania at a younger age, as well as an increase in impulsivity and sensation-seeking traits. Cannabis disorders are classified under the DSM-IV and ICD-10 criteria and include intoxication, abuse, dependence, as well as cannabis-induced psychotic and anxiety disorders.",
        "The most common psychiatric events associated with the consumption of cannabis are anxiety, depression, and psychotic disorders, which include a range of symptoms such as paranoia, exacerbation of manic episodes in those with affective psychoses, particularly bipolar disorder, and an increased likelihood of developing schizophrenia in vulnerable populations. Cannabis use can also lead to cannabis use disorders, characterized by cannabis intoxication, abuse, and dependence as defined by DSM-IV and ICD-10 criteria. Acute adverse effects include anxiety states, cognitive impairments, tachycardia, and orthostatic hypotension, while chronic effects may involve mood disorders, neurocognitive impairments, and exacerbation of psychotic disorders. Impulsivity and sensation-seeking traits have been observed in recreational cannabis users, which are not only common in chronic drug abusers but also present in those who consume cannabis recreationally.",
        "The most common psychiatric events associated with the consumption of cannabis include anxiety disorders, depressive disorders, and psychotic disorders. These conditions can range from acute reactions such as anxiety or paranoia during intoxication to more chronic effects like depression and exacerbation of pre-existing psychotic symptoms in vulnerable individuals. Cannabis use has also been linked to an increased risk of developing schizophrenia and other psychoses, particularly among those with a genetic predisposition or existing mental health conditions. Additionally, cannabis withdrawal can cause irritability, anxiety, sleep disturbances, and in some cases, more severe psychiatric symptoms.",
        "The most common psychiatric events associated with the consumption of cannabis include an increased risk for the development and exacerbation of psychotic disorders, such as schizophrenia, particularly in individuals with a pre-existing genetic predisposition. Cannabis use is also linked to first-episode psychosis, characterized by severe symptoms that can sometimes be managed with antipsychotics and mood stabilizers. It may lead to poor treatment adherence and an increased risk of relapse in individuals with psychotic disorders. Moreover, cannabis use can be involved in the onset of comorbid mental illnesses at an earlier age. While not all experiencing psychosis from cannabis will have a negative outcome on their overall mental health trajectory, these symptoms are cause for clinical concern and require careful management to prevent progression to more severe mental health conditions.",
        "The most common psychiatric events associated with cannabis consumption include anxiety disorders, depressive disorders, psychotic disorders such as schizophrenia, and substance use disorders. Acute adverse effects can consist of anxiety, paranoia, and psychosis, which can manifest as an acute anxiety state or even paranoid episodes. Cannabis use is also linked to exacerbation of psychotic disorders in vulnerable individuals and can affect mood, leading to disorders like depression. Additionally, there is a significant association between cannabis use and the development or worsening of psychiatric conditions such as attention deficit-hyperactivity disorder and conduct disorders, especially in adolescents and young adults. Chronic effects of cannabis can lead to cannabis use disorders, withdrawal syndrome, and neurocognitive impairments.",
        "The most common psychiatric events associated with cannabis consumption include anxiety disorders, depressive disorders, psychotic disorders, and cannabis use disorders. Specifically, cannabis use has been linked to the exacerbation of psychotic disorders in vulnerable individuals, mood disorders, and an increased risk of psychiatric disorders such as schizophrenia, depression, anxiety, and substance use disorder. Acute adverse mental effects can mimic psychiatric disorders like schizophrenia and bipolar disorder. Additionally, cannabis use is associated with a withdrawal syndrome upon cessation in dependent individuals. Other psychiatric effects include paranoia, psychosis, and cannabis-induced anxiety, which has been observed in emergency department patients. There is also evidence suggesting a cross-sectional association between recreational cannabis use and depression, anxiety, and suicide.",
        "The most common psychiatric events associated with cannabis consumption include anxiety, depression, psychosis, and paranoia. Additionally, cannabis use can be linked to mania and hypomania, as well as exacerbation of existing psychiatric conditions.",
        "The most common psychiatric events associated with cannabis consumption include anxiety disorders, depression, psychotic syndromes, cognitive impairment, and addictive behavior. Studies have shown that cannabis use is linked to an increased risk of progression to schizophrenia, particularly in individuals with a genetic loading. Additionally, research has found associations between cannabis use and mood disorders, including mania and bipolar disorder. Other psychiatric events reported include obsessive-compulsive behavior, interpersonal sensitivity, depression, anxiety, phobic anxiety, and paranoid ideation, particularly among frequent users. Furthermore, studies have also highlighted the potential for cardiovascular adverse events, such as myocardial infarction and strokes, suicidal ideas and attempts, worsening of epilepsy, and sedative disorders, all of which are concerning and warrant further investigation."
      ],
      "exact_answer": [
        [
          "panic attack psychotic states dependence abuse cognitive disorders amotival syndrome anxiety disorder suicidal idea and attempt Hallucinogenic effects Stimulant effects Aggressive behavior Addictive behaviors Bipolar Disorder"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What are the most severe adverse effects of the birth control pill?",
      "documents": [
        "21865146"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 536,
          "text": "Authors present a young woman who developed acute myocardial infarction in association with several unconsidered risk factors including the use of contraceptive pills.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "21865146"
        },
        {
          "offsetInBeginSection": 406,
          "offsetInEndSection": 587,
          "text": "SUMMARY: Background Combined oral contraceptives (COCs) are associated with an increased risk of venous thromboembolism (VTE), which is shown to be more pronounced in women with her",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27121914"
        },
        {
          "offsetInBeginSection": 1405,
          "offsetInEndSection": 1608,
          "text": "ree cohort studies. In COC-users, mild and severe thrombophilia increased the risk of VTE almost 6-fold (rate ratio [RR], 5.89; 95% confidence interval [CI], 4.21-8.23) and 7-fold (RR, 7.15; 95% CI, 2.93",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27121914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 504,
          "text": "Background Varicose veins are a rare side effect of birth control pills, linked to hormonal changes that may weaken vein walls and valves, impair blood flow, and increase venous pressure. Factors like sedentary behavior, prolonged standing or sitting, and genetic predisposition may worsen the risk. Additionally, contraceptive hormones can promote fluid retention and venous stasis, further contributing to vein dilation. The direct link between birth control pills and varicose veins remains unclear, a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39901997"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-06T11:09:44.018Z",
        "round": 10
      },
      "id": "6777b9c5592fa4887300000f",
      "ideal_answer": [
        "The most severe adverse effects of the birth control pill can include serious cardiovascular issues such as blood clots leading to deep vein thrombosis, pulmonary embolism, stroke, and heart attack. These risks are generally higher among women who smoke, are over the age of 35, or have other predisposing factors.",
        "Studies have shown that while oral contraceptive pills (OCPs) are generally safe, they can cause several adverse effects that may alter the quality of life for women who use them. The most severe side effects include an increased risk of four cardiovascular diseases: hypertension, venous thromboembolism, stroke, and myocardial infarction. Breakthrough bleeding is also a significant concern, with 69.6% of participants experiencing at least one side effect, including mood swings, weight gain or increase appetite, decreased libido, and nausea. Additionally, OCPs have been linked to an elevated risk of venous thrombotic events (VTE), particularly during the first year of use.",
        "The most severe adverse effects of birth control pills include an increased risk of venous thromboembolism (VTE), particularly in women with hereditary thrombophilia. Other serious side effects, though rare, can include deep vein thrombosis, severe migraines with aura, and hyperkalemia. While the risk of stroke is a concern, especially in women with migraines with aura, modern low-dose contraceptives have shown a reduced risk compared to older formulations. Additionally, some formulations may cause depression and mood alterations. It\u0027s important for women with specific risk factors, such as thrombophilia, to consult healthcare providers before using oral contraceptives."
      ],
      "exact_answer": [
        [
          "venous thromboembolism",
          "stroke",
          "blood clots",
          "deep vein thrombosis",
          "Pulmonary embolism"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What are the treatments for Adhesive Capsulitis or \"Frozen Sholder\"",
      "documents": [
        "17054278",
        "37398735",
        "24284277",
        "23557890",
        "25271097",
        "8186599",
        "31475043",
        "31514191"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 600,
          "text": "ackground: Although several studies have reported the effectiveness of acupuncture treatment for adhesive capsulitis (AC), research on pharmacopuncture therapy for AC remains limited. We compared the effectiveness and safety of pharmacopuncture and physiotherapy for AC.Methods: This pragmatic, randomized, controlled, parallel-group pilot study enrolled patients with limitations of shoulder movement and a numeric rating scale (NRS) score for shoulder pain ≥5 randomized (1:1) to the pharmacopuncture therapy (PPT) and physiotherapy (PT) groups. Treatment sessions were administered twice weekly f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39224580"
        },
        {
          "offsetInBeginSection": 681,
          "offsetInEndSection": 1221,
          "text": "fter excluding nine patients for other concomitant pathologies (five for calcific tendinopathy and four for rotator cuff injury), 36 patients were randomized into two groups: one group was treated with glenohumeral hydrodistension, the other with glenohumeral hydrodistension combined with bursal injection. Assessments were conducted at baseline and then 2, 4, and 6 months after treatment, focusing on changes in pain levels, functional scores, and range of motion in all planes. Each group followed a home-based rehabilitation protocol.R",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39264535"
        },
        {
          "offsetInBeginSection": 2028,
          "offsetInEndSection": 2155,
          "text": "Conclusions Our findings suggest that IA PRP injections provide better long-term results than IA CS injections for managing FS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37398735"
        },
        {
          "offsetInBeginSection": 2444,
          "offsetInEndSection": 2846,
          "text": "There were minimal adverse effects reported.AUTHORS\u0027 CONCLUSIONS: Available data from two placebo-controlled trials and one no-treatment controlled trial provides \"Silver\" level evidence (www.cochranemsk.org) that oral steroids provides significant short-term benefits in pain, range of movement of the shoulder and function in adhesive capsulitis but the effect may not be maintained beyond six weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "17054278"
        },
        {
          "offsetInBeginSection": 1505,
          "offsetInEndSection": 1863,
          "text": "There was a significant difference in the mean Constant score between the normal-weight and overweight groups at 8 weeks.CONCLUSION: Active range of motion exercise after an intra-articular injection of corticosteroid and lidocaine improved pain and functional outcome at 8 weeks in normal-weight (BMI \u003c 25 kg/m(2)) patients with primary adhesive capsulitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "23557890"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 38,
          "text": "Oral steroids for adhesive capsulitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "17054278"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 743,
          "text": "The PTI were given grades of recommendation that ranged from A to C.CONCLUSIONS: Therapeutic exercises and mobilization are strongly recommended for reducing pain, improving range of motion (ROM) and function in patients with stages 2 and 3 of frozen shoulder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24284277"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "BACKGROUND: Adhesive capsulitis (also termed frozen shoulder) is a common condition characterised by spontaneous onset of pain, progressive restriction of movement of the shoulder and disability that restricts activities of daily living, work and leisure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "25271097"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 735,
          "text": "The authors investigate the mechanism of action and the long-term clinical result of distention arthrography for the treatment of patients with frozen shoulder.PATIENTS AND METHODS: Sixteen patients with adhesive capsulitis of the shoulder were treated with therapeutic capsular distention by using intra-articular injection of a 30-mL mixture of lidocaine, corticosteroid, and contrast media immediately following diagnostic arthrography.RESULTS: Capsular disruption was demonstrated in all cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "8186599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Electrotherapy modalities for adhesive capsulitis (frozen shoulder).",
          "beginSection": "title",
          "endSection": "title",
          "document": "25271097"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 870,
          "text": "The goal of any treatment is to reduce pain and restore shoulder movement.OBJECTIVE: Objective of the present study is to evaluate the efficacy of gleno-humeral hydrodistension associated with physical therapy in patients with diagnosed adhesive capsulitis comparing the outcomes in term of pain and range of motion in patients with a phase 1 and a phase 2 disease.METHOD: Between January 2022 and April 2023, We evaluated 87 patients with adhesive capsulitis, 47 were excluded for others concomitant pathologies, finally 40 patients were enrolled for the study, of whom 23 had capsulitis in stage 1 and 17 in stage ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38844748"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 604,
          "text": "Treatment modalities for FS include medication, local steroid injection, physiotherapy, hydrodistension, manipulation under anesthesia, arthroscopic capsular release, and open capsular release. Conservative management leads to improvement in most case",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31475043"
        },
        {
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1261,
          "text": "The Shoulder Pain and Disability Index showed improvement in both pain and disability score in group B -compared to group A, and improvement was significant at 6 weeks and 3 months.CONCLUSION: The results demonstrate the advantages of physiotherapy plus intra-articular steroid injection in idiopathic frozen shoulder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31514191"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Manual therapy and exercise for adhesive capsulitis (frozen shoulder)",
          "beginSection": "title",
          "endSection": "title",
          "document": "25157702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "BACKGROUND: Adhesive capsulitis (also termed frozen shoulder) is commonly treated by manual therapy and exercise, usually delivered together as components of a physical therapy intervention. This review is one of a series of reviews that form an update of the Cochrane review, \u0027Physiotherapy interventions for sh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "25157702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Chiropractic treatment of frozen shoulder syndrome (adhesive capsulitis) utilizing mechanical force, manually assisted short lever adjusting procedures",
          "beginSection": "title",
          "endSection": "title",
          "document": "7790781"
        },
        {
          "offsetInBeginSection": 1016,
          "offsetInEndSection": 1520,
          "text": "exercises, and corticosteroid injections combined with physical therapy modalities that enhance pain management, range of motion, and functional capacity is highly advisable for the treatment of adhesive capsulitis, commonly known as \"frozen joints\". Furthermore, the addition of interventions both impacting and analyzing chronic hypoxia, low-grade inflammation, and sedentary life is proposed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37760901"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 468,
          "text": "BACKGROUND: Adhesive capsulitis (frozen shoulder) is characterised by pain and loss of range of motion of the glenohumeral joint. It can be present as primary (idiopathic) or secondary to surgery, trauma or other conditions that restrict the use of the shoulder joint. Various treatment options have been adopted including physiotherapy, manipulation under anaesthetic, hydrodilatation and arthroscopic or open capsular release but the optimal form of management remai",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34804214"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 564,
          "text": "mited. We compared the effectiveness and safety of pharmacopuncture and physiotherapy for AC.Methods: This pragmatic, randomized, controlled, parallel-group pilot study enrolled patients with limitations of shoulder movement and a numeric rating scale (NRS) score for shoulder pain ≥5 randomized (1:1) to the pharmacopuncture therapy (PPT) and physiotherapy (PT) groups. Treatment sessi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39224580"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-06T00:16:42.774Z",
        "round": 10
      },
      "id": "6772c6ae592fa48873000008",
      "ideal_answer": [
        "The treatment for Adhesive Capsulitis, or \u0027Frozen Shoulder,\u0027 includes a variety of conservative and surgical options. First-line treatments often involve non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections to manage pain and inflammation. Physical therapy is essential for improving range of motion and shoulder function. Hydrodilatation and capsular release are procedural options that can enhance mobility. Additionally, ultrasound-assisted hydrodistention, suprascapular nerve block, extracorporeal shockwave therapy, and manipulation are effective alternatives for managing symptoms and improving outcomes.",
        "The treatments for adhesive capsulitis, or frozen shoulder, include a combination of conservative and, if necessary, surgical approaches. Conservative treatments are typically first-line and include physical therapy, exercises, manual therapy, and corticosteroid injections to enhance range of motion and reduce pain. Hydrodilatation (or capsular distension), which involves injecting fluid into the joint capsule to stretch it, is also a common treatment. Additionally, suprascapular nerve block and ultrasound-assisted hydrodistention are utilized to relieve pain and improve functionality. In some cases, more invasive options like manipulation under anesthesia or capsulotomy might be considered if conservative measures are ineffective.",
        "Adhesive capsulitis, commonly known as frozen shoulder, can be managed with a range of treatments. These include physical therapy and exercises, which help in improving mobility. Medical treatments often feature corticosteroid injections and NSAIDs to reduce inflammation. More invasive options include hydrodilatation, manipulation under anesthesia, and capsular release or capsulotomy when necessary. Other therapies like suprascapular nerve blocks, extracorporeal shockwave therapy, and acupuncture can also be beneficial, especially in chronic cases or when conventional treatments are inadequate.",
        "Adhesive capsulitis, or frozen shoulder, can be treated with several effective approaches. Common treatments include physical therapy and the use of non-steroidal anti-inflammatory drugs (NSAIDs). Hydrodilatation and corticosteroid injections are often used to reduce pain and increase shoulder mobility. Additionally, exercise and manual therapy from physical rehabilitation are integral. Techniques such as ultrasound-assisted hydrodistention, extracorporeal shockwave therapy, and pharmacopuncture also offer promising results in managing the condition. Suprascapular nerve block can be utilized for pain relief.",
        "The treatments for Adhesive Capsulitis, also known as \u0027Frozen Shoulder\u0027, include physical therapy and exercises, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, ultrasound-assisted hydrodistention, hydrodilatation, suprascapular nerve block, extracorporeal shockwave therapy, acupuncture, pharmacopuncture, and oral steroids. These treatments aim to decrease pain and improve the range of motion and shoulder function, with some therapies like corticosteroid injections providing short-term relief.",
        "Adhesive Capsulitis, or \u0027Frozen Shoulder\u0027, can be treated using a variety of methods. Common treatments include physical therapy and non-steroidal anti-inflammatory drugs (NSAIDs) to improve movement and reduce pain. Corticosteroid injections and hydrodilatation help decrease inflammation and increase joint space. Ultrasound-assisted hydrodistention and suprascapular nerve block are also effective in managing symptoms. Additionally, manual therapy, acupuncture, and electrotherapy provide alternative or complementary treatment options.",
        "Adhesive capsulitis, also known as frozen shoulder, is a challenging condition to treat clinically. Common first-line treatment options include suprascapular nerve block, intra-articular corticosteroid injection, hydrodilatation, and physical therapy. Combining these treatment options has been shown to improve patient outcomes, such as pain, range of motion, and shoulder function. Additionally, ultrasound-assisted hydrodistention of the glenohumeral joint combined with targeted exercise has been successful in improving pain relief, reducing disability, and increasing range of motion in patients with stage 1 and 2 adhesive capsulitis. Other treatments, such as gleno-humeral hydrodistension associated with physical therapy, have also been effective in improving pain and range of motion. Furthermore, homoeopathic remedies and angiotensin receptor blockers have also been explored as potential treatments for adhesive capsulitis.",
        "The treatment of Adhesive Capsulitis, also known as \u0027Frozen Shoulder\u0027, involves a range of approaches tailored to the severity and stage of the condition. Common initial treatments include physical therapy to improve range of motion and NSAIDs to alleviate pain and inflammation. Corticosteroid injections can be used for inflammation control. Ultrasound-assisted hydrodistention, hydrodilatation, and suprascapular nerve block are also valuable techniques used to improve shoulder function. Extracorporeal shockwave therapy and pharmacopuncture represent adjunctive therapies enhancing pain and mobility outcomes. If conservative measures fail, surgical interventions or shoulder manipulation under anesthesia may be considered.",
        "Treatment for Adhesive Capsulitis or \u0027Frozen Shoulder\u0027 encompasses a spectrum of conservative and surgical interventions. Conservative treatments include manual therapy, exercise, corticosteroid injections, hydrodilatation, and physical therapy focusing on pain alleviation, improved range of motion, and enhanced functionality. More severe cases or those unresponsive to conservative management may benefit from surgical options like arthroscopic or open capsular release. Additional treatment strategies include manipulation under anesthesia and arthrographic distension.",
        "Treatment for Adhesive Capsulitis, or \u0027Frozen Shoulder\u0027, encompasses a range of conservative and surgical options. Non-invasive methods include manual therapy, exercise, corticosteroid injections, and physical therapy to alleviate pain and restore shoulder function. When conservative treatments fail, more invasive procedures like arthroscopic or open capsular releases can be performed. Chiropractic adjustments involving mechanical force and manual techniques are also utilized in some cases.",
        "Treatment for Adhesive Capsulitis or \u0027Frozen Shoulder\u0027 encompasses a spectrum of conservative and surgical interventions. Conservative treatments include manual therapy, exercise, corticosteroid injections, physical therapy modalities, and extracorporeal shockwave therapy. Surgical options comprise arthroscopic or open capsular release, manipulation under anesthesia, and hydrodilatation. The approach varies depending on the etiology and severity of the condition, with idiopathic cases responding well to non-operative therapy or closed manipulation, and post-traumatic or postsurgical cases potentially requiring more aggressive interventions."
      ],
      "exact_answer": [
        [
          "non-steroidal anti-inflammatory drugs (NSAIDs)",
          "physical therapy",
          "corticosteroid injections",
          "hydrodilatation",
          "capsular release",
          "manipulation",
          "capsulotomy",
          "intraarticular steroid injections",
          "arthroscopic capsular release",
          "extracorporeal shockwave therapy",
          "suprascapular nerve block"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Which organ dysfunction score is best for evaluating paediatric sepsis?",
      "documents": [],
      "snippets": [],
      "type": "factoid",
      "id": "65844e9b06a2ea257c000004",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": false,
      "body": "Should ganaxolone be used for treatment of status epilepticus?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1827,
          "offsetInEndSection": 2081,
          "text": "Of the three deaths, none was considered related to ganaxolone; all occurred 9-22 days after completing ganaxolone.SIGNIFICANCE: IV ganaxolone achieved rapid and durable seizure control in patients with RSE, and showed acceptable safety and tolerability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35748707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Super Refractory Status Epilepticus Improved After Emergency Use of Ganaxolone: Case Report",
          "beginSection": "title",
          "endSection": "title",
          "document": "38895012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience",
          "beginSection": "title",
          "endSection": "title",
          "document": "36325100"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-03-06T02:04:50.999Z",
        "round": 12
      },
      "id": "677e816e592fa4887300001a",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": false,
      "body": "What is the difference between Gene Set Enrichment Analysis (GSEA) and Over-Representation Analysis (ORA)?",
      "documents": [],
      "snippets": [],
      "type": "factoid",
      "id": "677ed900592fa4887300002c",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "Should gender-affirming surgery be performed in people under 18 years of age?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-01-22T11:19:36.784Z",
        "round": 9
      },
      "id": "6593d2e006a2ea257c000019",
      "ideal_answer": [
        "The decision to perform gender-affirming surgery (GAS) on individuals under 18 years of age involves balancing medical, psychological, and ethical considerations. Data indicates that breast and chest surgeries are the most common procedures in adolescents aged 12-18, often aimed at alleviating gender dysphoria and improving mental health outcomes. Hormonal therapy plays a preparatory role for some patients, though its long-term impact on surgical results is still under study. More complex procedures, such as genital reconstruction, are primarily performed on older patients due to additional medical and psychological considerations. The appropriateness of GAS for minors requires a multidisciplinary approach, careful assessment of individual circumstances, and comprehensive informed consent to ensure the best possible outcomes.",
        "Gender-affirming surgery can be performed on individuals under 18 under specific circumstances, supported by international guidelines and when deemed appropriate for the individual\u0027s mental health and quality of life. While restrictions and legal guidelines often set 18 as the age of consent, there are instances where these surgeries, such as chest wall masculinization, have been provided to individuals under 18 to support their gender identity and improve mental health outcomes.",
        "Studies suggest that gender-affirming surgeries are being increasingly performed on transgender adolescents, with many undergoing procedures such as mastectomies before the age of 18. These interventions, when conducted in accordance with international guidelines, have been associated with improvements in mental health and quality of life for gender-diverse individuals. However, the legal and regulatory landscape varies, with some regions requiring individuals to be at least 18 years old for certain surgical procedures. This highlights a tension between current medical practices and legal restrictions, underscoring the need for further discussion and clarification on the appropriate age for such interventions.",
        "While there is a lack of consensus, current evidence suggests that gender-affirming surgeries should generally be reserved for those aged 18 and over due to the irreversible nature of the procedures and ethical concerns regarding maturity and consent. However, puberty blockers and hormone therapies are commonly used in adolescents to support gender transitions.",
        "Gender-affirming surgery may be considered in carefully selected individuals under 18 years of age, particularly adolescents diagnosed with clear and persistent gender dysphoria, following thorough evaluation and multidisciplinary team assessment. However, the decision to proceed with surgery should take into account the individual\u0027s physical and emotional maturity, potential long-term implications, and available evidence-based guidelines. In some cases, such as clitoroplasty for clitoromegaly, surgical intervention during infancy has been shown to yield highly satisfactory outcomes, suggesting that early intervention can be beneficial when medically indicated. Nevertheless, each case requires a nuanced consideration of the unique circumstances, weighing the potential benefits against the risks and uncertainties associated with irreversible surgical interventions in minors."
      ]
    },
    {
      "answerReady": true,
      "body": "What is the best approach to evaluate learning disabilities in children?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 961,
          "text": "for problematic kids.Design: We established four steps for launching neuropsychological work at primary schools: 1) setting up a screening group for neuropsychological assessment of all children entering the first year of school; 2) a comprehensive neuropsychological assessment of the children who showed poor results in the first step of the study; 3)ateam remediation program; and 4) evaluation of the remediation results by a new neuropsychological assessment at the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36733820"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-06T10:54:53.748Z",
        "round": 10
      },
      "id": "6593d9fe06a2ea257c00001c",
      "ideal_answer": [
        "The best approach to evaluating learning disabilities in children involves a multifaceted strategy that combines various assessment tools and methods. It begins with comprehensive medical examinations, including vision and hearing tests, along with an analysis of school performance. Standardized assessments such as the Strengths and Difficulties Questionnaire (SDQ) and the Wechsler Intelligence Scale for Children-Revised (WISC-R) are valuable for identifying specific challenges. Additionally, computer game-based modules like YALU Learning Disability Evaluation Kit offer an engaging way to diagnose disabilities with 85% accuracy, which can be enhanced by parental input. To ensure unbiased results, regression approaches are employed to minimize the influence of intelligence test scores. Early identification through these methods supports timely intervention and personalized rehabilitative strategies, addressing conditions such as dyslexia, dyspraxia, dysgraphia, and dyscalculia effectively. This comprehensive approach ensures a well-rounded evaluation, leading to better outcomes for children with learning disabilities.",
        "The best approach to evaluate learning disabilities in children involves a comprehensive and multidisciplinary method, considering various factors such as medical examination, vision and hearing tests, and analysis of school performance. Studies suggest that regression approaches can be effective in diagnosing co-occurring learning disabilities, as they are less likely to be biased by the child\u0027s intelligence test score. Additionally, the use of software-based evaluation kits, such as YALU, which incorporates computer game modules, can help identify learning disabilities with an accuracy of 85%. These kits can screen for different types of learning disabilities, including Dyslexia, Dyspraxia, Dysgraphia, and Dyscalculia, and provide a customized rehabilitative approach. Early diagnosis, ideally from age 3 to 6, is crucial in starting early medical treatments and helping children return to a normal condition, highlighting the importance of a thorough and timely evaluation process."
      ]
    },
    {
      "answerReady": true,
      "body": "Which pathophysiological pathways are involved in the symptom FATIGUE?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1528,
          "text": "Physical fatigue was negatively correlated with GABA+ in SMC and PFC (r \u003d -0.428 and -0.472 respectively, p ≤  0.04) and positively with PFC Glx (r \u003d 0.480, p \u003d  0.028).CONCLUSION: The associations between fatigue and GABA + and Glx suggest that there might be dysregulation of GABAergic/glutamatergic neurotransmission in the pathophysiological mechanism of central fatigue in MS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33657474"
        },
        {
          "offsetInBeginSection": 1362,
          "offsetInEndSection": 1478,
          "text": "These studies provide new insight into the diverse actions of IFN-γ in fatigue, energy metabolism, and autoimmunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37185821"
        },
        {
          "offsetInBeginSection": 1163,
          "offsetInEndSection": 1350,
          "text": "igued than in nonfatigued patients. Serum IL-6 levels (pg/mL) were higher in the fatigued group (5.1 ± 3.4) than in the nonfatigued group (1.6 ± 1.5; P \u003c 0.001); serum albumin and creatin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "25135658"
        },
        {
          "offsetInBeginSection": 1408,
          "offsetInEndSection": 1853,
          "text": "Results also replicated several specific genomic effects previously observed in fatigued cancer survivors, including upregulated expression of α-synuclein (SNCA) and hemoglobin subunits (HBA and HBB).CONCLUSIONS: Cancer survivors\u0027 heightened fatigue levels may be partially explained by activation of specific immune cell subsets, thereby providing a potential molecular biomarker for clinical interventions targeting the remediation of fatigue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "29579369"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-03-04T13:29:37.229Z",
        "round": 8
      },
      "id": "6593dce006a2ea257c00001d",
      "ideal_answer": [
        "Fatigue is a complex symptom with multiple pathophysiological pathways. Key mechanisms include alterations in gut-brain axis activity, gut dysbiosis, and increased gut permeability, as seen in conditions like chronic fatigue syndrome. In fibromyalgia, metabolic disruptions such as tyrosine, purine, and pyrimidine pathway changes, as well as glutaminergic neurotransmission abnormalities, play a role. Cancer-related fatigue involves phospholipid metabolism disturbances, endocannabinoid system changes, and glycerophospholipid imbalances. Post-COVID-19 fatigue is linked to dysautonomia, micro-clotting, impaired oxygen delivery, and disruptions in cellular energy metabolism. These pathways highlight the importance of tailored therapeutic strategies to address the underlying causes of fatigue.",
        "Fatigue involves multiple pathophysiological pathways, including central nervous system dysfunction characterized by inflammation, reduced glucose metabolism, brain atrophy, demyelination, and axonal damage. It also implicates hypofunction of the glutamatergic system due to decreased acetyl-carnitine uptake in specific brain regions. Additionally, metabolic changes, particularly in response to stress, play a role. Abnormalities in neuromuscular junctions and myotendinous junctions contribute to fatigue symptoms, especially in conditions like major depressive disorder. The involvement of inflammation, the hypothalamic-pituitary-adrenal (HPA) axis, and the autonomic nervous system is suggested, though further research is needed. In fibromyalgia, fatigue is linked to chronic widespread pain and disruptions in both ascending pain and descending inhibitory sensory pathways. These mechanisms underscore the complexity of fatigue across various chronic illnesses.",
        "Studies suggest that fatigue is a complex symptom involving multiple pathophysiological pathways, including chronic inflammation, autonomic imbalance, HPA-axis dysfunction, and mitochondrial damage. Pro-inflammatory cytokines, such as interleukin-1 and -6, tumor necrosis factor-alpha, and tryptophan catabolites, are implicated in the mechanisms causing fatigue. Additionally, dysregulation of neurotransmitter systems, including GABAergic/glutamatergic transmission, and alterations in brain networks involved in cognitive/attentional processes are also associated with fatigue. Mitochondrial dysfunction, driven by immune dysfunction-related changes in myocyte mitochondria, is proposed as a critical role in fatigue-related pathogenesis. Furthermore, studies indicate that inflammation may be a common link between fatigue, pain, and depression, and that biologic agents targeting inflammatory cytokines can be effective in alleviating fatigue.",
        "Fatigue involves various pathophysiological pathways, including neuromuscular and myotendinous junction aberrations, non-dopaminergic and extrastriatal dopaminergic pathways, and disruptions in networks connecting the basal ganglia, thalamus, limbic system, and cortex. It is linked with hypocortisolemia impacting the hypothalamic-pituitary-adrenal axis and increased pro-inflammatory cytokine levels. There is dysregulation involving the central and autonomic nervous systems, neurotransmitter imbalances like GABAergic/glutamatergic signaling, and alterations in metabolic pathways such as galactose metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis."
      ],
      "exact_answer": [
        [
          "elevated adrenocorticotropin (ACTH) levels HPA axis dysfunction activation of proinflammatory cytokines (TNF-alpha, IL-1beta and IL-6) disturbances of astroglia metabolism decreased levels of noradrenaline decreased levels of serotonin proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) glutaminergic transmission astroglia metabolism disturbances decreased neurotransmitters noradrenaline and serotonin dysregulation of GABAergic/glutamatergic neurotransmission tyrosine metabolism purine metabolism pyrimidine metabolism glutaminergic metabolism aberrations in neuromuscular and myotendinous junctions tyrosine pathway purine pathway pyrimidine pathway p38 MAPK signaling pathway functional and structural changes of cerebral gray matter oxidative stress IO\u0026NS pathways central serotoninergic system",
          "Gut dysbiosis, altered gut-brain axis activity, increased gut permeability, bacterial translocation, abnormal tryptophan metabolism, and reduced activity of the kynurenine pathway",
          "Disrupted tyrosine, purine, and pyrimidine metabolism, and glutaminergic neurotransmission abnormalities in fibromyalgia",
          "Disruptions in phospholipid metabolism, endocannabinoid system alterations, glycerophospholipid abnormalities, and anandamide level changes in cancer-related fatigue",
          "Dysautonomia, micro-clotting, impaired oxygen delivery, and cellular energy metabolism changes in Long COVID-related fatigue"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Which genes are associated with neonatal sepsis survival?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1413,
          "offsetInEndSection": 1519,
          "text": "In conclusion, SNP of TNF-α -308 gene and IL-6 level are not associated with mortality in neonatal sepsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39816047"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 345,
          "text": "Variations in the tumor necrosis factor-alpha gene (TNF-α) -308G/A may be linked to neonatal sepsis mortality by modulating interleukins (ILs) involved in the immune response cascade, such as IL-6.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39816047"
        }
      ],
      "type": "list",
      "id": "677ecab2592fa48873000026",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "Is Deferiprone effective for Parkinson’s Disease?",
      "documents": [
        "39973479"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 979,
          "offsetInEndSection": 1132,
          "text": "Although 30 mg/kg deferiprone treated patients showed a trend for improvement in motor-UPDRS scores and quality of life, this did not reach significance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28469157"
        },
        {
          "offsetInBeginSection": 1618,
          "offsetInEndSection": 1937,
          "text": "Adverse events possibly related to deferiprone were reported in 35.7%-88.9% across all deferiprone groups vs. 42.9% for placebo.CONCLUSIONS: SKY and EMBARK studies indicate that deferiprone combined with L-dopa does not provide significant motor function benefit, while the absence of L-dopa treatment worsens symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39973479"
        },
        {
          "offsetInBeginSection": 858,
          "offsetInEndSection": 1023,
          "text": "However, a clinical study with the iron chelator deferiprone in patients with Parkinson\u0027s disease has not shown positive effects but rather worsened clinical symptom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38002094"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2023-01-19T03:20:50.326Z",
        "round": 1
      },
      "id": "63adc949c6c7d4d31b000019",
      "ideal_answer": [],
      "exact_answer": "no"
    },
    {
      "answerReady": false,
      "body": "Which genes of IL-17 signalling pathway are upregulated in sepsis?",
      "documents": [],
      "snippets": [],
      "type": "list",
      "id": "677eab59592fa48873000023",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "How does Gene Set Enrichment Analysis (GSEA) work?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-01-21T17:37:20.776Z",
        "round": 9
      },
      "id": "677ecc12592fa48873000028",
      "ideal_answer": [
        "Gene Set Enrichment Analysis (GSEA) works by using predefined gene sets to analyze and identify significant biological changes in gene expression data. It ranks genes to determine which predefined sets are overrepresented at the top or bottom of a rank-ordered list of genes from microarray data, indicating potential functional categories of interest.",
        "Gene Set Enrichment Analysis (GSEA) works by calculating the significance of the association between an annotated gene set and a differential expression signature. It typically uses a running sum statistic and permutation tests to assess the enrichment of gene sets across high-throughput expression data, identifying pathways and biological processes relevant to the data.",
        "Gene Set Enrichment Analysis (GSEA) is a computational method that evaluates whether an a priori defined set of genes displays statistically significant, concordant differences in expression between two biological states. It ranks these genes based on expression levels from genome-wide mRNA datasets, identifying significant biological changes and processes linked to specific phenotypes or conditions.",
        "Gene Set Enrichment Analysis (GSEA) is a computational method that assesses whether a predefined set of genes shows statistically significant, concordant differences between two biological states. It uses ranks of gene expression to identify significant biological changes in microarray data, aiding in the interpretation of gene set-phenotype associations and pathway-level expression changes.",
        "Gene Set Enrichment Analysis (GSEA) is a computational method that evaluates whether a predefined set of genes shows statistically significant, concordant differences between two biological states. By ranking genes based on differential expression, it identifies enrichment related to biological functions or pathways, revealing significant dependencies between gene sets and observed phenotypes.",
        "Gene Set Enrichment Analysis (GSEA) is a computational method used to determine if a pre-defined set of genes exhibits statistically significant, concordant differences between two biological states. It achieves this by ranking genes based on differential expression and identifying enrichment in specific gene sets, enabling the discovery of significant biological processes and pathways.",
        "Gene Set Enrichment Analysis (GSEA) works by utilizing pre-defined gene sets, ranking genes based on their expression levels, calculating an enrichment score reflecting the degree of overrepresentation, and employing permutation tests to determine statistical significance, ultimately revealing significant biological changes and patterns within genomic data."
      ]
    },
    {
      "answerReady": true,
      "body": "Is Cinpanemab effective for Early Parkinson’s Disease?",
      "documents": [],
      "snippets": [],
      "type": "yesno",
      "answerReady_on": {
        "date": "2023-01-29T21:48:07.683Z",
        "round": 2
      },
      "id": "63adca9ec6c7d4d31b00001d",
      "ideal_answer": [],
      "exact_answer": "no"
    },
    {
      "answerReady": false,
      "body": "Is bacterial more common than viral paediatric sepsis?",
      "documents": [],
      "snippets": [],
      "type": "yesno",
      "id": "6584542106a2ea257c000006",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What is the percentage of women that have successfully undergone fertility treatment in the European Union?",
      "documents": [],
      "snippets": [],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-01-22T11:19:17.134Z",
        "round": 9
      },
      "id": "6593d3ab06a2ea257c00001a",
      "ideal_answer": [
        "In the European Union, around 24% of women have successfully achieved at least one viable pregnancy after undergoing fertility treatment. This percentage reflects the success rate after an average of 2.48 treatment cycles per individual in a study cohort.",
        "In the European Union, the success rate of fertility treatments such as in vitro fertilization is typically reported as around 21-22% deliveries per ART cycle and clinical pregnancy rates between 29% and 32.4% per embryo transfer, as per recent reports.",
        "In the European Union, the clinical pregnancy rates per embryo transfer for in vitro fertilization range from approximately 29% to 35.44%, while the live birth rates per embryo transfer are around 26% to 26.78%.",
        "According to recent studies, the clinical pregnancy rate per embryo transfer was 35.44% while the live birth rate per embryo transfer was 26.53%. Additionally, a study from our institution reported that IUI-H in women below 40 years of age resulted in 10.6% twin and 0.6% triplet pregnancies. Furthermore, it is noted that the number of ART cycles has increased in Europe over the past few years, with a reported percentage of deliveries per ART cycle being 21-22%. These statistics suggest that approximately 26.53% of women undergoing fertility treatment successfully achieve a live birth, although the overall success rate may vary depending on the specific treatment and age group.",
        "In the European Union, the success rates for fertility treatments, such as assisted reproductive technologies (ART), show that the percentage of deliveries per ART cycle is around 21% to 22%, according to recent reports."
      ],
      "exact_answer": [
        [
          "24%",
          ""
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Is there a four-gene diagnostic signature for neonatal early-onset sepsis with bacterial infection?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1202,
          "offsetInEndSection": 1844,
          "text": "Through bioinformatics analysis, a diagnostic four-gene model that can accurately distinguish neonatal EOS in newborns with bacterial infection was constructed, which can be used as an auxiliary test for diagnosing neonatal EOS with bacterial infection in the future.CONCLUSION: In the current study, we analyzed gene expression profiles of neonatal EOS patients from public databases to develop a genetic model for predicting sepsis, which could provide insight into early molecular changes and biological mechanisms of neonatal EOS.WHAT IS KNOWN: • Infants with suspected EOS usually receive empiric antibiotic therapy directly after birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36527479"
        }
      ],
      "type": "yesno",
      "id": "677ecc65592fa48873000029",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "Bepirovirsen was developed for treatment of which disease?",
      "documents": [
        "39950613"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1363,
          "text": "Participants with CHB infection ≥6 months and serum HBsAg ≥50 IU ml-1 were enrolled from seven centers across Hong Kong and the Republic of Korea and randomized (3:1 within each dose cohort) to receive bepirovirsen or placebo via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8 and 11) and once weekly during weeks 3 and 4 (days 15 and 22).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34642494"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "INTRODUCTION: Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile following 4 weeks of treatment in participants with chronic hepatitis B virus (HBV) infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37393402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "INTRODUCTION: Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile following 4 weeks of treatment in participants with chronic hepatitis B virus (H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37393402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "INTRODUCTION: Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile following 4 weeks of treatment in participants with chronic hepatitis B virus (HB",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37393402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39950613"
        },
        {
          "offsetInBeginSection": 942,
          "offsetInEndSection": 1254,
          "text": "In patients with chronic HBV receiving both bepirovirsen and ETV or TFV in the B-Clear study (NCT04449029), NA plasma concentrations and pharmacokinetic parameters were similar to those published without bepirovirsen coadministration, suggesting no effect of bepirovirsen coadministration on NA pharmacokinetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39950613"
        },
        {
          "offsetInBeginSection": 667,
          "offsetInEndSection": 941,
          "text": "Bepirovirsen plasma pharmacokinetic parameters and concentration-time profiles in patients with chronic HBV in the CS3 study (NCT02981602) were similar with or without ETV or TFV coadministration, indicating no effect of NA coadministration on bepirovirsen pharmacokinetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39950613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infectio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39950613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "INTRODUCTION: Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therap",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38796564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Bepirovirsen is a developmental antisense oligonucleotide (ASO) for treatment of chronic hepatitis B virus infectio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39268699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infectio",
          "beginSection": "title",
          "endSection": "title",
          "document": "36346079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studie",
          "beginSection": "title",
          "endSection": "title",
          "document": "38796564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND \u0026 AIMS: Bepirovirsen, an antisense oligonucleotide targeting pregenomic and mRNA transcripts of HBV, has been conjugated to N-acetyl galactosamine (GSK3389404) to enhance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35714812"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 438,
          "text": "INTRODUCTION: Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therapy. Understanding the impact that clinical characteristics may have on bepirovirsen exposure is important for determining efficacious and well-tolerated dosing regimens. This analysis evaluated demographics and clinical characteristics associated with bepirovirsen exposure using a population pharmacokinetic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38796564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 403,
          "text": "INTRODUCTION: Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile following 4 weeks of treatment in participants with chronic hepatitis B virus (HBV) infection. The objective of the phase 2b study B-Clear is to access the efficacy and safety of bepirovirsen in participants with chronic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37393402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Bepirovirsen is a developmental antisense oligonucleotide (ASO) for treatment of chronic hepatitis B virus infection. No pharmacokinetic (PK) studies comparing participants with hepatic impairment (HI) and healthy participants (HPs) have been conducted with ASOs. Given the target patient population, characterization of bepirovirsen PK in HI was imperative. This phase 1, nonrandomized, open-label study (NCT04971928) evaluated the PKs of a single 300-mg dose of bepirovirsen in participants with HI and matche",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39268699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection. Given the importance of coadministration of bepirovirsen and standard-of-care nucleos(t)ide analogs (NAs), we evaluated drug-drug interactions (DDIs) between bepirovirsen, entecavir (ETV), and tenofovir (TFV) using in vitro and clinical data obtained through innovative study design and sampling strategy. Static models employing in vitro data indicated that bepirovirsen is not ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39950613"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2023-01-13T23:14:50.793Z",
        "round": 1
      },
      "id": "63adc82ec6c7d4d31b000016",
      "ideal_answer": [],
      "exact_answer": [
        [
          "hepatitis b"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Are there any trials for a single vaccine against most allergies?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 684,
          "text": " to 0.95)). We hypothesise that a single dose of whole-cell vaccine in early infancy is protective against IgE-mediated food allergy.METHODS AND ANALYSIS: This adaptive double",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33334840"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-02-20T14:06:12.236Z",
        "round": 11
      },
      "id": "6777bcec592fa48873000013",
      "ideal_answer": [
        "There are no trials currently for a single vaccine that targets most allergies. Research is mostly focused on specific allergens or groups of allergens with efforts in combining multiple epitopes for targeted therapies.",
        "This study investigates whether a mixed whole-cell/aP vaccine schedule can prevent allergic diseases in the first year of life, focusing on IgE-mediated food allergies. It also explores tackling Bet v 1-mediated birch pollen and associated food allergies by combining immunologically relevant epitopes from Bet v 1, apple, and hazelnut into a single hybrid protein, MBC4. The trial evaluates this approach to address multiple allergies with a single solution."
      ],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What is geniospasm?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "BACKGROUND: Geniospasm is a rare and generally benign movement disorder of the chin yet with potentially debilitating complication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35672188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Background: Geniospasm is a rare genetic disorder characterized by paroxysmal rhythmic or irregular movements of the chin and lower lip due to repetitive contractions of the mentalis muscl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32874771"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Background: Geniospasm is a rare genetic disorder characterized by paroxysmal rhythmic or irregular movements of the chin and lower lip due to repetitive contractions of the me",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32874771"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Geniospasm is a hereditary disorder characterized by episodic, usually stress-induced involuntary trembling of the chin. Nineteen families from Europe and the U.S.A. suffering from this disorder have been described since 1894. We present three cases from two newly detected families. There was no evidence of any other nervous system abnormality, although abnormal EEG, sleep disorders, and involvement of other facial muscles have been described in rare cases. Geniospasm is transmitted as an autosomal-dominan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "8341298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 37,
          "text": "Geniospasm: hereditary chin trembling",
          "beginSection": "title",
          "endSection": "title",
          "document": "8341298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 499,
          "text": "Hereditary geniospasm is an unusual movement disorder causing episodes of involuntary tremor of the chin and the lower lip. Episodes typically start in early childhood and may be precipitated by stress, concentration, and emotion. Hereditary geniospasm is inherited as an autosomal dominant trait, and its cause is not known. We report the results of a genomewide genetic linkage study in a four-generation British family with hereditary geniospasm. Positive two-point LOD scores were obtained for 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "9382105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Hereditary geniospasm is an unusual movement disorder causing episodes of involuntary tremor of the chin and the lower li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "9382105"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2023-01-19T03:18:54.666Z",
        "round": 1
      },
      "id": "63adc90bc6c7d4d31b000018",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "What is the optimal age to start screening for learning disorders?",
      "documents": [
        "27976553"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Screening 5 and 6 year-old children starting primary school for development and language.",
          "beginSection": "title",
          "endSection": "title",
          "document": "27976553"
        },
        {
          "offsetInBeginSection": 846,
          "offsetInEndSection": 1048,
          "text": "Preschool screening seems effective in detecting children with lower than average developmental skills, and the school system may provide a practical opportunity for providing support to those children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27976553"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-02-06T11:03:52.759Z",
        "round": 10
      },
      "id": "6777bb95592fa48873000010",
      "ideal_answer": [
        "The optimal age to start screening for learning disorders is usually between the ages of 3 and 6. Starting at this age is beneficial because it coincides with significant developmental milestones and schooling begins, allowing for early interventions that can be crucial for the child\u0027s educational and developmental success.",
        "Studies suggest that six years old is considered a key age for screening children for learning disabilities, as early diagnosis at this stage can facilitate timely medical interventions and help kids return to a normal condition.",
        "The ideal age to start screening for learning disorders is before school entry, typically between ages 3 to 6. Screening at this early age can help in the early identification of disorders like dyslexia and ADHD, which allows for more effective interventions during a period of high brain plasticity.",
        "The optimal age to start screening for learning disorders is between age 3 and 6. Early screening, even before children start school, can facilitate timely interventions, with age 6 being a critical period as children begin elementary education.",
        "The optimal age for screening learning disorders begins as early as three years old and continues up to six years old. Early diagnosis during this period is crucial for initiating timely medical interventions, which can significantly improve the effectiveness of treatments and help children return to a normal developmental trajectory. Screening at the age of six, when children typically start elementary school, is particularly key, as it aligns with their entry into formal education and allows for early identification of potential learning challenges.",
        "Screening for learning disorders should ideally begin between the ages of 3 to 6, as this timeframe allows for early identification and intervention during critical periods of development and the onset of formal education, thereby facilitating timely support and accommodations for affected children."
      ],
      "exact_answer": [
        [
          "3 to 6 years"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Can IFI27 predict RSV infection in preterm infants?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 2130,
          "offsetInEndSection": 2477,
          "text": "Moreover, high-expression IFI27 was associated with more severe cases (p \u003d 0.041), more requirements of mechanical ventilation (p \u003d 0.034), more frequent hospitalization (p \u003c 0.001) and longer cumulative hospital stay (p \u003d 0.012).CONCLUSION: IFI27 might serve to predict RSV infection and evaluate the severity of RSV infection in preterm infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33388093"
        },
        {
          "offsetInBeginSection": 2334,
          "offsetInEndSection": 2441,
          "text": "hospital stay (p \u003d 0.012).CONCLUSION: IFI27 might serve to predict RSV infection and evaluate the severity ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33388093"
        }
      ],
      "type": "yesno",
      "id": "677ecb2e592fa48873000027",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "Please list the agricultural chemicals related to Parkinson\u0027s Disease.",
      "documents": [
        "20094060",
        "27598189"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 576,
          "offsetInEndSection": 1062,
          "text": "The animal models most relevant to PD include those generated by neurotoxic chemicals that selectively disrupt the catecholaminergic system such as 6-hydroxydopamine; 1-methyl-1,2,3,6-tetrahydropiridine; agricultural pesticide toxins, such as rotenone and paraquat; the ubiquitin proteasome system inhibitors; inflammatory modulators; and several genetically manipulated models, such as α-synuclein, DJ-1, PINK1, Parkin, and leucine-rich repeat kinase 2 transgenic or knock-out animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24158912"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 876,
          "text": "Exposure to pyrethroids, a significant class of the most widely used agricultural chemicals, has been associated with an increased risk of Parkinson\u0027s disease (PD). However, although many different pyrethroids induce roughly the same symptoms of Parkinsonism, the underlying mechanisms remain unknown. To find the shared key features among these mechanisms, we focused on 3-phenoxybenzoic acid (3-PBA), a common and prominent metabolite of most pyrethroids produced via hydrolysis by CEs in mammals. To determine the contribution of 3-PBA to the initiation and progression of PD, we performed in vivo and in vitro experiments, respectively, and found that 3-PBA not only accumulates in murine brain tissues over time but also further induces PD-like pathologies (increased α-syn and phospho-S129, decreased TH) to the same or even greater extent than the precursor pyrethroid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35605864"
        },
        {
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1348,
          "text": "cattle) to 1.79 (peas), P \u003c 0.05]. Rotenone, diquat, paraquat and several dithiocarbamates were associated with an increased risk of PD [OR \u003d 1.31 (cuprobam) to 1.57 (rotenone)], especially in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "29136149"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Parkinson\u0027s disease (PD) is a complex disorder that arises from genetic and environmental factors. The current investigation endeavors to investigate the role of exposure to organochlorine (OCPs) and organophosphate pesticides (OPPs), recognized as the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39485576"
        },
        {
          "offsetInBeginSection": 1343,
          "offsetInEndSection": 1541,
          "text": "Glyphosate, the world\u0027s most heavily applied herbicide, and an active ingredient in Roundup® and Paraquat, a toxic herbicide, has shown to be associated with the odds of premature mortality from PD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30558363"
        },
        {
          "offsetInBeginSection": 828,
          "offsetInEndSection": 1089,
          "text": "In addition to a brief historical overview of the toxin-induced PD models, this study provides a detailed description of exiting models in which Parkinsonism is initiated via the exposure of animals to such agricultural chemicals as rotenone, paraquat, and mane",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "15258850"
        },
        {
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1158,
          "text": "LTS: In 110 PD cases and 358 controls, PD was associated with use of a group of pesticides that inhibit mitochondrial complex I [odds ratio (OR)\u003d1.7; 95% confidence interval (CI), 1.0-2.8] including rotenone (OR\u003d2.5; 95% CI, 1.3-4.7) and with use of a group of pesticides that cause oxidative stress (OR \u003d 2.0; 95% CI, 1.2-3.6), incl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "21269927"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 779,
          "text": "Most studies show that rotenone and paraquat are linked to increased PD risk and PD-like neuropathology. Organochlorines have also been linked to PD in human and laboratory studie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27598189"
        },
        {
          "offsetInBeginSection": 590,
          "offsetInEndSection": 775,
          "text": "Among other pesticides, paraquat (PQ) has been linked to PD by epidemiological studies and experimental work in rodents, in which it causes lesions in the substantia nigra, pars compact",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "20094060"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Exposure to pyrethroids, a significant class of the most widely used agricultural chemicals, has been associated with an increased risk of Parkinson\u0027s disease (PD). However, although many different pyrethroids induce roughly the same symptoms of Parkinsonism, the underlying mechanisms remain unknown. To find the shared key features among these mechanisms, we focused on 3-phenoxybenzoic acid (3-PBA), a common and prominent metabolite of most pyrethroids produced via hydrolysis by CEs in mammals. To determin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35605864"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 502,
          "text": "While a number of genetic mutations are associated with Parkinson\u0027s disease (PD), it is also widely acknowledged that the environment plays a significant role in the etiology of neurodegenerative diseases. Epidemiological evidence suggests that occupational exposure to pesticides (e.g., dieldrin, paraquat, rotenone, maneb, and ziram) is associated with a higher risk of developing PD in susceptible populations. Within dopaminergic neurons, environmental chemicals can have an array of adverse effect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30740124"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-06T00:31:27.074Z",
        "round": 10
      },
      "id": "6772c43b592fa48873000006",
      "ideal_answer": [
        "Agricultural chemicals such as Paraquat, Rotenone, Maneb, Ziram, Dieldrin, Glyphosate, Permethrin, Dichlorvos, and Pyrethroids have been associated with an increased risk of Parkinson\u0027s Disease. These chemicals may contribute to the neurodegenerative processes underlying the disease.",
        "Several agricultural chemicals have been associated with an increased risk of Parkinson\u0027s Disease. These include Glyphosate, Paraquat, Dichlorvos, Permethrin (specifically for animal use), and Benomyl. While the exact mechanisms are not fully understood, exposure to these chemicals is linked to a higher likelihood of developing Parkinson\u0027s Disease.",
        "There is evidence linking several agricultural chemicals to an increased risk of Parkinson\u0027s Disease, including paraquat, maneb, ziram, dieldrin, rotenone, pyrethroids, organophosphates, and endosulfan. These pesticides might contribute to the development of the disease through their neurotoxic effects.",
        "Agricultural chemicals such as paraquat, maneb, ziram, dieldrin, pyrethroids, and rotenone have been associated with an increased risk of Parkinson\u0027s Disease. These substances are believed to contribute to the disease\u0027s development due to their neurotoxic effects, particularly affecting dopaminergic neurons.",
        "Agricultural chemicals that have been associated with an increased risk of Parkinson\u0027s Disease include ziram, paraquat, maneb, dieldrin, pyrethroids, and rotenone. These chemicals are thought to contribute to Parkinson\u0027s Disease due to their neurotoxic effects, which may lead to dopaminergic neuron damage.",
        "Paraquat, rotenone, maneb, ziram, dieldrin, pyrethroids, and mancozeb are agricultural chemicals that have been associated with an increased risk of Parkinson\u0027s disease. These chemicals are believed to have neurotoxic effects that may play a role in the onset or progression of the disease.",
        "Pesticides and fungicides linked to Parkinson\u0027s disease include rotenone, paraquat, maneb, ziram, dieldrin, pyrethroids, and mancozeb. Chronic exposure to these chemicals has been associated with an increased risk of developing Parkinson\u0027s disease due to their potential neurotoxic effects.",
        "The agricultural chemicals linked to Parkinson\u0027s Disease include paraquat, rotenone, maneb, ziram, dieldrin, pyrethroids (such as permethrin), organophosphate pesticides like dichlorvos and dimethoate, triazole fungicides including propiconazole and tebuconazole, and glyphosate. Additionally, diquat is another herbicide associated with PD. Exposure to combinations of these chemicals, particularly paraquat combined with maneb or ziram, has been shown to significantly increase the risk of developing Parkinson\u0027s Disease compared to individual exposures.",
        "Several agricultural chemicals have been associated with an increased risk of Parkinson\u0027s disease. These include the herbicides paraquat and rotenone, the fungicide maneb, and the insecticide dieldrin. Other involved chemicals are ziram, organophosphates like diazinon, chlorpyrifos, parathion, and pyrethroids. These chemicals are believed to contribute to the development of Parkinson\u0027s disease through their neurotoxic properties, although the specific mechanisms are still under study.",
        "The agricultural chemicals related to Parkinson\u0027s Disease mentioned in the provided research papers are: \n1. Rotenone \n2. Maneb \n3. Paraquat \n4. Herbicides \n5. Insecticides \n6. Industrial chemicals, including light stabilizers used in the production of polyolifins used in plastics. \n7. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) \n8. Pesticides used in the tree fruit sector of the agricultural industry, including those associated with handling or directly contacting pesticides.\n\nIt\u0027s essential to note that the pathogenesis of Parkinson\u0027s Disease is multifactorial, and the exact mechanisms by which these chemicals contribute to the development of the disease are not fully understood.",
        "Rotenone, Paraquat, Maneb, Ziram, Dieldrin, and Pyrethroids are agricultural chemicals that have been associated with an increased risk of developing Parkinson\u0027s Disease. These chemicals are often used as pesticides or fungicides in farming, and their potential neurotoxic effects contribute to PD risk.",
        "Rotenone, Paraquat, Maneb, Ziram, and pyrethroids are agricultural chemicals that have been associated with an increased risk of developing Parkinson\u0027s Disease. These chemicals are often used as pesticides and herbicides in farming.",
        "Agricultural chemicals associated with Parkinson\u0027s Disease include paraquat, rotenone, maneb, ziram, dieldrin, glyphosate, pyrethroids, 3-phenoxybenzoic acid (3-PBA), organochlorine insecticides, carbamate insecticides, and fungicides.",
        "Paraquat, rotenone, maneb, ziram, dieldrin, glyphosate, pyrethroids, organochlorine pesticides, organophosphate pesticides, fungicides, and fumigants have been associated with an increased risk of Parkinson\u0027s Disease. These findings are supported by both human and animal studies, highlighting the importance of considering environmental factors in the etiology of this complex disorder."
      ],
      "exact_answer": [
        [
          "Paraquat",
          "Rotenone",
          "Maneb",
          "Ziram",
          "Dieldrin",
          "lyphosate",
          "Permethrin",
          "Dichlorvos",
          "Pyrethroids",
          "Benomyl",
          "diquat",
          "endosulfan",
          "organophosphates",
          "Chlordecone",
          "2,4-dichlorophenoxyacetic acid (2,4-D)"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Is Lecanemab effective for early Alzheimer’s Disease?",
      "documents": [
        "37495380",
        "39581354",
        "37902139",
        "38836991",
        "39767824"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 698,
          "text": "In June 2021, the FDA approved aducanumab, an anti-Aβ monoclonal antibody for early AD based on its ability to reduce brain amyloid plaques, while two other amyloid-clearing antibodies (lecanemab and donanemab) have recently produced encouraging cognitive and clinical results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36586644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "BACKGROUND: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36544184"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "BACKGROUND: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36544184"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 710,
          "text": "2021, the FDA approved aducanumab, an anti-Aβ monoclonal antibody for early AD based on its ability to reduce brain amyloid plaques, while two other amyloid-clearing antibodies (lecanemab and donanemab) have recently produced encouraging cognitive and clinical results. We reviewed",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36586644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "[Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer\u0027s disease].",
          "beginSection": "title",
          "endSection": "title",
          "document": "38692883"
        },
        {
          "offsetInBeginSection": 1531,
          "offsetInEndSection": 1829,
          "text": "In the OLE, lecanemab 10 mg/kg biweekly treatment produced dose-dependent reductions in amyloid PET SUVr, improvements in plasma Aβ42/40 ratio, and reductions in plasma p-tau181.CONCLUSIONS: Lecanemab treatment resulted in significant reduction in amyloid plaques and a slowing of clinical decline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36544184"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 760,
          "text": "Furthermore, lecanemab has been shown to effectively reduce Aβ accumulation in patients with early Alzheimer\u0027s disease, which might contribute not only to delaying the progression of cognitive decline, but also to improving the quality of life of patients and their families.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39034660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 450,
          "text": "The introduction of lecanemab has dramatically changed the field of dementia medicine. Lecanemab, defined as an anti-amyloid-β (Aβ) drug, comprises an antibody against Aβ, a protein structure believed to cause Alzheimer\u0027s disease. This drug represents a new direction in dementia treatment. In a phase III study, lecanemab was found to significantly slow cognitive decline, while showing manageable levels of amyloid-related imaging abnormalities, wh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39034660"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 229,
          "text": "n the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer\u0027s disease but is only marginally",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38414336"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 489,
          "text": "Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer\u0027s disease, mild cognitive impairment due to Alzheimer\u0027s disease (AD) and mild AD dementia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33865446"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 300,
          "text": "There is no cure for Alzheimer\u0027s disease, which is the sixth leading cause of death in the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer\u0027s disease but is only marginally effective. Other antibodies are being developed including solanezumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38414336"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 760,
          "text": "Lecanemab, defined as an anti-amyloid-β (Aβ) drug, comprises an antibody against Aβ, a protein structure believed to cause Alzheimer\u0027s disease. This drug represents a new direction in dementia treatment. In a phase III study, lecanemab was found to significantly slow cognitive decline, while showing manageable levels of amyloid-related imaging abnormalities, which are side-effects of lecanemab. Furthermore, lecanemab has been shown to effectively reduce Aβ accumulation in patients with early Alzheimer\u0027s disease, which might contribute not only to delaying the progression of cognitive decline, but also to improving the quality of life of patients and their families.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39034660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer\u0027s disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37357276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Lecanemab (Leqembi©, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer\u0027s disease (AD) in several countries, including the US and Japan.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39487946"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "The approval of anti-amyloid β (Aβ) monoclonal antibodies (lecanemab) for the treatment of patients with early preclinical stage of Alzheimer\u0027s disease (AD) by the Food and Drug Administration, suggests the reliability and importance of brain Aβ clearance for AD therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39304744"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 514,
          "text": "More recently, advances in the development of Lecanemab, an anti-amyloid-β monoclonal antibody, have shown positive results in reducing brain A burden and slowing cognitive decline in patients with early- stage Alzheimer\u0027s disease in the Phase III clinical trial (Clarity Alzheimer\u0027s disease).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39688567"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer\u0027s disease (AD) to be initiated in early AD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37357276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "With recent data demonstrating that lecanemab treatment can slow cognitive and functional decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug and potentially other monoclonal antibody infusions targeting β-amyloid protein will imminently be realistic options for some patients with AD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37495380"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Background: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer\u0027s disease, and aducanumab has been recalled.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39767824"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer\u0027s disease with mild cognitive impairment or mild dementia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37902139"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer\u0027s disease (AD) after their phase III trials reached endpoints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39581354"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 363,
          "text": "The US Food and Drug Administration (FDA) approval of lecanemab for early-stage Alzheimer\u0027s disease (AD) represents an exciting new chapter in the management of neurodegenerative disease, but likewise presents numerous clinical, technical, and financial logistical challenges for both academic and non-academic medical institutions hoping to administer this drug.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38836991"
        },
        {
          "offsetInBeginSection": 2509,
          "offsetInEndSection": 2824,
          "text": "dema or effusions in 12.6%.CONCLUSIONS: Lecanemab reduced markers of amyloid in early Alzheimer\u0027s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36449413"
        },
        {
          "offsetInBeginSection": 1682,
          "offsetInEndSection": 2013,
          "text": "uctions in plasma p-tau181.CONCLUSIONS: Lecanemab treatment resulted in significant reduction in amyloid plaques and a slowing of clinical decline. Data indicate that rapid and pronounced amyloid reduction correlates with clinical benefit and potential disease-modifying effects, as well as the potential to use plasma biomarkers t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36544184"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Use of lecanemab for the treatment of Alzheimer\u0027s disease: A systematic review",
          "beginSection": "title",
          "endSection": "title",
          "document": "38867460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer\u0027s Disease",
          "beginSection": "title",
          "endSection": "title",
          "document": "38779110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Safety and efficacy of lecanemab for Alzheimer\u0027s disease: a systematic review and meta-analysis of randomized clinical trials",
          "beginSection": "title",
          "endSection": "title",
          "document": "37213538"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 510,
          "text": "The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a number of matters that deserve further consideration. The success of blinding was not assessed, even as infusion reactions and the cerebral pathology underlying amyloid-related imaging abnormalities could have signaled to man",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38484213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "INTRODUCTION: There is no cure for Alzheimer\u0027s disease, which is the sixth leading cause of death in the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer\u0027s disease but is only marginally effective. Other antibodies are being developed including ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38414336"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2023-02-16T16:10:18.953Z",
        "round": 3
      },
      "id": "63adc8d8c6c7d4d31b000017",
      "ideal_answer": [],
      "exact_answer": "yes"
    },
    {
      "answerReady": true,
      "body": "What are the causes of depression in children under 11?",
      "documents": [
        "18306467",
        "37093526"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1798,
          "offsetInEndSection": 2005,
          "text": " with depressive symptoms in both cohorts. Low paternal age was a risk factor for depressive symptoms in the less developed city, São Luís, whereas low birth weight was a risk factor for depressive symptoms ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "22863172"
        },
        {
          "offsetInBeginSection": 1068,
          "offsetInEndSection": 1488,
          "text": "In addition, results from the logistic regression analyses indicated that parental reporting of problem internalization, total behavior problems, and social competence were independent predictors of child depression not identified by the anxious/depressed subscale.CONCLUSION: It is believed that extensive behavioral problems reported by parents and several sociodemographic factors are related to childhood depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "18306467"
        },
        {
          "offsetInBeginSection": 1184,
          "offsetInEndSection": 1316,
          "text": "Children that witnessed or were victims of violence in the neighborhood were also more likely to have comorbid anxiety and depressio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37093526"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-01-22T11:20:29.810Z",
        "round": 9
      },
      "id": "63ac45e4c6c7d4d31b000015",
      "ideal_answer": [
        "Depression in children under 11 is influenced by multiple factors. Psychological causes include internalizing disorders and emotional dysregulation, as reflected in increased prevalence with self-reported emotional disorders. Biological causes involve dysregulations in the hypothalamus-pituitary-adrenal (HPA) axis, with alterations in cortisol and immune biomarkers observed in children with ADHD. Additionally, environmental stressors, such as high parental stress and caregiver burden, can negatively impact children\u0027s emotional well-being, increasing their risk for developmental and mood disorders.",
        "Depression in children under 11 can be caused by various interrelated factors. Key causes include the influence of parental depression or bipolar disorder, stressful events, and loss. Children with psychological conditions such as attention, learning, conduct, or anxiety disorders are at a higher risk of depression. External influences like traumatic experiences and socioeconomic stress, such as community poverty and unemployment, also play a role. Children\u0027s self-perception, specifically a tendency towards depressive attributional styles and low self-perceived competence, are additional contributors.",
        "Research suggests that various factors contribute to the development of depression in children under 11. Studies indicate that children who experience stress, loss, or have attention, learning, conduct, or anxiety disorders are at higher risk for depressive disorders. Additionally, children living with a parent who has depression are more likely to develop depression themselves. Other significant predictors include family history of depression, subclinical depressive symptoms, anxiety, stressful life events, and neurobiological dysregulation. Furthermore, being female, having low paternal age or low birth weight, experiencing negative events in the family, childhood emotional abuse, and adverse socioeconomic conditions are also associated with an increased risk of depression in children.",
        "Depression in children under 11 can be caused by a variety of factors including child abuse and neglect, bullying, chronic stress, parental depression, loss of significant relationships, and pre-existing mental health disorders like attention, learning, conduct, or anxiety disorders. Additionally, broader socio-economic factors such as community poverty and unemployment, as well as low self-perceived competence, can contribute to the development of depressive symptoms in children.",
        "Depression in children under 11 is influenced by a combination of factors, including parental mental health issues such as maternal depression and anxiety, which can affect children both during pregnancy and postpartum. Maternal stress during pregnancy is particularly linked to increased risks of depression in later childhood, especially if the child was born small for gestational age. Exposure to abuse, neglect, or intimate partner violence also significantly elevates the risk of depressive symptoms. Bullying at school further contributes to such risks, along with young maternal age and lower intelligence test scores. Additionally, cognitive factors like a child\u0027s ability to regulate emotions play a role, while post-traumatic stress disorder often co-occurs with depression in trauma-exposed children. Together, these genetic, environmental, and social elements create a multifaceted landscape of risk factors for childhood depression.",
        "Depression in children under 11 can be caused by various factors, including parental intimate partner violence, maternal depression, and paternal concurrent affective symptoms. Studies have shown that increasing maternal stress during pregnancy is associated with an increased risk of symptoms of moderate to severe depression in 11-year-old children, especially those who were born small for gestational age (SGA). Additionally, child abuse and neglect are linked to a higher risk of developing depression, with physically abused children and those experiencing multiple types of abuse being at increased risk of lifetime major depressive disorder (MDD). Furthermore, gender nonconformity is a strong predictor of depressive symptoms in children, particularly among males and heterosexuals. Other factors such as being bullied at school, lower intelligence test scores, and young maternal age can also contribute to the development of depression in children under 11. Overall, these studies suggest that a combination of genetic, environmental, and social factors can contribute to the onset of depression in young children."
      ],
      "exact_answer": [
        [
          "parental mental health issues",
          "socioeconomic factors",
          "Risk factors include family history of depression, trauma or abuse, neglect, parental conflict, social isolation, chronic illness, learning disabilities, and substance abuse",
          "combination of genetic, environmental, and psychological factors",
          "school stress",
          "Bullying"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "What is the treatment of the helps syndrome?",
      "documents": [],
      "snippets": [],
      "type": "factoid",
      "id": "677e81be592fa4887300001b",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "In which childhood cancers has CAR-T cell therapy been used?",
      "documents": [
        "30120708"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 656,
          "text": "In the pediatric, adolescent, and young adult (P-AYA) populations, Tisagenlecleucel (Kymriah®) exemplifies the success of CAR T-cell therapy, demonstrating significant efficacy in treating relapsed or refractory acute lymphoblastic leukemia (r/r ALL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39900318"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving treatment for children with relapsed/refractory B-cell hematologic malignancies, and remains an important investigational therapy for other childhood cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39844726"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "PURPOSE OF REVIEW: Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30120708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "OPINION STATEMENT: Chimeric antigen receptor (CAR) T-cell therapy has become the standard of care for children and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), and it is a highly promising therapy under investigation for adults with relapsed disease. Despite having potentially life-threatening toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the benefits of CAR T-cell therapy far outweigh these risks, parti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34097135"
        },
        {
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1332,
          "text": "trategies that are being used to overcome tumor-mediated immunosuppression in solid tumors; these strategies have the potential to improve clinical outcomes of CAR T cell therapy for children with sarcoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34572932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 498,
          "text": "Immune-based therapies have now been credentialed for pediatric cancers with the robust efficacy of chimeric antigen receptor (CAR) T cells for pediatric B cell acute lymphocytic leukemia (ALL), offering a chance of a cure for children with previously lethal disease and a potentially more targeted therapy to limit treatment-related morbidities. The developmental origins of most pediatric cancers make them ideal targets for immune-based therapies that capitalize on the differential expression o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34113750"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-03-04T10:22:00.039Z",
        "round": 8
      },
      "id": "6593d1f206a2ea257c000018",
      "ideal_answer": [
        "CAR-T cell therapy has been used in treating childhood cancers such as acute lymphoblastic leukemia (ALL), diffuse midline glioma (DMG), and diffuse intrinsic pontine glioma (DIPG). These therapies have shown promise, particularly in pediatric hematologic malignancies like ALL, where they have achieved high remission rates. However, the application in solid tumors like DMG and DIPG is still in the experimental stages and has shown limited success with significant challenges.",
        "CAR-T cell therapy has been used in the treatment of pediatric sarcomas, medulloblastoma, relapsed/refractory childhood B-cell acute lymphoblastic leukemia (B-ALL), and rhabdomyosarcoma.",
        "CAR-T cell therapy has been used in childhood cancers including acute lymphoblastic leukemia (ALL), osteosarcoma, medulloblastoma, and Ewing sarcoma. It has shown significant efficacy in treating relapsed or refractory acute lymphoblastic leukemia, and preclinical studies suggest potential benefits in pediatric solid tumors such as osteosarcoma, medulloblastoma, and Ewing sarcoma.",
        "CAR-T cell therapy has been utilized in treating childhood cancers, notably acute lymphoblastic leukemia (ALL) and neuroblastoma. It has shown high efficacy in pediatric B-cell ALL, achieving complete remission rates and offering a promising approach for cases that are resistant or refractory to standard treatments.",
        "CAR-T cell therapy has been successfully used in various childhood cancers, particularly in B-cell acute lymphoblastic leukemia (B-ALL), where it has achieved high remission rates of up to 90%. Studies have also explored its application in solid tumors such as neuroblastoma, with some patients showing good responses to GD2-targeting CAR-T cell therapy. Additionally, researchers are investigating the use of CAR-T cells against other pediatric cancers, including those that express HER2, NY-ESO, GD2, EGFR, GPC3, B7-H3, and MAGE-A4 antigens. Furthermore, CAR-T cells have been tested in combination with other treatments for diffuse intrinsic pontine glioma (DIPG), a universally fatal childhood cancer, showing promising results in preclinical models.",
        "CAR-T cell therapy has primarily focused on hematological malignancies such as acute lymphocytic leukemia (ALL). However, recent studies suggest potential applications in solid pediatric tumors like neuroblastoma, osteosarcoma, and medulloblastoma, although data remains limited compared to ALL. Notably, research exploring CAR-T cell therapies specifically targeting Ewing\u0027s Sarcoma and Diffuse intrinsic pontine glioma shows promising early-stage clinical trials indicating some success but further investigation is warranted due to their rarity and complexity.",
        "CAR-T cell therapy has been most notably used in childhood B-cell acute lymphoblastic leukemia (B-ALL), where it has shown remarkable success with high remission rates, particularly for relapsed or refractory cases. It is also being applied to neuroblastoma targeting GD2 and explored in other solid tumors such as diffuse intrinsic pontine glioma (DIPG) using HER2-targeted cells. Additionally, research is expanding its use to various sarcomas and other cancers by targeting antigens like NY-ESO, EGFR, GPC3, B7-H3, and MAGE-A4. The FDA has approved CAR-T therapy for pediatric and young adult B-ALL and diffuse large B-cell lymphoma (DLBCL)."
      ],
      "exact_answer": [
        [
          "B-cell acute lymphoblastic leukemia B cell acute lymphoblastic leukemia acute lymphoblastic leukemia pediatric midline gliomas diffuse midline glioma (DMG) diffuse intrinsic pontine glioma (DIPG) diffuse midline glioma diffuse intrinsic pontine glioma pediatric sarcomas including osteosarcoma and alveolar rhabdomyosarcomas medulloblastoma childhood B-cell acute lymphoblastic leukemia (B-ALL) rhabdomyosarcoma",
          "B cell cancers"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Which is the most common pathogen in paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1647,
          "offsetInEndSection": 2090,
          "text": "Sepsis due to the most resistant organisms (A. baumannii and K. pneumoniae Carbapenemase [KPC]-producing bacteria, n \u003d 20; 39%) was associated with higher mortality (P \u003d 0.001) and significantly associated with exposure to carbapenem and vancomycin before onset of sepsis (cases exposed \u003d 13/20; 65%, P \u003c 0.001).CONCLUSION: MDROs are the most common cause of sepsis at our NICU and are associated with higher mortality compared with non-MDROs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28642139"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2024-01-16T21:40:37.625Z",
        "round": 5
      },
      "id": "6584593f06a2ea257c000008",
      "ideal_answer": [
        "The most common pathogen in paediatric sepsis may vary depending on the geographic location and the population studied. However, Staphylococcus aureus is commonly reported as a leading cause of sepsis. Other pathogens such as Group B Streptococcus (GBS), Klebsiella species, Enterobacter, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii have also been identified in various studies as common causative agents of sepsis in children.",
        "The most common pathogen in pediatric sepsis varies depending on the geographic area and the patient\u0027s age and health conditions, but Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus are frequently reported. GBS (Group B streptococcus) is considered the leading pathogen in early-onset sepsis in neonates.",
        "Staphylococcus aureus (S. aureus) is one of the most frequently isolated pathogens in pediatric cases of sepsis, including both early and late-onset sepsis. It is a common gram-positive microorganism and plays a significant role as a pathogen associated with sepsis and toxic shock. In addition to Staphylococcus aureus, other common pathogens that can cause sepsis in pediatric patients are various species of Streptococcus, Enterococcus, and Gram-negative organisms like Klebsiella pneumoniae, the latter being associated with the highest mortality in the context of sepsis as per the provided snippets. The prevalence of specific pathogens may vary by region and by specific patient populations such as neonates in intensive care units, where CONS (coagulase-negative staphylococci) has emerged as a common pathogen. This suggests that while Staphylococcus aureus is commonly implicated, the etiology of pediatric sepsis can be broad and influenced by various factors including geography and healthcare settings.",
        "The most common pathogens involved in pediatric sepsis vary depending on the patient population and the geographical location, but generally, Gram-positive bacteria like Staphylococcus spp (including Staphylococcus aureus and coagulase-negative Staphylococci such as S. epidermidis and S. haemolyticus), and Enterococcus spp are among the leading causes of sepsis in children. In neonates, particularly very low birth weight (VLBW) infants, Gram-negative bacteria such as E. coli can be prevalent causes of early-onset sepsis (EOS). Other Gram-negative bacteria like Klebsiella pneumoniae are also significant, and often associated with late-onset sepsis (LOS) in preterm infants. The presence of antibiotic-resistant strains, such as extended-spectrum β-lactamase (ESBL) producing E. coli and K. pneumoniae, adds to the complexity of treating pediatric sepsis.",
        "The most common pathogen in pediatric sepsis can vary depending on the age group and region, but overall, Escherichia coli (E. coli) and Staphylococcus aureus are frequently identified as significant causative agents in infants with clinical suspicion of serious invasive infections. In very low birth weight (VLBW) infants, Gram-negative organisms, particularly E. coli, are documented as leading pathogens of early onset sepsis (EOS), whereas Group B Streptococcus (GBS) is the most common pathogen in EOS, especially in infants with a gestational age of less than 28 weeks. Additionally, Klebsiella pneumoniae is also notable as a common pathogen in pediatric sepsis cases. These findings stress the need for accurate diagnostic tools and effective management strategies to address pediatric sepsis.",
        "The most common pathogen in pediatric sepsis is Staphylococcus aureus, a gram-positive microorganism that is frequently isolated in cases of neonatal and pediatric sepsis.",
        "Escherichia coli, Coagulase-negative staphylococci, Staphylococcus aureus, and Klebsiella pneumoniae are the most common pathogens in paediatric sepsis.",
        "The most common pathogens in pediatric sepsis are Escherichia coli and Group B Streptococcus. These bacteria are frequently identified in cases of invasive bacterial infections in young children, with Escherichia coli being particularly common in community-acquired infections.",
        "The most common pathogens associated with pediatric sepsis include Coagulase-negative Staphylococcus (especially in neonatal and late-onset sepsis), Staphylococcus aureus, and Klebsiella pneumoniae. The prevalence of these pathogens can vary based on location and specific patient populations.",
        "Staphylococcus aureus, Klebsiella pneumoniae, and coagulase-negative staphylococci are among the most common pathogens responsible for pediatric sepsis, with variations depending on the age of the child and the onset of sepsis.",
        "Pediatric sepsis is commonly caused by pathogens such as Staphylococcus aureus, Group B Streptococcus (GBS), Klebsiella pneumoniae, and coagulase-negative staphylococci (CoNS). These pathogens vary depending on factors such as the age and health status of the child, as well as the timing of the infection, with some being more prevalent in early-onset versus late-onset sepsis.",
        "The most common pathogens in paediatric sepsis vary depending on factors such as gestational age and the setting of infection acquisition. Staphylococcus aureus and Coagulase-negative staphylococci (CoNS) are frequently identified as leading causes, particularly in preterm neonates and cases of late-onset sepsis. Group B Streptococcus (GBS) is prominent in early-onset sepsis among full-term infants. Additionally, Klebsiella pneumoniae and Escherichia coli are significant, especially in hospital-acquired and community-acquired infections, respectively. While different pathogens dominate specific contexts, Staphylococcus aureus emerges as a consistently common cause across various paediatric populations.",
        "The most common pathogens in pediatric sepsis are Staphylococcus aureus, coagulase-negative staphylococci, and Group B streptococcus, with the prevalence varying based on factors such as the age of the child and onset type of sepsis.",
        "The most common pathogens responsible for paediatric sepsis include Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Coagulase-negative staphylococci, and Group B Streptococcus. These pathogens vary based on the patient\u0027s age and onset time of the sepsis.",
        "While Staphylococcus aureus is a common pathogen in pediatric sepsis, Coagulase-negative staphylococci (CoNS) and Group B Streptococcus (GBS) are also frequently isolated in specific age groups or settings.",
        "Group B Streptococcus and Escherichia coli are the most common pathogens in pediatric sepsis, particularly in neonatal sepsis, accounting for approximately two-thirds of invasive bacterial infections in this age group."
      ],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "Why are autoimmune diseases more common in women?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-20T14:03:11.391Z",
        "round": 11
      },
      "id": "6777bc37592fa48873000012",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "What is the mechanism of action of Tofersen?",
      "documents": [
        "39932579"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 828,
          "text": "Background: In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels had been demonstrated.Methods: Between 03/2022 and 04/2023, 24 patients with SOD1-ALS from ten German ALS reference centers were followed-up until the cut-off date for ALS functional rating scale revised (ALSFRS-R), progression rate (loss of ALSFRS-R/month), NfL, phosphorylated neurofilament heavy chain (pNfH) in cerebrospinal fluid (CSF), and adverse events.Findings: During the observation period, median ALSFRS-R decreased from 38.0 (IQR 32.0-42.0) to 35.0 (IQR 29.0-42.0), corresponding to a median progression rate of 0.11 (IQR -0.09 to 0.32) points of ALSFRS-R lost per month.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38384337"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 476,
          "text": "The recent approval of Tofersen, targeting SOD1-related ALS, highlights the importance of precise genetic diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39932579"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 282,
          "text": "On 25 April 2023, tofersen was approved in the USA for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37316681"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "BACKGROUND: Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32640130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "OBJECTIVE: Patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1 ALS) treated with tofersen have shown slowing of disease progression, and disease stabilization with recovery of function in some patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39783194"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 496,
          "text": "Tofersen, an antisense oligonucleotide, in SOD1 related ALS, has joined the bandwagon of FDA-approved drugs for ALS recentl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38022476"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "text": "OBJECTIVE: Tofersen, an antisense oligonucleotide, has recently received FDA and EMA approval for treating amyotrophic lateral sclerosis (ALS) in adults with SOD1 gene mutations. This systematic review and meta-analysis synthesized evidence on tofersen\u0027s safety and efficacy in patients with SOD1-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39820998"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "BACKGROUND: The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36129998"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2023-01-19T03:21:47.417Z",
        "round": 1
      },
      "id": "63adc9e7c6c7d4d31b00001a",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "Is focused ultrasound safe for blood brain barrier opening in treatment of glioblastoma?",
      "documents": [
        "34395286",
        "38555449"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 469,
          "text": "The use of transcranial focused ultrasound (FUS) has recently been investigated for opening the BBB to facilitate drug delivery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34395286"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "38555449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "Focused ultrasound (FUS) in the presence of microbubbles can transiently open the blood-brain barrier (BBB) to increase therapeutic agent penetration at the targeted brain site to benefit recurrent glioblastoma (rGBM) treatment. This study is a dose-escalating pilot trial using a device combining neuronavigation and a manually operated frameless FUS system to treat rGBM patients. The safety and feasibility were established, while a dose-dependent BBB-opening effect was observed, which reverted to baselin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33547073"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "BACKGROUND: Focused ultrasound (FUS) shows promise for enhancing drug delivery to the brain by temporarily opening the blood-brain barrier (BBB), and it is increasingly used in the clinical setting to treat brain tumours. It remains however unclear whether FUS is being introduced in an ethically and methodologically sound manner. The IDEAL-D framework for the introduction of surgical innovations and the SYRCLE and ROBINS-I tools for assessing the risk of bias in animal studies and non-randomized trials, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37672093"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-02-05T18:14:48.503Z",
        "round": 10
      },
      "id": "677e80fd592fa48873000018",
      "ideal_answer": [],
      "exact_answer": "yes"
    },
    {
      "answerReady": true,
      "body": "What is the mechanism of action of Ponsegromab?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 807,
          "text": "In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and physical activity, along with suppressed serum GDF-15 levels.METHODS: In this phase 2, randomized, double-blind, 12-week trial, we assigned patients with cancer cachexia and an elevated serum GDF-15 level (≥1500 pg per milliliter) in a 1:1:1:1 ratio to receive ponsegromab at a dose of 100 mg, 200 mg, or 400 mg or to receive placebo, administered subcutaneously every 4 weeks for three doses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39282907"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 512,
          "text": "This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, in adults with advanced cancer, cachexia, and elevated GDF-15 serum concentration.PATIENTS AND METHODS: Participants (n \u003d 10) received open-label ponsegromab subcutaneous 200 mg every 3 weeks for 12 weeks in addition to standard-of-care anticancer treatmen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37982848"
        },
        {
          "offsetInBeginSection": 1691,
          "offsetInEndSection": 2098,
          "text": "Adverse events of any cause were reported in 70% of the patients in the ponsegromab group and in 80% of those in the placebo group.CONCLUSIONS: Among patients with cancer cachexia and elevated GDF-15 levels, the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms, findings that confirmed the role of GDF-15 as a driver of cachexi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39282907"
        },
        {
          "offsetInBeginSection": 506,
          "offsetInEndSection": 1009,
          "text": "a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signalling. Preclinical and preliminary phase 1 data suggest that ponsegromab-mediated inactivation of circulating GDF-15 may lead to improvement in key characteristics of cachexia. The primary objective of this phase 2 study is to assess the effect of ponsegromab on body weight in patients with cancer, cachexia and elevated GDF-15 concentrations. Secondary objectives include assessing physical activity, physical fun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38500292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 344,
          "text": "PURPOSE: Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, in adults with advanced cancer, cachexia, and elevated GDF-15 serum concentration.PATIEN",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37982848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 462,
          "text": "BACKGROUND: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and physical activity, along with suppressed serum G",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39282907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "PURPOSE: Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, in adults with advanced cancer, cachexia, and elevated GDF-15 serum conc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37982848"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-01-22T10:48:59.462Z",
        "round": 9
      },
      "id": "677e8514592fa48873000020",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "Please summarize what is known about the cause of Cutaneous T cell lymphoma",
      "documents": [
        "7860737"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 391,
          "text": "The results implicate mutations in 17 genes in CTCL pathogenesis, including genes involved in T cell activation and apoptosis, NF-κB signaling, chromatin remodeling and DNA damage response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "26192916"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "For nearly two decades it has been suspected that the cutaneous T cell lymphoma, mycosis fungoides (MF), and its leukemic variant, the Sézary syndrome, are caused by the human T lymphotropic virus (HTLV-I/II).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "7860737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "7860737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 504,
          "text": "The etiology of cutaneous T-cell lymphoma remains unknown, although an association with viral infection, in particular certain retroviruses and human herpesviruses, has been suggested. The purpose of this study was to examine skin biopsies of cutaneous T-cell lymphoma for the presence of Epstein-Barr virus, herpes simplex virus type 1 and type 2, and human herpesvirus-6 by using the polymerase chain reaction. Lesional skin biopsies from 30 patients with cutaneous T-cell lymphoma were studied. Contro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "8227605"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-06T00:01:52.727Z",
        "round": 10
      },
      "id": "6772e4ed592fa4887300000a",
      "ideal_answer": [
        "The cause of Cutaneous T-cell lymphoma (CTCL) is not fully understood, but it involves the malignant transformation of T-cells. Factors such as T-cell receptor engagement and possibly the microbiota seem to be crucial for the progression of the disease. Additionally, activation of proteins like STAT3, NFAT, and NF-κB has been associated with advanced stages of the disease.",
        "Cutaneous T-cell lymphoma (CTCL) is believed to arise from a combination of genetic mutations and environmental factors. Studies have identified mutations in 17 genes that contribute to its pathogenesis, particularly those involved in T cell activation, apoptosis, NF-κB signaling, chromatin remodeling, and DNA damage response. While HTLV-I is a known cause of adult T-cell leukemia/lymphoma (ATLL), it does not appear to play a significant role in CTCL. The disease is also hypothesized to stem from chronic antigenic stimulation, potentially triggered by chemical or microbial exposures that activate malignant T cells through their receptors. However, no specific antigens have been definitively identified as causative triggers for this lymphoma.",
        "The exact cause of Cutaneous T cell lymphoma (CTCL) remains unknown. It is hypothesized to be linked to chronic antigenic stimulation possibly due to environmental exposures such as chemicals or microbes. Additionally, genetic mutations and factors influencing T cell signaling, such as immune system processes and NF-kB signaling, have been implicated. However, the precise triggers or causes are still not fully understood.",
        "The cause of cutaneous T-cell lymphoma (CTCL), which includes forms like mycosis fungoides and Sezary syndrome, is not well understood. It is believed to involve chronic antigen stimulation from unknown exposures such as chemicals or microbes. While genetic mutations and environmental triggers have been implicated, no specific cause is conclusively identified.",
        "Cutaneous T-cell lymphoma (CTCL) is a group of non-Hodgkin T-cell lymphomas that primarily affect the skin but can spread to other organs. The cause of CTCL is not fully understood, but chronic antigen stimulation from chemical or microbial exposures is considered a key factor. Antigenic triggers may activate malignant T cells through TCR signaling, leading to the disease. The condition is also linked to immune dysfunction, inflammatory cytokines, and neuroimmune interactions. Additionally, CTCL is associated with severe pruritus, diagnostic delays, and an increased risk of cutaneous and systemic infections.",
        "The exact cause of Cutaneous T cell lymphoma (CTCL) remains unknown. However, it involves the clonal expansion of malignant T cells in the skin, potentially triggered by chronic antigen stimulation from unidentified environmental factors such as chemicals and microbes. Genetic mutations related to T cell activation and NF-κB signaling also play a role in its pathogenesis.",
        "Cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides, appears to have a multifactorial etiology involving both environmental and genetic factors. While specific triggers remain unknown, UV exposure has been implicated as a potential risk factor, particularly in the development of Sezary syndrome. Additionally, certain viral infections may contribute to the pathogenesis of CTCL. Familial clustering suggests a hereditary component, although no clear-cut familial pattern or mendelian inheritance has been established. Genetic predisposition, possibly through polygenic mechanisms, may heighten susceptibility to the disease, especially in individuals exposed to environmental insults such as UV light.",
        "Cutaneous T-cell lymphoma (CTCL), also known as mycosis fungoides, has been linked to various genetic and environmental factors. Research suggests that CTCL may arise due to a combination of somatic mutations and epigenetic alterations, leading to the clonal expansion of malignant T-cells. Studies have identified specific genetic abnormalities, such as NOTCH2 and JAK3 mutations, which contribute to the pathogenesis of CTCL. Additionally, chronic exposure to certain chemicals, like polychlorinated biphenyls (PCBs) and pesticides, has been implicated in increasing the risk of developing CTCL. However, no definitive causal link between any particular agent and CTCL has been established, indicating that the etiology of this malignancy remains multifactorial and complex. Further research is needed to fully elucidate the underlying causes of CTCL.",
        "Cutaneous T cell lymphoma (CTCL) involves a clonal proliferation of malignant T cells in the skin, often hypothesized to be initiated or sustained by chronic antigen stimulation due to unknown exposures. Factors implicated in CTCL pathogenesis include mutations in genes related to T cell activation, apoptosis, NF-kB signaling, chromatin remodeling, and DNA damage response. Additionally, chemical and microbial stimuli may serve as antigenic triggers of the malignancy.",
        "Cutaneous T-cell lymphoma (CTCL) is characterized by the clonal expansion of malignant T cells in the skin. The exact causes are not fully understood, but factors potentially include genetic mutations in genes involved in T cell activation, apoptosis, and chromatin remodeling, as well as chronic antigen stimulation from unknown exposures such as chemicals or microbes.",
        "Cutaneous T-cell lymphoma (CTCL) arises from a clonal expansion of malignant T cells in the skin, driven primarily by chronic antigen stimulation. While the exact triggers remain unidentified, they may include chemical or microbial agents that activate T cell receptor signaling. Although HTLV-I is linked to other T-cell disorders, it isn\u0027t strongly associated with CTCL. Instead, mutations in genes involved in T cell activation, apoptosis, and DNA repair pathways contribute to its pathogenesis. Thus, CTCL\u0027s development involves a combination of environmental triggers and genetic alterations affecting immune regulation.",
        "Cutaneous T-cell lymphoma (CTCL) involves a clonal expansion of malignant T-cells in the skin, possibly triggered by chronic antigen stimulation from environmental exposures such as chemicals or microbes, although the specific antigens remain unidentified. Genetic mutations in genes related to T-cell activation, apoptosis, and other pathways play a role in its pathogenesis. The role of viruses like HTLV in CTCL is less clear compared to other regions-specific T-cell lymphomas.",
        "Cutaneous T-cell lymphoma (CTCL) is a multifactorial disorder with an uncertain etiology. Proposed contributors include viral infections, such as retroviruses and human herpesviruses, chemical antigens, chronic antigen stimulation, and genetic mutations impacting T-cell regulation and DNA integrity. Research has identified diverse driver mutations, including somatic copy number variants, but a definitive causal link remains elusive. Further investigation is necessary to clarify the complex interplay of factors leading to CTCL.",
        "Cutaneous T-cell lymphoma (CTCL) is believed to be caused or perpetuated by chronic antigen stimulation due to unknown exposures, with potential triggers ranging from chemicals to microbes. Studies have implicated mutations in 17 genes in CTCL pathogenesis, including those involved in T cell activation and apoptosis, NF-?B signaling, chromatin remodeling, and DNA damage response. While the exact cause of CTCL remains unclear, it is thought to involve a clonal expansion of malignant cells accumulating in the skin, with chronic antigen stimulation playing a key role. The condition has been linked to various immune cells, inflammatory cytokines, and neuroimmune interactions, although the precise mechanisms underlying its development are still not fully understood. Unlike adult T-cell leukemia/lymphoma (ATLL), which is caused by human T-lymphotropic virus type I (HTLV-I), CTCL does not appear to be associated with this or other herpesviruses, and its etiology remains a subject of ongoing investigation."
      ]
    },
    {
      "answerReady": true,
      "body": "Are there clinical trials on hormonal male birth control methods?",
      "documents": [
        "20478443",
        "16731547"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 450,
          "text": "OBJECTIVE: To assess men\u0027s preferences for healthcare provider from whom they would obtain hormonal male contraceptive (HMC) methods.STUDY DESIGN: We asked participants from 3 clinical trials of investigational HMC methods-an oral pill (11β-Methyl-19-nortestosterone-17β-dodecylcarbonate, 11β-MNTDC), intramuscular or subcutaneous injection (Dimethandrolone undecanoate), and transdermal gel (Nestorone and testosterone)-to rank their top 3 preferred",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35550379"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 493,
          "text": "BACKGROUND: We assessed attitudes towards and acceptability of male hormonal contraception among volunteers participating in a clinical trial of a prototype regimen, consisting of progestin and testosterone injections.METHODS: After completing screening, eligible men were randomly assigned to the no-treatment group (n \u003d 40) or to receive injections of norethisterone enanthate and testosterone undecanoate or placebo at different intervals (n \u003d 50) according to a blocked randomization list.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "16731547"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 395,
          "text": "Of the different strategies, hormonal methods aimed at suppression of spermatogenesis have been most extensively studies, are most promising, and are the only approach with the potential of breakthrough in the near future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "20478443"
        },
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 1014,
          "text": " next decade. Investigators have tested androgen plus progestin approaches using oral, transdermal, subdermal, and injectable drug formulations and demonstrated the short-term safety and reversibility of hormonal male contraception. The most commonly reported side effects associated with hormonal male contraception include weight gain, acne, slight suppression of serum high-density cholesterol, mood changes, and changes in libido. Efficacy trials of hormonal male contraceptives have demonstrated cont",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33005125"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2024-03-04T12:01:14.267Z",
        "round": 8
      },
      "id": "6593d46c06a2ea257c00001b",
      "ideal_answer": [
        "Yes, there are clinical trials on hormonal male birth control methods. These trials have evaluated combinations such as testosterone undecanoate and etonogestrel, as well as monthly depot medroxyprogesterone acetate with testosterone esters, showing effectiveness in suppressing spermatogenesis and promising potential as reversible contraception methods for men.",
        "Yes, there are clinical trials on hormonal male birth control methods. These trials focus on evaluating the effectiveness and acceptability of various hormonal substances for male fertility regulation, including different combinations of androgens and gestagens, as well as cyproterone acetate.",
        "Yes, there are clinical trials on hormonal male birth control methods. As of June 2023, two hormonal male contraceptive methods are undergoing phase II clinical trials for safety and efficacy. These methods involve the use of a long-acting combination of an androgen plus a progestin, which have been shown to be efficacious, reversible, and well-tolerated in clinical trials with healthy men. Additionally, a randomized, placebo-controlled clinical trial by the pharmaceutical industry has demonstrated the effectiveness of a combination of testosterone undecanoate and etonogestrel in suppressing spermatogenesis in volunteers. Overall, these developments suggest that the first marketed male hormonal contraceptive method is likely to be a long-acting hormonal method.",
        "Yes, there are ongoing clinical trials on hormonal male birth control methods. Studies have shown that these methods, which involve administering hormones such as testosterone alone or in combination with a progestin, can effectively and reversibly suppress sperm production in men, making them a potential new option for male contraception. Several regimens, including injectable testosterone undecanoate, dimethandrolone undecanoate, and transdermal Nestorone plus testosterone gel, have been tested in clinical trials with promising results, demonstrating high efficacy and reversibility. However, further research is needed to identify the best delivery system and formulation for widespread use. Several large-scale phase IIb and III trials are ongoing or planned to evaluate the safety, efficacy, and feasibility of these methods in preventing pregnancies.",
        "Yes, there are clinical trials on hormonal male birth control methods. Recent advancements in male contraception have led to the development of various hormonal approaches, including combinations of androgens and progestins. Clinical trials have demonstrated the efficacy and reversibility of these hormonal methods, with some formulations showing contraceptive efficacy rates higher than condoms. Notable agents currently in clinical trials include dimethandrolone undecanoate and testosterone combined with segesterone acetate. These trials are crucial for expanding contraceptive options for men and addressing the global need for effective male contraceptives."
      ],
      "exact_answer": "yes"
    },
    {
      "answerReady": true,
      "body": "What would be the main disadvantages of screening for dementia in asymptomatic older populations?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-20T14:24:18.882Z",
        "round": 11
      },
      "id": "6777bfbe592fa48873000016",
      "ideal_answer": [
        "The main disadvantages of screening for dementia in asymptomatic older populations include psychological harm due to anxiety and depression, risk of stigmatization and social exclusion, the high misclassification risk, particularly among those with minimal literacy and low socioeconomic status, and unresolved issues in diagnosing and treating mild cognitive impairment (MCI).",
        "The main disadvantages of screening for dementia in asymptomatic older populations include psychological harm such as anxiety and depression, risk of stigmatization and social exclusion, high misclassification rates especially in individuals with low literacy and socioeconomic status, and the unresolved issues around defining, diagnosing, and treating mild cognitive impairment.",
        "The main disadvantages of screening for dementia in asymptomatic older populations include the potential for psychological distress such as anxiety and depression, risks of stigmatization or social exclusion, and concerns about the accuracy of screening tools like the MMSE. These tools can lead to misclassification, particularly in individuals with low literacy levels, which is a significant issue in low- and middle-income countries where illiteracy rates among older adults are high."
      ]
    },
    {
      "answerReady": true,
      "body": "What is the target of Ublituximab?",
      "documents": [
        "39745891"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1400,
          "text": "This review provides an updated overview of the involvement of B cells in the immune pathophysiology and pathology of MS. We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34382120"
        },
        {
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1414,
          "text": "rovides an updated overview of the involvement of B cells in the immune pathophysiology and pathology of MS. We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab. Suggestions r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34382120"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Ublituximab (ublituximab-xiiy; BRIUMVI™) is a glycoengineered anti-CD20 monoclonal antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis (MS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36920653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Ublituximab (ublituximab-xiiy; BRIUMVI™) is a glycoengineered anti-CD20 monoclonal antibody developed by TG Therapeutics, Inc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36920653"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 577,
          "text": "The clinical trial utilized 1)a therapeutic anti-CD20 monoclonal antibody (mAb), ublituximab, which destroys CLL cells by an antibody-dependent cellular phagocytosis (ADCP) mechanism; 2)a B cell receptor (BCR) signaling inhibitor, umbralisib, which blocks PI3Kẟ; 3)and an anti-apoptosis inhibitor, venetoclax, which blocks cell survival promoted by BCL-2 that stops mitochondria from initiating apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39745891"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 406,
          "text": "Ublituximab is a monoclonal antibody that binds to the B-cell antigen CD20 with enhanced B-cell targeting.AREAS COVERED: This evaluation is of the identical ULTIMATE (UbLiTuximab In Multiple Sclerosis Treatment Effects) I and II trials comparing ublituximab (TG-1101) and teriflunomide in relapsing multiple sclerosi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36317532"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 509,
          "text": "Ublituximab (ublituximab-xiiy) is the latest approved chimeric glycoengineered anti-CD20 monoclonal antibody (mAb) for the treatment of relapsing forms of MS.AREAS COVERED: In this narrative review, the authors explore the safety and effectiveness of data derived from the Phase 2 and Phase 3 ublituximab trials and from their respective post-hoc analyse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37842819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35779372"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 356,
          "text": "Reassembling the other three anti-CD20 mAbs already in use for MS (rituximab, ocrelizumab and ofatumumab), ublituximab leads to depletion of B cells but spars long-lived plasma cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37156035"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 237,
          "text": "Ublituximab is a novel, glycoengineered anti-CD20 monoclonal antibody with single-agent activity in relapsed CL",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27982425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "BACKGROUND: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32351164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Background: Ublituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39512280"
        },
        {
          "offsetInBeginSection": 710,
          "offsetInEndSection": 923,
          "text": "the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35378683"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 607,
          "text": "Rituximab, ocrelizumab, ofatumumab, ublituximab and BCD-132 are anti-CD20 therapies that are either undergoing clinical development, or have been approved, for the treatment of M",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37906325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "BACKGROUND: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32351164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "INTRODUCTION: The involvement of B-cells in multiple sclerosis has only recently emerged. Ublituximab is a monoclonal antibody that binds to the B-cell antigen CD20 with enhanced B-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36317532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab",
          "beginSection": "title",
          "endSection": "title",
          "document": "28220479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 481,
          "text": "Background: Ublituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I and II studies showed significant improvements in annualized relapse rate, total number of gadolinium-enhancing (Gd+) T1 lesions, and total number of new or enlarging T2 at Week 96, as well as improvement in the proportion of participants with no evidence of disease activity (NEDA) from Weeks 24-96 with ublituximab vs. t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39512280"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti-tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti-CD20 monoclonal antibody, in rituximab-relapsed or -refractory patients with B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukaemia (CLL). Induction therapy (doses of 450-1200 mg) consisted of 4 weekly infusions in cycle 1 for NHL and 3 weekly infusions in cycles 1 and 2 for CLL. Patients received ublituximab maintenance monthly durin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28220479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis",
          "beginSection": "title",
          "endSection": "title",
          "document": "32351164"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2023-01-19T03:23:02.127Z",
        "round": 1
      },
      "id": "63adca12c6c7d4d31b00001b",
      "ideal_answer": [],
      "exact_answer": [
        [
          "CD20"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "How does Over-Representation Analysis (ORA) work?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-01-21T17:38:47.648Z",
        "round": 9
      },
      "id": "677ed8b8592fa4887300002b",
      "ideal_answer": [
        "Over-Representation Analysis (ORA) works by determining the biological processes or pathways that are enriched in a set of genes of interest, typically genes that are differentially expressed or co-expressed under certain conditions. It involves comparing the frequency of certain gene sets within the list to their expected frequency in a reference set to identify statistically significant enrichment.",
        "Over-Representation Analysis (ORA) is a statistical method used to determine whether certain genes or biological attributes are more prevalent in predefined sets, such as pathways, than would be expected by chance. It typically employs the hypergeometric test to analyze each term or set in isolation. However, it doesn\u0027t account for the dependence structure of hierarchical relationships within sets, like those found in Gene Ontology terms.",
        "Over-Representation Analysis (ORA) is used to determine if certain genes or variables are more prevalent in a set than expected by chance. It compares a list of interest, often derived from high-throughput experiments, to predefined sets or pathways to assess enrichment in functional categories.",
        "Over-Representation Analysis (ORA) is a statistical method used to assess whether a predefined set of genes, variables, or pathways is more prevalent or enriched in a specific list of interest than expected by chance, relative to a background list. It is commonly applied to identify functional categories or pathways linked to biological significance based on gene enrichment.",
        "Over-Representation Analysis (ORA) is a statistical method used to assess the enrichment of functional categories, such as gene sets or pathways, in a list of interest compared to a background list. It aims to determine if these categories are more prevalent than expected by chance, helping to identify biological relevance.",
        "Over-Representation Analysis (ORA) is a statistical method used to determine if a set of variables, such as genes in a gene list, are more prevalent in a specific category or pathway compared to a background list. It objectively assesses whether these functional categories are enriched beyond what is expected by chance.",
        "Over-Representation Analysis (ORA) compares a set of genes of interest to a background list to assess if certain functional categories are more prevalent than expected by chance. It applies statistical methods to determine the significance of the enrichment of these functional categories.",
        "Over-Representation Analysis (ORA) works by assessing whether specific functional categories, like pathways or gene sets, are more prevalent in a gene list of interest compared to a background list, using statistical methods to determine significance compared to what would be expected by chance.",
        "Over-Representation Analysis (ORA) is a statistical method used to determine if a set of genes or pathways is significantly represented in a list of differentially expressed or co-expressed genes compared to a reference set. It identifies enrichments by calculating the difference between observed and expected frequencies of specific gene sets, providing insights into underlying biological processes and functions. By addressing challenges such as the \u0027background problem\u0027 and \u0027false discovery rate issue, new approaches incorporating prior biological knowledge and machine learning continue to improve ORA\u0027s accuracy and utility in omics data interpretation."
      ]
    },
    {
      "answerReady": true,
      "body": "What is VANCOUVER syndrome.",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 704,
          "text": "d Neurogenic Cough Occurring due to Unilateral Vascular Encroachment of its Root (VANCOUVER syndrome) and present the salient features of this condition.METHODS: A case review is presented with d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31786948"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 1010,
          "text": " Compression of the sensory component will cause a neurogenic cough called VANCOUVER syndrome - an acronym for Vagus Associated Neurogenic Cough Occurring due to Unilateral Vascular Compression of its Root. Both are caused by direct compression of the root of the tenth cranial nerve at the brainstem by a blood vessel and can be cured by microvascular decompression (MVD). Since the symptoms of choking and cough are common and blood vessels are often abutting the vagus nerve at the brainstem, it is vital",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39911745"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-01-22T10:24:39.738Z",
        "round": 9
      },
      "id": "677e8136592fa48873000019",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "Which tools are used to predict mortality in paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1910,
          "offsetInEndSection": 2079,
          "text": "PDW≥14.1% at admission increases the risk of mortality by 5.7 times.Conclusion: Admission PDW is a fast and specific tool to predict the outcome of children with sepsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39205818"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-01-17T18:10:33.471Z",
        "round": 5
      },
      "id": "658447ca06a2ea257c000001",
      "ideal_answer": [],
      "exact_answer": [
        [
          "lactate",
          "plasma lactate",
          "lactate levels"
        ],
        [
          "Pediatric Risk of Mortality (PRISM) III score",
          "PRISM III"
        ],
        [
          "pediatric Sequential Organ Failure Assessment (pSOFA) score",
          "pSOFA"
        ],
        [
          "machine learning models such as Random Forest (RF)"
        ],
        [
          "Interleukin-8"
        ],
        [
          "PIM-3"
        ],
        [
          "Vascular Reactivity Index (VRI)",
          "VRI"
        ],
        [
          "high-sensitivity C-reactive protein (hs-CRP)",
          "hs-CRP"
        ],
        [
          "procalcitonin (PCT)",
          "PCT"
        ],
        [
          "PD-1 expression",
          ""
        ],
        [
          "T regulatory cells",
          "Tregs"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Is IL-17 signaling pathway related to sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1451,
          "offsetInEndSection": 1895,
          "text": "Moreover, the release of IL-1β and IL-18 and the levels of the molecules (NLRP3, NLRC4, Cleaved caspase-1, and Cleaved GSDMD) associated with caspase-1-dependent pyroptosis were up-regulated in pneumonia-induced sepsis.CONCLUSIONS: As NK-κB activation can promote the development of caspase-1-dependent pyroptosis, these findings suggested that the activation of the IL-17 signaling pathway could promote pyroptosis in pneumonia-induced sepsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32617294"
        }
      ],
      "type": "yesno",
      "id": "677eab2c592fa48873000022",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What disease is associated with chalk-stick fracture?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Spontaneous Chalk-Stick Fracture in Ankylosing Spondylitis: A Case Repor",
          "beginSection": "title",
          "endSection": "title",
          "document": "36531425"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 498,
          "text": "We present a 61-year-old man with long-standing AS who presented with anterior and posterior longitudinal ligament rupture and T12 and L1 vertebral endplates fractures (a so called \"chalk-stick fracture\") without reporting any prior trauma and discuss relevant issue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36531425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Concurrently Occurring Spinal Cord Cross-Section and Aortic Injury After a Chalk-Stick Fracture and Dislocation in Patient with Ankylosing Spondylitis: Clinical Image",
          "beginSection": "title",
          "endSection": "title",
          "document": "38278209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "BACKGROUND: Patients with ankylosing spondylitis (AS) are especially prone to sustaining spinal fractures. A 72-year-old male with AS had a previous T10/11 chalkstick fracture requiring a T8-L1 fusion 1 year ago. He subsequently presented with a newly diagnosed acute chalkstick fracture of L1 which was treated wit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34992906"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2023-01-19T03:27:29.554Z",
        "round": 1
      },
      "id": "63adcb54c6c7d4d31b00001f",
      "ideal_answer": [],
      "exact_answer": [
        [
          "ankylosing spondylitis"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Which four genes account to the majority of the familial ALS cases?",
      "documents": [
        "37904275",
        "31822699",
        "33414559",
        "32471232",
        "34404558"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 553,
          "offsetInEndSection": 646,
          "text": "Preliminary screening for the four main ALS genes (SOD1, C9ORF72, TARDBP, FUS) was conducted.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37904275"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "SMN complex member Gemin3 self-interacts and has a functional relationship with ALS-linked proteins TDP-43, FUS and Sod1.",
          "beginSection": "title",
          "endSection": "title",
          "document": "31822699"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 464,
          "text": "Screening of four main genes (C9orf72, SOD1, TARDBP and FUS) identified the causes in 15% of Amyotrophic Lateral Sclerosis (ALS) patients (two third of the familial cases and 8% of the sporadic ones) but their respective contribution to ALS phenotype varies according the age of disease onse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33810837"
        },
        {
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1108,
          "text": "Interestingly, the Maltese ALS patient cohort was found to be negative for deleterious variants in C9orf72, SOD1, TARDBP or FUS genes, which are the most commonly mutated ALS genes globall",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33414559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1026,
          "text": "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the death of motor neurons in the spinal cord and brainstem. ALS has a diverse genetic origin; at least 20 genes have been shown to be related to ALS. Most familial and sporadic cases of ALS are caused by variants of the SOD1, C9orf72, FUS, and TARDBP genes. Genome editing using clustered regularly interspaced short palindromic repeats/CRISPR-associated system 9 (CRISPR/Cas9) can provide insights into the underlying genetics and pathophysiology of ALS. By correcting common mutations associated with ALS in animal models and patient-derived induced pluripotent stem cells (iPSCs), CRISPR/Cas9 has been used to verify the effects of ALS-associated mutations and observe phenotype differences between patient-derived and gene-corrected iPSCs. This technology has also been used to create mutations to investigate the pathophysiology of ALS. Here, we review recent studies that have used CRISPR/Cas9 to understand the genetic underpinnings of ALS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32471232"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Recent studies have identified SOD1, FUS, TARDBP and C9orf72 as major ALS-related genes in both European and Asian population",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34404558"
        },
        {
          "offsetInBeginSection": 395,
          "offsetInEndSection": 529,
          "text": "Specifically, we summarize current literature of the major genes underlying ALS, SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72 and PFN",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24369373"
        },
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 943,
          "text": "Because of these findings and the urgent need to find a cure for ALS, many trials have focused on familial ALS targeting the four most important genes linked to the disease: C9orf72, SOD1, TARDBP and FU",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36336493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Due to novel gene therapy opportunities, genetic screening is no longer restricted to familial cases of ALS (FALS) cases but also aplies to the sporadic populations (SALS). Screening of four main genes (C9orf72, SOD1, TARDBP and FUS) identified the causes in 15% of Amyotrophic Lateral Sclerosis (ALS) patients (two third of the familial cases and 8% of the sporadic ones) but their respective contribution to ALS phenotype varies according the age of disease onset. The genetic overlap between ALS and othe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33810837"
        },
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 1018,
          "text": " indistinguishable forms of ALS occur as sporadic disease in the absence of known mutation, or can be initiated by genetic mutations. About two-third of familial cases are triggered by mutations of four genes that are chromosome 9 open reading frame 72 (C9ORF72), Cu/Zn superoxide dismutase (SOD1), fused in sarcoma/translocated in liposarcoma (FUS/TLS), TAR-DNA binding protein 43 (TDP43). There is at present no succesfull treatment against ALS and the identification of novel signalling pathways, molecular",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "25613506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "Mutations in C9ORF72, SOD1, TARDBP, and FUS genes account for approximately two-third of familial cases and 5% of sporadic amyotrophic lateral sclerosis (ALS) cases. We present the first case of an ALS patient carrying a de novo nonsense mutation in exon 14 of the FUS gene (c.1483c\u003et; p.R495X) with an apparently familial ALS. This mutation causes a phenotype characterized by a young age at onset, a rapid course (\u003c24 months), and a bulbar onset with early respiratory involvement with a predominant lowe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24439481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Although the pathophysiology of amyotrophic lateral sclerosis remains currently unknown, involvement of genetic factors is worldwide accepted as a key clue in the motor neuron death. Since 1993 and the discovery of mutation in the SOD1 gene, number of genes linked to or promoting ALS had always growing. Among them, only four (SOD1, TARDBP, FUS and C9ORF72 genes) are unanimously recognized as convincing causative genetic factors for more than 60% of familial and probably 10% of sporadic ALS cases. Geographi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24703222"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-01-22T10:32:43.826Z",
        "round": 9
      },
      "id": "677e821c592fa4887300001c",
      "ideal_answer": [],
      "exact_answer": [
        [
          "SOD1"
        ],
        [
          "FUS"
        ],
        [
          "TARDBP"
        ],
        [
          "C9orf72"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Can transcriptomic profiling differentiate between gram-positive and gram-negative sepsis in preterm infants?",
      "documents": [],
      "snippets": [],
      "type": "yesno",
      "id": "677ec8eb592fa48873000024",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": false,
      "body": "Is CYSTM1 gene associated with paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1554,
          "offsetInEndSection": 1793,
          "text": "As pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic efficacy in the validation set.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        },
        {
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 2027,
          "text": "all, after overlapping key module genes and DEGs, we detected 402 overlapping genes. As pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic efficacy in the validation set. As indicated by the immune cell infiltration analysis, multiple immune cells may be involved in the development of pediatric sepsis. Additionally, all diagnostic characteristics may correlate with immune cells to varying degrees.CONC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        }
      ],
      "type": "yesno",
      "id": "677edaa2592fa48873000030",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": false,
      "body": "Is PIK3CA gene related to neonatal sepsis?",
      "documents": [],
      "snippets": [],
      "type": "yesno",
      "id": "677eca7a592fa48873000025",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "Success of T-cell receptor (TCR) therapy in lung cancer in women.",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-20T14:25:04.766Z",
        "round": 11
      },
      "id": "6777c29b592fa48873000017",
      "ideal_answer": [
        "T-cell receptor (TCR) therapy has shown promising potential in treating lung cancer in women, particularly by targeting antigens such as MAGE-A4, which is expressed in lung cancer. While promising, the success is variable and further preclinical and clinical studies are necessary to establish its overall efficacy and safety.",
        "While there is a dearth of specific data on the success of T-cell receptor (TCR) therapy in lung cancer in women, related research suggests that females may exhibit enhanced immune responses to treatments like immune checkpoint inhibitors, implying a potential advantage in TCR therapy. However, definitive conclusions await dedicated studies examining TCR therapy in lung cancer patients stratified by sex, taking into account factors influencing TCR diversity and functionality, such as hormonal influences and genetic predispositions."
      ]
    },
    {
      "answerReady": false,
      "body": "Is it feasible to use ultra-rapid exome sequencing in order to test critically ill infants and children with suspected monogenic conditions?",
      "documents": [],
      "snippets": [],
      "type": "yesno",
      "id": "677ed9ba592fa4887300002d",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What is the mechanism of action of Prasinezumab?",
      "documents": [
        "39971932"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 437,
          "text": "\u0027s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson\u0027s disease.METHODS: In this phase 2 trial, we randomly assigned participants with early-stage Parkinson\u0027s disease in a 1:1:1 ratio to receive intravenous placebo or prasinezumab at a dose of 1500 mg or 4500 mg every ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 223,
          "text": "s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson\u0027s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38622249"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 458,
          "text": "The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson\u0027s disease.METHODS: In this phase 2 trial, we randomly assigned participants with early-stage Parkinson\u0027s disease in a 1:1:1 ratio to receive intravenous placebo or prasinezumab at a dose of 1500 mg or 4500 mg every 4 weeks for 52 weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 800,
          "text": "BACKGROUND: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson\u0027s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson\u0027s disease.METHODS: In this phase 2 trial, we randomly assigned participants with early-stage Parkinson\u0027s disease in a 1:1:1 ratio to receive intravenous placebo or prasinezumab at a dose of 1500 mg or 4500 mg every 4 weeks for 52 weeks. The primary end point was the change from baseline to week 52 in the sum of scores on parts I, II, and III of the Movement Disorder Society-sponsored revision of the Unified Parkinson\u0027s Disease Rating Scale (MDS-UPDRS; range, 0 to 236, with higher scores indicating greater impairment). Secondary end points included the dopamine transporter",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 220,
          "text": "\u0027s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinso",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 232,
          "text": "Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson\u0027s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 221,
          "text": "s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35921451"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "A post hoc subgroup analysis has suggested potential therapeutic benefits of prasinezumab, a humanized monoclonal anti-α-synuclein antibody, in patients with rapidly progressing Parkinson\u0027s disease (PD), despite initial trials showing limited impact on primary outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39971932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson\u0027s diseas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38622249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "A post hoc subgroup analysis has suggested potential therapeutic benefits of prasinezumab, a humanized monoclonal anti-α-synuclein antibody, in patients with rapidly progressing Parkinson\u0027s disease (PD), despite initial trials showing limited impact on primary outcome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39971932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "A post hoc subgroup analysis has suggested potential therapeutic benefits of prasinezumab, a humanized monoclonal anti-α-synuclein antibody, in patients with rapidly progressing Parkinson\u0027s disease (PD), despite initial trials showing limited impact on primary outcomes. Caution is needed due to the retrospective nature of subgroup analyses, and potential confounding factors that may have influenced the observed treatment effects in specific patient subsets. Critical considerations are provided here fo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39971932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 500,
          "text": "Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson\u0027s disease. Although in the PASADENA phase 2 study, the primary endpoint (Movement Disorder Society Unified Parkinson\u0027s Disease Rating Scale (MDS-UPDRS) sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III). We report here a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38622249"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2023-01-19T03:23:53.808Z",
        "round": 1
      },
      "id": "63adca61c6c7d4d31b00001c",
      "ideal_answer": []
    },
    {
      "answerReady": true,
      "body": "Please list the symptoms that differentiate mucopolysaccharidosis-plus syndrome (MPSPS) from mucopolysaccharidosis.",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Several years ago, dozens of cases were described in patients with symptoms very similar to mucopolysaccharidosis (MPS). This new disease entity was described as mucopolysaccharidosis-plus syndrome (MPSPS). The name of the disease indicates that in addition to the typical symptoms of conventional MPS, patients develop other features such as congenital heart defects and kidney and hematopoietic system disorders. The symptoms are highly advanced, and patients usually do not survive past the second year o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39273517"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-05T13:02:39.895Z",
        "round": 10
      },
      "id": "6772c17f592fa48873000004",
      "ideal_answer": [
        "Mucopolysaccharidosis-plus syndrome (MPSPS) differs from typical mucopolysaccharidosis (MPS) because patients exhibit additional symptoms such as congenital heart defects, renal disorders, and hematopoietic system disorders. These symptoms are not ordinarily found in classical MPS cases, making them distinctive for MPSPS.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is differentiated from typical mucopolysaccharidosis by symptoms such as hyperactivity, aggressiveness, delayed development, and progressive mental deterioration, which may not be as prominent in the general mucopolysaccharidosis spectrum.",
        "Studies suggest that mucopolysaccharidosis-plus syndrome (MPSPS) is differentiated from conventional mucopolysaccharidosis by its additional symptoms, including congenital heart defects, renal abnormalities such as high urinary excretion of protein and impairments in renal filtration, and hematopoietic system disorders characterized by progressive anemia, thrombocytopenia, and hypoplastic bone marrow.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) differs from mucopolysaccharidosis because it includes additional symptoms such as congenital heart defects, renal disorders, and hematopoietic system disorders. These are not typically present in standard forms of mucopolysaccharidosis.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is distinguished from conventional mucopolysaccharidosis by additional features such as congenital heart defects, renal disorders, and hematopoietic system disorders. This includes symptoms like progressive anemia, thrombocytopenia, and secondary hemophagocytic lymphohistiocytosis (HLH).",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is a rare lysosomal storage disorder caused by a mutation in the VPS33A gene. Unlike conventional mucopolysaccharidosis (MPS), MPSPS presents with additional symptoms including renal dysfunction (high urinary protein excretion, hypoalbuminemia, and glomerular damage), hematopoietic abnormalities (progressive anemia, thrombocytopenia, and hypoplastic bone marrow), and congenital heart defects. Patients with MPSPS do not exhibit the typical lysosomal enzyme deficiencies seen in MPS, despite glycosaminoglycan (GAG) accumulation. The disease has a severe and rapidly progressive course, often leading to early mortality, and is currently managed through symptomatic treatment rather than curative therapies.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) differs from classic mucopolysaccharidosis by exhibiting additional symptoms such as congenital heart defects, renal dysfunction, and hematopoietic system disorders. These additional symptoms are termed the \u0027plus\u0027 symptoms and are not usually present in conventional MPS cases.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) differentiates from classical mucopolysaccharidosis by featuring symptoms such as congenital heart defects, renal disorders, and hematopoietic system disorders. Additionally, MPSPS can be associated with severe cases of secondary hemophagocytic lymphohistiocytosis (HLH), which is not typical in classical mucopolysaccharidosis.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) differs from conventional mucopolysaccharidosis due to the presence of additional symptoms like congenital heart defects, renal and hematopoietic system disorders, progressive anemia, thrombocytopenia, high urinary protein excretion, and hypoalbuminemia.",
        "Symptoms that differentiate mucopolysaccharidosis-plus syndrome (MPSPS) from mucopolysaccharidosis include congenital heart defects, renal disorders, hematopoietic system disorders, excessive glycosaminoglycan excretion in the urine, high levels of heparan sulfate in the plasma, and a more aggressive disease course with poor prognosis, often not surviving past the second year of life."
      ],
      "exact_answer": [
        [
          "hematopoietic system disorders",
          "renal disorders",
          "ongenital heart defects",
          "progressive mental deterioration",
          "aggressiveness",
          "delayed development",
          "secondary hemophagocytic lymphohistiocytosis (HLH)",
          "Hematopoietic abnormalities: progressive anemia, thrombocytopenia, hypoplastic bone marrow",
          "Renal dysfunction: high urinary protein excretion, hypoalbuminemia, glomerular damage",
          "progressive anemia",
          "thrombocytopenia",
          "secondary hemophagocytic lymphohistiocytosis (HLH)"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Is morphomics associated with the study of body image or body dysmorphia?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1496,
          "offsetInEndSection": 1741,
          "text": "Only visceral fat area retained its predictive ability in patients with a BMI \u003e 30 kg/m(2).CONCLUSIONS: Morphomic measurements correlate with the likelihood of developing postoperative donor site dehiscence after DIEP flap breast reconstruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24911410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Body composition analysis, also referred to as analytic morphomics, morphomics, or morphometry, describes the measurement of imaging biomarkers of body composition such as muscle and adipose tissue, most commonly on computed tomography (CT) image",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31268959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "BACKGROUND: Analytic morphomics, or more simply, \"morphomics,\" refers to the measurement of specific biomarkers of body composition from medical imaging, most commonly computed tomograph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30744586"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 247,
          "text": "imitations. Analytic morphomics, a novel process to measure body composition using computational image-processing algorithms, may offer further prognosti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "27228403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 505,
          "text": "INTRODUCTION: The term \u0027morphomics\u0027 stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review statistical approaches used to evaluate these markers and suggest practical statistical recommendations. Area covered: We identified statistical methods used recently to take into accoun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28277100"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 403,
          "text": "BACKGROUND: Morphomics are three-dimensional measurements of aspects of the human anatomy generated by computed tomographic (CT) imaging. The purpose of this study was to generate preliminary data on the efficacy of morphomics, as a potential risk stratification tool, in predicting abdominal donor site wound-healing complications in patients undergoing abdominal perforator flap breast reconstruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24911410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "BACKGROUND: Analytic morphomics, or more simply, \"morphomics,\" refers to the measurement of specific biomarkers of body composition from medical imaging, most commonly computed tomography (CT) images. An emerging body of literature supports the use of morphomic markers measured on single-slice CT images for risk prediction in a range of clinical populations. However, uptake by healthcare providers been limited due to the lack of clinician-friendly software to facilitate measurements. The objectives of th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30744586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 508,
          "text": "Analytic morphomics refers to the accurate measurement of specific biological markers of human body composition in diagnostic medical imaging. The increasing prevalence of disease processes that alter body composition including obesity, cachexia, and sarcopenia has generated interest in specific targeted measurement of these metrics to possibly prevent or reduce negative health outcomes. Typical morphomic measurements include the area and density of muscle, bone, vascular calcification, visceral fat, an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38624049"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "Body composition analysis, also referred to as analytic morphomics, morphomics, or morphometry, describes the measurement of imaging biomarkers of body composition such as muscle and adipose tissue, most commonly on computed tomography (CT) images. A growing body of literature supports the use of such metrics derived from routinely acquired CT images for risk prediction in various patient populations, including those with lung cancer. Metrics include cross-sectional area and attenuation of skeletal muscl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31268959"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-02-06T00:22:29.975Z",
        "round": 10
      },
      "id": "6772c615592fa48873000007",
      "ideal_answer": [
        "Morphomics is not associated with the study of body image or body dysmorphia. Instead, it is focused on analyzing body composition, specifically through medical imaging techniques like CT scans, to assess and predict health outcomes related to body fat and muscle content.",
        "No, morphomics is not associated with the study of body image or body dysmorphia. It involves analyzing 3D medical imaging data to assess anatomical features, often for predicting health outcomes or assessing risk in medical situations.",
        "Morphomics involves the study and analysis of body composition through medical imaging techniques, primarily focusing on biological markers in muscle and adipose tissues. It does not concern itself with psychological aspects such as body image or body dysmorphia.",
        "Morphomics is not associated with the study of body image or body dysmorphia. It involves the analysis of body composition using imaging techniques to assess muscle and fat tissues, primarily for diagnosing health conditions and predicting medical outcomes, not for studying body image issues.",
        "Morphomics is not directly associated with the study of body image or body dysmorphia. It involves the analysis of body composition through medical imaging to assess biomarkers related to muscle and adipose tissues, primarily for medical diagnostic and prognostic purposes.",
        "No, morphomics is related to the measurement and analysis of body composition through biomarkers, not the psychological study of body image or body dysmorphia.",
        "Morphomics is not primarily associated with the study of body image or body dysmorphia. Its main focus lies in the analytical measurement of body composition and anatomical features through medical imaging, although it might incidentally intersect with conditions affecting body perception like muscle dysmorphia.",
        "While morphomics may incidentally intersect with the study of body image or body dysmorphia, primarily through its application in assessing individuals with body dysmorphic disorders, its main focus lies in the objective measurement of body composition using medical imaging techniques, making it distinct from the subjective realm of body perception and image disturbances."
      ],
      "exact_answer": "no"
    },
    {
      "answerReady": true,
      "body": "Most common physical signs of self-harm in pre-teenagers.",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "BACKGROUND: Nonsuicidal self-harm includes cutting, scratching, burning and minor overdosing. There have been few studies that have examined the rate of self-harm and mental-health correlates among community-based youth. We performed a population-based study to determine the prevalence of nonsuicidal self-harm, its mental-health correlates and help-seeki",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "18227450"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-06T18:36:42.639Z",
        "round": 10
      },
      "id": "6777b5e1592fa4887300000d",
      "ideal_answer": [
        "Studies indicate that among adolescent girls, cutting is the most common method of self-harm, with 76% also reporting skin tearing, and 72% scratching/pinching. In contrast, boys tend to exhibit different methods, including wound-healing hindrance (85%) and striking objects (80%), but also report high rates of cutting.",
        "The most common physical signs of self-harm in pre-teenagers are cutting, burning, scratching, carving, skin tearing, and pinching. These actions are typically non-suicidal, repetitive, and may be linked with mental health challenges such as depression or dissociation.",
        "The most common physical signs of self-harm in pre-teenagers include cutting, scratching, burning, and carving. These behaviors typically occur without suicidal intent and are often used as a coping mechanism to manage emotional distress."
      ],
      "exact_answer": [
        [
          "cutting",
          "scratching",
          "burning"
        ],
        [
          "scratching/pinching",
          "wound-healing hindrance"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Are there new European Union formal efforts to increase the number of clinical trials aimed at improving the mental health of children?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 907,
          "text": "The aim of this multi-site randomised controlled trial is to determine the clinical and cost-effectiveness of adding a modular psychological intervention to usual care for the mental health disorders in comparison to assessment-enhanced usual care alone.METHODS: In total, 334 participants aged 3-18 years attending epilepsy services will be screened for mental health disorders with the Strengths and Difficulties Questionnaire (SDQ) and the diagnostic Development and Wellbeing Assessment (DAWBA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33573674"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 1410,
          "text": "This Randomized Controlled Trial (RCT) was conducted in eleven European countries, with Sweden as the coordinating centre, and was designed to identify an effective way to promote mental health and reduce suicidality and risk taking behaviours among adolescents.OBJECTIVE: To describe the methodological and field procedures in the SEYLE RCT among adolescents, as well as to present the main characteristics of the recruited sample.METHODS: Analyses were conducted to determine: 1) representativeness of study sites compared to respective national data; 2) response rate of schools and pupils, drop-out rates from baseline to 3 and 12 month follow-up, 3) comparability of samples among the four Intervention Arms; 4) properties of the standard scales employed: Beck Depression Inventory, Second Edition (BDI-II), Zung Self-Rating Anxiety Scale (Z-SAS), Strengths and Difficulties Questionnaire (SDQ), World Health Organization Well-Being Scale (WHO-5).RESULTS: Participants at baseline comprised 12,395 adolescents (M/F: 5,529/6,799; mean age\u003d14.9±0.9) from Austria, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Romania, Slovenia and Spain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "23679917"
        },
        {
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1396,
          "text": "This is the protocol of a multi-centre, open label, blind-rated, randomised controlled effectiveness trial of clozapine vs TAU (any other oral antipsychotic monotherapy licenced in the British National Formulary) for 12 weeks in 260 children and young people with TRS (12-24 years old).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38355533"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2024-03-04T12:58:35.049Z",
        "round": 8
      },
      "id": "6593debd06a2ea257c00001f",
      "ideal_answer": [
        "No, the snippets do not provide evidence of new formal efforts by the European Union to increase the number of clinical trials specifically aimed at improving the mental health of children. The snippets describe a focused trial on refugee families, which involves a mental health intervention, but it does not mention a broader EU initiative targeting children\u0027s mental health.",
        "No, there are no explicit mentions of new European Union formal efforts specifically aimed at increasing clinical trials for improving the mental health of children in the provided snippets. The snippets discuss initiatives like Improve-MH focused on mental health interventions for refugee families, but they do not indicate an EU-wide formal effort targeting children\u0027s mental health clinical trials exclusively.",
        "No, there are no specific new formal efforts by the European Union mentioned in the snippets to increase the number of clinical trials focused on improving children\u0027s mental health. The snippets discuss various studies and research efforts, but none indicate a new EU initiative targeting children\u0027s mental health clinical trials specifically.",
        "No, there are no new formal efforts by the European Union specifically aimed at increasing the number of clinical trials to improve the mental health of children according to the provided information.",
        "There is limited evidence suggesting any recent or ongoing European Union formal efforts specifically targeting an increase in clinical trials focused on enhancing the mental health of children. While the provided abstracts cover various aspects of child development, such as the impact of nutritional status, minimal brain dysfunction, and early trauma on cognitive and emotional outcomes, none directly mention EU initiatives for increasing clinical trials in pediatric mental health. Research and interventions discussed pertain to specific developmental challenges like language delays, hyperactivity, and post-traumatic stress, often focusing on educational or therapeutic approaches rather than large-scale clinical trial programs driven by EU policy. Therefore, it appears that no significant EU-driven push towards expanding clinical trials in this domain has been highlighted in the given sources.",
        "Based on the provided articles, there is no explicit mention of new formal efforts by the European Union specifically aimed at increasing the number of clinical trials for improving the mental health of children. However, Article 2 discusses the unmet needs and opportunities in psychopharmacological treatments for children and adolescents, highlighting the involvement of the European Medicines Agency and the European College of Neuropsychopharmacology-Child and Adolescent Network. This suggests ongoing discussions and potential interest in addressing mental health issues in this demographic, but it does not confirm any formal EU initiatives specifically targeting an increase in clinical trials for children\u0027s mental health."
      ],
      "exact_answer": "no"
    },
    {
      "answerReady": true,
      "body": "DNX-2401 Virus was tested for which tumors?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "PURPOSE: Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain of patients with recurrent glioblastoma.PATIENTS AND METHODS: Dose-escalation phase I study with 3+3 cohorts, dosing 107 to 1 × 1011 viral particles (vp) in 20 patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35176144"
        },
        {
          "offsetInBeginSection": 508,
          "offsetInEndSection": 1016,
          "text": " Clinical trials evaluating intratumoral DNX-2401 in adults with recurrent glioblastoma have demonstrated that the virus has a favorable safety profile and can prolong survival. Subsequently, these results have encouraged the transition of this biologically active therapy from adults into the pediatric population. To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "29594041"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2023-01-19T03:26:38.126Z",
        "round": 1
      },
      "id": "63adcaefc6c7d4d31b00001e",
      "ideal_answer": [],
      "exact_answer": [
        [
          "Diffuse Intrinsic Pontine Glioma"
        ],
        [
          "Glioma"
        ],
        [
          "Glioblastoma"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Is trofinetide effective for the Rett Syndrome?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 450,
          "text": "INTRODUCTION: Trofinetide was recently approved for the treatment of Rett syndrome (RTT) on the basis of the efficacy and safety findings of the phase 3 LAVENDER study, which used a body weight-based dosing regimen. Exposure-response (E-R) efficacy modeling was used to characterize relationships between trofinetide exposure measures (maximum drug concentration and area under the concentration-time curve for the dosing interval of 0-12 h [AUC0-12]",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38363467"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 459,
          "text": "Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37191913"
        },
        {
          "offsetInBeginSection": 407,
          "offsetInEndSection": 601,
          "text": "Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration for the treatment of RTT in adult and pediatric patients aged 2 years and older.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38318312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "BACKGROUND: Trofinetide was approved for the treatment of Rett syndrome (RTT) in patients aged ≥2 years based on the results of the 12-week, randomized, phase 3 LAVENDER study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39025065"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38035006"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "INTRODUCTION: Oral trofinetide administered using a body weight-banded dosing regimen was approved in the US for the treatment of Rett syndrome (RTT) in patients aged ≥ 2 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39692836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38035006"
        },
        {
          "offsetInBeginSection": 1209,
          "offsetInEndSection": 1412,
          "text": "Significant improvement for trofinetide compared with placebo was observed for the coprimary efficacy endpoints, suggesting that trofinetide provides benefit in treating the core symptoms of Rett syndrom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37291210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1872,
          "text": "Rett syndrome (RTT) is a rare disability causing female-oriented pediatric neurodevelopmental unmet medical need. RTT was recognized in 1966. However, over the past 56 years, the United States Food and Drug Administration (USFDA) has authorized no effective treatment for RTT. Recently, Trofinetide was approved by the USFDA on 10 March 2023 as the first RTT treatment. This article underlines the pharmaceutical advancement, patent literature, and prospects of Trofinetide. The data for this study were gathered from the PubMed database, authentic websites (Acadia Pharmaceuticals, Neuren Pharmaceuticals, and USFDA), and free patent databases. Trofinetide was first disclosed by Neuren Pharmaceuticals in 2000 as a methyl group containing analog of the naturally occurring neuroprotective tripeptide called glycine-proline-glutamate (GPE). The joint efforts of Acadia Pharmaceuticals and Neuren Pharmaceuticals have developed Trofinetide. The mechanism of action of Trofinetide is not yet well established. However, it is supposed to improve neuronal morphology and synaptic functioning. The patent literature revealed a handful of inventions related to Trofinetide, providing excellent and unexplored broad research possibilities with Trofinetide. The development of innovative Trofinetide-based molecules, combinations of Trofinetide, patient-compliant drug formulations, and precise MECP2-mutation-related personalized medicines are foreseeable. Trofinetide is in clinical trials for some neurodevelopmental disorders (NDDs), including treating Fragile X syndrome (FXS). It is expected that Trofinetide may be approved for treating FXS in the future. The USFDA-approval of Trofinetide is one of the important milestones for RTT therapy and is the beginning of a new era for the therapy of RTT, FXS, autism spectrum disorder (ASD), brain injury, stroke, and other NDDs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37568516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1617,
          "text": "BACKGROUND: Rett syndrome (RTT) is an uncommon inherited neurodevelopmental disorder that affects brain development, mostly in females. It results from mutation in MECP2 gene in the long arm (q) of the X chromosome.OBJECTIVE: Trofinetide is a recently developed drug that has a neuroprotective effect on neurons, and it is our aim in this meta-analysis to evaluate its efficacy and safety in treating Rett syndrome patients.METHODS: We searched 5 databases (PubMed, Scopus, Embase, Web of Science, and Cochrane Library databases) to identify randomized controlled trials (RCTs) comparing Trofinetide and placebo in patients with Rett syndrome until August 13, 2023.Our primary outcomes were the Clinical Global Impression-Improvement (CGI) and the Rett syndrome Behavior Questionnaire (RSBQ). We used Risk of Bias Assessment tool-2 (ROB2) to assess the methodological quality of the included randomized controlled trials.RESULTS: Three RCTs with a total of 325 patients were included with a follow-up duration ranging from one month to three months. 186 patients received the intervention drug (Trofinetide) and 138 received the placebo. Trofinetide was found to reduce CGI and RSBQ significantly more than placebo (MD \u003d -0.35, 95% CI [-0.52 to -0.18], P 0.0001), (MD \u003d -3.40, 95% CI [-3.69 to -3.12], P 0.00001) respectively. Most adverse events did not show any statistical difference between Trofinetide and the placebo.CONCLUSION: Trofinetide offers promise as a potential effective and safe therapeutic opportunity for a population without many available treatments, with improvements seen on both CGI and RSBQ a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38771525"
        },
        {
          "offsetInBeginSection": 1709,
          "offsetInEndSection": 1883,
          "text": ".30 to 36.84, P ≤ 0.00001).CONCLUSIONS: Trofinetide demonstrated statistically significant improvements in CGI-I and RSBQ in pediatrics and adult patients with Rett. Side eff",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39020317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 3418,
          "text": "INTRODUCTION: Trofinetide was recently approved for the treatment of Rett syndrome (RTT) on the basis of the efficacy and safety findings of the phase 3 LAVENDER study, which used a body weight-based dosing regimen. Exposure-response (E-R) efficacy modeling was used to characterize relationships between trofinetide exposure measures (maximum drug concentration and area under the concentration-time curve for the dosing interval of 0-12 h [AUC0-12]) and efficacy endpoints in RTT clinical studies to support the trofinetide dosing regimen.METHODS: Efficacy endpoints were modeled using trofinetide exposure measures predicted from the population pharmacokinetic model and Bayesian estimates. The analysis population for each E-R model comprised individuals receiving placebo or trofinetide who had available trofinetide exposure measures. Efficacy endpoints were scores from the Rett Syndrome Behaviour Questionnaire (RSBQ), the Clinical Global Impression-Improvement, the Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist (CSBS-DP-IT) Social Composite, and the Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC).RESULTS: Higher trofinetide exposure was associated with improvements in RSBQ, CSBS-DP-IT Social Composite, and RTT-COMC scores. Assuming target trofinetide AUC0-12 values of 800-1200 μg·h/mL, the reductions in RSBQ total scores at week 12 were approximately five- to seven-fold greater with trofinetide (range 3.55-4.94) versus placebo (0.76). Significant E-R relationships were also found for the CSBS-DP-IT Social Composite and RTT-COMC scores.CONCLUSION: E-R efficacy modeling demonstrated significant relationships between trofinetide exposure and RSBQ, CSBS-DP-IT Social Composite, and RTT-COMC scores. Trofinetide is efficacious within the target exposure range, supporting the approved dosing regimen for trofinetide.TRIAL REGISTRATION: NCT01703533, NCT02715115, NCT04181723.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38363467"
        },
        {
          "offsetInBeginSection": 1123,
          "offsetInEndSection": 1395,
          "text": "erated and generally safe. Trofinetide at 200 mg/kg bid showed statistically significant and clinically relevant improvements relative to placebo on the Rett Syndrome Behaviour Questionnaire, RTT-Clinician Domain Specific Concerns-Visual Analog Scale, and Clinical Global ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30918097"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 499,
          "text": "oals for RTT. Trofinetide, the first approved pharmacologic treatment for RTT, confers improvements in RTT symptoms but is associated with adverse GI events, primarily diarrh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38869952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Trofinetide in Rett syndrome: A brief review of safety and efficacy",
          "beginSection": "title",
          "endSection": "title",
          "document": "38024580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 57,
          "text": "Trofinetide treatment for Rett syndrome: Lessons to learn",
          "beginSection": "title",
          "endSection": "title",
          "document": "39395401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials",
          "beginSection": "title",
          "endSection": "title",
          "document": "39020317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy",
          "beginSection": "title",
          "endSection": "title",
          "document": "39525048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome",
          "beginSection": "title",
          "endSection": "title",
          "document": "38232652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials",
          "beginSection": "title",
          "endSection": "title",
          "document": "39824747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Development of trofinetide for the treatment of Rett syndrome: from bench to bedside",
          "beginSection": "title",
          "endSection": "title",
          "document": "38318312"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 367,
          "text": "Recently, Trofinetide was approved by the USFDA on 10 March 2023 as the first RTT treatmen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37568516"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-01-22T10:34:09.472Z",
        "round": 9
      },
      "id": "677e8278592fa4887300001d",
      "ideal_answer": [],
      "exact_answer": "yes"
    },
    {
      "answerReady": true,
      "body": "What is the best non-invasive method to diagnose endometriosis?",
      "documents": [
        "21159047"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1503,
          "offsetInEndSection": 1786,
          "text": "All patients who were operated had histologic findings of endometriotic lesions involving the rectal wall, as indicated by EUS.CONCLUSION: EUS and elastosonography offers a non-invasive and sensitive technique to better define the endometriotic infiltration in the rectosigmoid wall.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "21159047"
        },
        {
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1427,
          "text": "For patients suspected of having deep pelvic endometriosis, transvaginal sonography should be the first line of diagnosis. Endometriosis cysts are better diagnosed with TVS, whereas torus, uterosacral ligaments, intestine, and bladder endometriosis lesions are best diagnosed using MRI. When it comes to detecting intestine or rectal nodules, as well as rectovaginal septum nodules, MRI should be the imaging tool of choic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35885670"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-01-22T11:41:09.123Z",
        "round": 9
      },
      "id": "6777b471592fa4887300000c",
      "ideal_answer": [
        "The best non-invasive method to diagnose endometriosis is transvaginal sonography (TVS). TVS has been shown to have high diagnostic accuracy and reproducibility for detecting deep infiltrating endometriosis (DIE) and endometriomas, and it is well-regarded for its sensitivity and specificity when performed by skilled professionals.",
        "The best non-invasive methods for diagnosing endometriosis include high-resolution ultrasound-based imaging, which enables visualization and tracking of lesion evolution, and MR relaxometry, which has proven effective in distinguishing endometriosis-associated ovarian cancer (EAOC) from ovarian endometriomas (OE). These methods provide valuable insights for clinical practice and treatment evaluation.",
        "Currently, there are no established non-invasive methods to diagnose all subtypes of endometriosis, as clinical assessment, ultrasound, and MRI have not been formally recognized as replacements for surgery in this regard. Imaging techniques such as ultrasound perform well in diagnosing advanced stages (rASRM Stage 3 or 4) but are insufficient for early stages (Stage 1 or 2), where laparoscopy remains necessary. While alternatives like biomarkers, genetic tests, and miRNAs are under exploration, they are not yet established in clinical practice, leaving laparoscopic inspection with histological confirmation as the gold standard for diagnosis.",
        "Based on a study, there is currently no best non-invasive method to diagnose endometriosis in clinical practice. While non-invasive diagnostic methods such as clinical assessment, ultrasound, and magnetic resonance imaging may be appropriate for advanced stages of endometriosis, they are not yet qualified as replacement tests for surgery in diagnosing all subtypes. There are also no established non-invasive methods to diagnose patients with endometriosis. Therefore, there is a need for non-invasive or minimally invasive tests to accurately diagnose the location and extent of endometriotic lesions. Low invasive tests including imaging, genetic tests, biomarkers, or miRNAs could be potential solutions. At present, the only conclusive way to diagnose endometriosis is through laparoscopic inspection with histological confirmation. Noninvasive markers of endometriosis have the potential to enable sooner diagnosis, leading to more timely treatment and better surgical planning, particularly for early-stage endometriosis.",
        "MRI, transvaginal ultrasound with bowel preparation (TVUS-BP), and Raman spectroscopy are among the best non-invasive methods for diagnosing endometriosis. MRI and TVUS-BP provide reliable imaging to detect various forms of endometriosis, while Raman spectroscopy offers a promising diagnostic potential by analyzing blood sera.",
        "The best non-invasive methods to diagnose endometriosis are transvaginal ultrasound (TVUS), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and potentially Raman spectroscopy. These imaging modalities, particularly TVUS and MRI, provide high sensitivity and specificity and are effective alternatives to the invasive laparoscopy procedure. In addition, Raman spectroscopy is emerging as a non-invasive diagnostic technique for endometriosis.",
        "The best non-invasive methods to diagnose endometriosis include transvaginal ultrasound (TVUS), MRI, Raman spectroscopy, and FTIR spectroscopy. TVUS and MRI are particularly good at detecting pelvic endometriosis and deep infiltrating endometriosis with high accuracy, whereas Raman and FTIR spectroscopy show promise as non-invasive diagnostic approaches using blood sera and cervical swabs, respectively.",
        "Several studies have investigated non-invasive methods for diagnosing endometriosis, with varying degrees of success. Transvaginal ultrasonography (TVUS) has been found to be a highly accurate and reproducible method for diagnosing deep endometriosis, with sensitivity and specificity comparable to diagnostic laparoscopy. Additionally, studies have explored the use of biomarkers in plasma samples, such as annexin V, VEGF, CA-125, and sICAM-1/or glycodelin, which have shown promising results in diagnosing endometriosis with high sensitivity and acceptable specificity. Other non-invasive techniques, including MRI, FTIR spectroscopy, and Raman spectroscopy, have also been investigated, with MRI being capable of detecting many manifestations of endometriosis in a reliable manner. Overall, while no single method has emerged as the definitive non-invasive diagnostic tool, TVUS and biomarker analysis appear to be the most promising approaches, offering a balance of accuracy and invasiveness."
      ],
      "exact_answer": [
        [
          "transvaginal ultrasonography",
          "MRI"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Is MMP8 gene associated with paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1527,
          "offsetInEndSection": 1766,
          "text": "ted 402 overlapping genes. As pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic effi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        },
        {
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 2027,
          "text": "all, after overlapping key module genes and DEGs, we detected 402 overlapping genes. As pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic efficacy in the validation set. As indicated by the immune cell infiltration analysis, multiple immune cells may be involved in the development of pediatric sepsis. Additionally, all diagnostic characteristics may correlate with immune cells to varying degrees.CONC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        },
        {
          "offsetInBeginSection": 1556,
          "offsetInEndSection": 1794,
          "text": " pediatric sepsis diagnostic indicators, CYSTM1 (AUC \u003d 0.988), MMP8 (AUC \u003d 0.973), and CD177 (AUC \u003d 0.986) were investigated and demonstrated statistically significant differences (P \u003c 0.05) and diagnostic efficacy in the validation set. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37115484"
        }
      ],
      "type": "yesno",
      "id": "677eda5e592fa4887300002e",
      "ideal_answer": [],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What is the function of a TMEM protein?",
      "documents": [
        "39940865",
        "37293153"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 592,
          "text": "TMEM proteins have been implicated in cancer-related processes, including cell proliferation, migration, epithelial-mesenchymal transition, metastasis, and resistance to chemotherapy and radiotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39940865"
        },
        {
          "offsetInBeginSection": 1751,
          "offsetInEndSection": 2024,
          "text": "Overexpression studies suggested selected TMEMs may take part in carcinogenesis processes such as cell adhesion, regulation of epithelial cell proliferation, and regulation of adaptive immune response, which could indicate a link to the development and progression of ccRCC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37293153"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Transmembrane proteins with unknown function (TMEMs) as ion channels: electrophysiological properties, structure, and pathophysiological roles",
          "beginSection": "title",
          "endSection": "title",
          "document": "38556553"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 215,
          "text": "TMEMs function as cellular membrane gates by modifying their conformation to control the influx and efflux of signals and molecule",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34359920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "A transmembrane protein (TMEM) is a type of protein that spans biological membranes. Many of them extend through the lipid bilayer of the plasma membrane but others are located to the membrane of organelles. The TMEM family gathers proteins of mostly unknown function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30574087"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 386,
          "text": "Recently, several TMEM proteins have been identified as functional ion channels. The structures and functions of these proteins have been extensively studied over the last two decades, starting with TMEM16A (ANO1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38556553"
        },
        {
          "offsetInBeginSection": 1212,
          "offsetInEndSection": 1393,
          "text": "s review highlights the potential for the discovery of novel ion channels within the TMEM protein family and the development of new therapeutic targets for related channelopathies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38556553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 504,
          "text": "Transmembrane proteins (TMEMs) are integral proteins that span biological membranes. TMEMs function as cellular membrane gates by modifying their conformation to control the influx and efflux of signals and molecules. TMEMs also reside in and interact with the membranes of various intracellular organelles. Despite much knowledge about the biological importance of TMEMs, their role in metabolic regulation is poorly understood. This review highlights the role of a single TMEM, transmembrane protein 13",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34359920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Transmembrane proteins (TMEM) are located in the different biological membranes of the cell and have at least one passage through these cellular compartments. TMEM proteins carry out a wide variety of functions necessary to maintain cell homeostasis TMEM165 participates in glycosylation protein, TMEM88 in the development of cardiomyocytes, TMEM45A in epidermal keratinization, and TMEM74 regulating autophagy. However, for many TMEM proteins, their physiological function remains unknown. The role of thes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37936608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "A transmembrane (TMEM) protein with an unknown function is a type of membrane-spanning protein expressed in the plasma membrane or the membranes of intracellular organelles. Recently, several TMEM proteins have been identified as functional ion channels. The structures and functions of these proteins have been extensively studied over the last two decades, starting with TMEM16A (ANO1). In this review, we provide a summary of the electrophysiological properties of known TMEM proteins that function as io",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38556553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 508,
          "text": "Transmembrane protein family members (TMEMs) span the entire lipid bilayer and act as channels that allow the transport of specific substances through biofilms. The functions of most TMEMs are unexplored. Numerous studies have shown that TMEMs are involved in the pathophysiological processes of various nervous system diseases, but the specific mechanisms of TMEMs in the pathogenesis of diseases remain unclear. In this review, we discuss the expression, physiological functions, and molecular mechanisms o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35035675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "Transmembrane (TMEM) proteins are integral membrane proteins that traverse biological membranes. Several members of the TMEM family have been linked to the development and progression of various tumors. However, the specific role and mechanism of TMEM44 in tumor biology remain largely unexplored. In this study, we initially conducted an extensive analysis using the TCGA database to investigate the expression patterns and survival associations of TMEM44 across various human tumors. Subsequently, we focuse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37561335"
        }
      ],
      "type": "factoid",
      "answerReady_on": {
        "date": "2025-02-05T12:57:23.308Z",
        "round": 10
      },
      "id": "6772beef592fa48873000003",
      "ideal_answer": [
        "TMEM proteins mainly act as channels or gates across cellular membranes, enabling the transport of ions and molecules. They play roles in various physiological processes, including acting as ion channels and potentially participating in pathways related to cancer metastasis, angiogenesis, and cardiac regeneration.",
        "TMEM proteins have diverse functions, including helping to assemble ATP synthase and mitochondrial complex I, suppressing cancer metastasis via the Wnt/β-catenin signaling pathway, and being involved in angiogenesis by regulating endothelial cell survival.",
        "TMEM proteins are transmembrane proteins that span cellular membranes and primarily function as channels or gates that control the transport of ions, signals, and other molecules across the membrane. They are involved in various physiological processes including ion transport, signaling, and have been implicated in cancer-related processes such as cell proliferation, migration, and metastasis.",
        "TMEM proteins serve as channels or gates in cellular membranes, allowing the transport of ions, signals, and molecules. They play key roles in various physiological processes, including ion channel activity, cell signaling, and transport functions, and are implicated in cancer-related processes such as cell proliferation and metastasis.",
        "TMEM proteins primarily function as transmembrane proteins that span biological membranes, acting as channels, gates, and mediators of various cellular processes including ion transport, signal transduction, and regulation of physiological functions, with emerging roles in disease states such as cancer, cardiovascular, and kidney diseases.",
        "TMEM proteins are integral membrane proteins that perform a wide array of functions critical for maintaining cell homeostasis, including serving as channels, participating in various biochemical pathways, and playing roles in the development and progression of diseases such as cancer, as well as in normal cellular processes like muscle cell differentiation and lipid metabolism."
      ],
      "exact_answer": [
        [
          "ion channels",
          "membrane gates",
          "transport of molecules",
          "Assembly of ATP synthase",
          "Suppression of cancer metastasis"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "Are cardiovascular diseases more common than cancer in women between 40 and 65 years of age?",
      "documents": [
        "33401236"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1587,
          "offsetInEndSection": 1834,
          "text": "Increased risks of arrhythmia, heart failure, pericarditis, and deep vein thrombosis persisted \u003e5 years after cancer diagnosis.CONCLUSIONS: Women with a history of breast cancer were at increased risk of several CVDs, persisting into survivorship.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "33401236"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-02-20T14:02:49.621Z",
        "round": 11
      },
      "id": "6777bbed592fa48873000011",
      "ideal_answer": [
        "Yes, cardiovascular diseases are more common than cancer in women between 40 and 65 years of age. Cardiovascular disease is a leading cause of death in women, even surpassing cancer, in this age group.",
        "Yes, cardiovascular diseases are more common than cancer in women between 40 and 65 years of age. Cardiovascular disease is a leading cause of death among women and remains a significant risk factor even after a breast cancer diagnosis."
      ],
      "exact_answer": ""
    },
    {
      "answerReady": true,
      "body": "What are the targets of Teclistamab?",
      "documents": [
        "39412823",
        "38245601"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Teclistamab (TECVAYLI®), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36352205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "ABSTRACT: Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38657201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "ABSTRACT: Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myelom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38657201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "ABSTRACT: Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38598713"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 523,
          "text": "We analyzed outcomes for 72 RRMM patients treated with teclistamab, a CD3 × BCMA bispecific antibody, 42% (30/72) of whom had prior BCMA-directed therapy exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38728378"
        },
        {
          "offsetInBeginSection": 1600,
          "offsetInEndSection": 1768,
          "text": "Bispecific antibodies are also emerging in the treatment of myeloma with teclistamab and elranatamab (anti-CD3 and anti-BCMA) or talquetamab (anti-GPRC5D and anti-CD3).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37827964"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 638,
          "text": "Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39676006"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38245601"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 464,
          "text": "Targeting both CD3 receptor complex on T cells and BCMA on myeloma cells, teclistamab leads to T-cell activation and subsequent lysis of BCMA+ cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38266057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "BACKGROUND AND HYPOTHESIS: Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B-cell maturation antigen (BCMA), and chimeric antigen receptor T-cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39805729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "ABSTRACT: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37878808"
        },
        {
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1461,
          "text": "Here, we summarize the data and FDA review supporting the accelerated approval of teclistamab, a B-cell maturation antigen-directed bispecific antibody that was the first bispecific CD3 T-cell engager approved for treatment of multiple myeloma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39412823"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 554,
          "text": "Teclistamab-cqyv is a humanized IgG4 antibody and a bispecific BCMA-director CD3 T-cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37848191"
        },
        {
          "offsetInBeginSection": 916,
          "offsetInEndSection": 1332,
          "text": "Recent advancements also involve monoclonal antibodies targeting surface antigens, such as elotuzumab (anti-CS1) and daratumumab (anti-CD38), bispecific t-cell engagers such as teclistamab (anti-BCMA/CD3) and Chimeric antigen receptor T (CAR-T)-based strategies, with a growing focus on drugs that exhibit increasingly targeted action against neoplastic plasma cells and relevant effects on the tumor microenvironmen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37509726"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 636,
          "text": "Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibod",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39676006"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory mult",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35661166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 509,
          "text": "ABSTRACT: Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). In the phase 1/2 MajesTEC-1 study, a cohort of patients who had prior BCMA-targeted therapy (antibody-drug conjugate [ADC] or chimeric antigen receptor T-cell [CAR-T] therapy) was enrolled to explore teclistamab in patients previously exposed to anti-BCMA treatment. At a median follow-up of 28.0 months (rang",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39172760"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35661166"
        },
        {
          "offsetInBeginSection": 318,
          "offsetInEndSection": 465,
          "text": "argeting both CD3 receptor complex on T cells and BCMA on myeloma cells, teclistamab leads to T-cell activation and subsequent lysis of BCMA+ cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38266057"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 246,
          "text": "ted target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34388396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "BACKGROUND: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma (RRMM) who have previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "37713090"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1842,
          "text": "ABSTRACT: Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P \u003c .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #N",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38052042"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-01-22T10:50:32.197Z",
        "round": 9
      },
      "id": "677e8578592fa48873000021",
      "ideal_answer": [],
      "exact_answer": [
        [
          "CD3"
        ],
        [
          "B-cell maturation antigen"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What are the adverses effect of Rare earth elements (REEs) on the body?",
      "documents": [
        "34987477"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 836,
          "text": "BACKGROUND: Broad-ranging adverse effects are known for rare earth elements (REE), yet only a few studies tested the toxicity of several REE, prompting studies focusing on multi-parameter REE toxicity.METHODS: Trichloride salts of Y, La, Ce, Nd, Sm, Eu and Gd were tested in Paracentrotus lividus sea urchin embryos and sperm for: (1) developmental defects in either REE-exposed larvae or in the offspring of REE-exposed sperm; (2) fertilization success; (3) mitotic anomalies in REE-exposed embryos and in the offspring of REE-exposed sperm, and (4) reactive oxygen species (ROS) formation, and malondialdehyde (MDA) and nitric oxide (NO) levels.RESULTS: REEs affected P. lividus larvae with concentration-related increase in developmental defects, 10(-6) to 10(-4)M, ranking as: Gd(III)\u003eY(III)\u003eLa(III)\u003eNd(III)≅Eu(III)\u003eCe(III)≅Sm(III).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "26970899"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 641,
          "text": "The results show La³+ had significant adverse effects on the growth and reproduction of worms above a concentration of 10 μmol L⁻¹.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "21510015"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1095,
          "text": "Prenatal exposure to rare earth elements (REEs) may contribute to adverse birth outcomes in previous studies. Cord blood vitamin D has been suggested to modify or mediate the effects of environmental exposures. However, none has investigated these roles of cord blood vitamin D in the associations of prenatal exposure to REEs with fetal growth. Maternal trimester-specific urinary concentrations of 13 REEs, cord blood total 25-hydroxyvitamin D at delivery, and birth weight (BW)-for-gestational age (GA) were determined in 710 mother-newborn pairs from Wuhan, China. Higher maternal average urinary concentrations of europium (Eu), gadolinium (Gd), dysprosium (Dy), holmium (Ho), erbium (Er), and ytterbium (Yb) across three trimesters, either individually or jointly, were significantly associated with lower BW-for-GA Z-scores and higher odds of small for gestational age (SGA) [β \u003d -0.092; 95 % confidence interval (CI): -0.149, -0.035 for BW-for-GA Z-scores, and odds ratio \u003d 1.60; 95 % CI: 1.14, 2.24 for SGA involved in each unit increase in weighted quantile sum index of REEs mixture].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38081430"
        },
        {
          "offsetInBeginSection": 450,
          "offsetInEndSection": 843,
          "text": "The comparative toxicities were tested of seven REEs, namely yttrium, lanthanum, cerium, neodymium, samarium, europium and gadolinium as chloride salts at concentrations ranging from 10-7 to 10-4 M. The evaluated endpoints included developmental defects and cytogenetic anomalies in REE-exposed embryos/larvae, and decreased fertilization success and offspring damage following sperm exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28721613"
        },
        {
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1214,
          "text": "Neodymium (Nd), Praseodymium (Pr), and Lanthanum (La) were the most important contributors in the mixture.Conclusion: The study findings indicated that early pregnancy exposure to lower levels of REE mixture was associated with an increased risk of GDM, and Nd, Pr, and La exhibited the strongest effects in the mixture.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34987477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Rare earth elements (REEs) are widely used in the industry, agriculture, biomedicine, aerospace, etc, and have been shown to pose toxic effects on animals, as such, studies focusing on their biomedical properties are gaining wide attention. However, environmental and population health risks of REEs are still not very clear. Also, the REEs damage to the nervous system and related molecular mechanisms needs further research. In this study, the L1 and L4 stages of the model organism Caenorhabditis elegans wer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34718030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "Rare earth elements (REEs) can cause neoplasms, reduce bone density, affect children\u0027s intelligence, etc., and diet is an important way for the human body to absorb REEs. With the increasing use of REEs, the impact on human health is becoming more and more important. So, we used a probabilistic assessment method with Monte Carlo simulation to evaluate the dietary intake of REEs by residents of a large light rare earth mining area in Shandong Province. 16 REEs in 447 samples (including wheat, maize, dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36191706"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Rare earth elements (REEs) can cause neoplasms, reduce bone density, affect children\u0027s intelligence, etc., and diet is an important way for the human body to absorb REE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36191706"
        }
      ],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-05T13:52:28.359Z",
        "round": 10
      },
      "id": "6772e791592fa4887300000b",
      "ideal_answer": [
        "Rare earth elements (REEs) can have several adverse effects on the body, such as causing neoplasms, reducing bone density, and potentially affecting intelligence negatively. They have also been associated with neurotoxicity, neurodevelopmental toxicity, and hepatic alterations. Prenatal exposure to REEs has been linked to adverse birth outcomes and developmental defects.",
        "Rare earth elements (REEs) can cause neoplasms, reduce bone density, affect children\u0027s intelligence, neurotoxicity, neurodevelopmental toxicity, and hepatic alterations. Additionally, chronic exposure to REEs, even at low doses, can lead to a wide range of adverse health effects.",
        "Rare earth elements (REEs) have been associated with various adverse health effects. Studies indicate that REEs can cause neuronal toxicity, leading to behavioral defects and neurodevelopmental issues in children, such as lower mental and psychomotor development scores. Prenatal exposure has been linked to negative birth outcomes, including reduced birth weight and increased risk of small for gestational age babies. Additionally, REEs may induce cardiovascular problems like hypertension and disrupt thyroid function, which is crucial for metabolism and brain development. Oxidative stress and cellular damage are also potential effects, along with severe health issues such as nephrogenic systemic fibrosis, pneumoconiosis, cytotoxicity, anti-testicular effects, and male sterility. These findings highlight the multifaceted risks REEs pose to human health across different systems.",
        "Rare earth elements (REEs) have various adverse effects on the body. They are associated with an increased risk of neoplasms, reduced bone density, and potential neurotoxicity and neurodevelopmental toxicity. Prenatal exposure can lead to adverse birth outcomes, and high intake might increase hypertension risk. REEs can also cause metabolic issues, impact intelligence in children, and result in hepatic alterations. Furthermore, they may affect embryogenesis and contribute to cardiovascular health risks.",
        "Rare earth elements (REEs) can have several adverse effects on the body. They may cause neoplasms, reduce bone density, and affect children\u0027s intelligence. Additionally, high intake of REEs might increase the risk of hypertension, and they can cause neuronal toxic damage. There are also potential impacts on metabolic syndrome and prenatal exposure may lead to adverse birth outcomes.",
        "Rare earth elements (REEs) can have several adverse effects on human health, particularly through occupational and environmental exposure. Key findings include respiratory tract damage from occupational exposure, increased risk of hypertension linked to REE accumulation in hair, and potential neurotoxic effects observed in animal studies. REEs have been associated with neoplasms, reduced bone density, and impaired immune function, particularly in children. Studies indicate that high levels of REEs can disrupt calcium metabolism, leading to various health issues. Additionally, proteomic analyses suggest that REE exposure may result in pathological changes, including neurovirulence and hepatotoxicity. Overall, while some studies indicate no immediate health risks at low exposure levels, the long-term effects and bioaccumulation of REEs warrant further investigation.",
        "Rare earth elements (REEs) can cause a wide range of adverse effects on the body, including neurotoxicity, neurodevelopmental toxicity, reduced bone density, behavioral defects, and potential increase in risk for conditions like hypertension and neoplasms. They can affect children\u0027s intelligence and are associated with adverse birth outcomes. Prenatal exposure to REEs may contribute to lower birth weight for gestational age and increased risk for small for gestational age (SGA) infants.",
        "Rare earth elements (REEs) can have adverse effects on the body, including increased risk of hypertension, neurotoxic damage, and behavioral defects. Prenatal exposure to REEs is associated with adverse birth outcomes, like lower birth weight and increased risk of small for gestational age infants and premature rupture of membranes. Furthermore, REEs have been linked to developmental defects and reproductive issues.",
        "Adverse effects of rare earth elements (REEs) on the body include increased risk of hypertension, neurotoxic damage, developmental defects, mitotic anomalies, and adverse birth outcomes such as small for gestational age (SGA). Additional effects include potential cardiovascular issues and cytogenetic toxicity, as REEs can accumulate in the body and affect embryogenesis and fertility.",
        "The adverse effects of rare earth elements (REEs) on the body can include hypertension, neurotoxic damage, adverse birth outcomes, increased risk of metabolic syndrome, and negative cardiovascular impacts.",
        "The adverse effects of rare earth elements (REEs) on the body include potential lung, skin, and eye irritations, increased risks of hypertension, neurotoxic damage, adverse birth outcomes, and potential cardiovascular impacts. High levels can lead to bioaccumulation, metabolic disruptions, and impacts on the nervous and circulatory systems, contributing to broader systemic health risks.",
        "Rare earth elements (REEs) have been shown to cause a broad spectrum of adverse health effects, including neoplasms, reduction in bone density, neurotoxicity, reproductive issues, and nephrological damage. These toxic effects are particularly pronounced following prolonged exposure, highlighting the need for cautious handling and regulation of REEs in various industries and applications.",
        "The adverse effects of rare earth elements (REEs) on the body are multifaceted. Studies have shown that exposure to REEs can lead to neurotoxic damage, such as neuronal toxicity and behavioral defects in model organisms like C. elegans. Prenatal exposure has been associated with adverse birth outcomes, including lower birth weight and an increased risk of small for gestational age babies, potentially mediated by disruptions in cord blood vitamin D levels. REEs can also impair fetal neurodevelopment, affecting mental and psychomotor development in children. Additionally, these elements may disrupt maternal thyroid function, leading to hormonal imbalances. Other significant health risks include nephrogenic systemic fibrosis from gadolinium-based agents, oxidative stress, pneumoconiosis, cytotoxicity, anti-testicular effects causing male sterility, reduced bone density, and increased risk of neoplasms. Overall, REEs pose a range of systemic health risks affecting neurological, developmental, cardiovascular, endocrine, renal, and reproductive systems.",
        "Rare earth elements (REEs) have been found to induce neoplasms, decrease bone density, impair cognitive functions, especially in children, and cause neurobehavioral abnormalities. They are also associated with severe kidney damage, nephrogenic systemic fibrosis, dysfunctional neurological disorders, fibrotic tissue injuries, oxidative stress, pneumoconiosis, cytotoxicity, anti-testicular effects, and male sterility. Moreover, prenatal exposure to REEs has been linked to adverse birth outcomes, including lower birth weights and altered fetal growth, potentially mediated by cord blood vitamin D levels.",
        "Studies have shown that rare earth elements (REEs) can have adverse effects on the body, including increased risk of hypertension, neuronal toxic damage, and behavioral defects. Prenatal exposure to REEs has been linked to adverse birth outcomes, such as lower birth weight and smaller size for gestational age. Additionally, REEs have been found to affect children\u0027s neurodevelopment, with higher concentrations of certain REEs during pregnancy associated with decreased mental and psychomotor development indices. Other potential health effects of REE exposure include disruptions in thyroid function, nephrogenic systemic fibrosis, severe damage to nephrological systems, dysfunctional neurological disorders, fibrotic tissue injury, oxidative stress, pneumoconiosis, cytotoxicity, anti-testicular effects, and male sterility. Overall, the studies suggest that exposure to REEs can have significant negative impacts on human health, particularly in terms of reproductive and developmental outcomes."
      ]
    },
    {
      "answerReady": true,
      "body": "Discoidin domain receptor (DDR)-1 has a crucial role in regulating vital processes, it is known to be associated with fibrosis?",
      "documents": [
        "29455614",
        "35665520",
        "30119248",
        "26956955",
        "39883387",
        "28536691",
        "36698236"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1384,
          "offsetInEndSection": 1707,
          "text": "Inhibition of either TGF-β receptor-I or phospho-p38 reversed the fibrocalcific DDR-1(-/-) phenotype, corroborating a causal relationship between DDR-1 and TGF-β in EV-mediated vascular calcification.CONCLUSIONS: DDR-1 interacts with the TGF-β pathway to restrict calcifying EV-mediated mineralization and fibrosis by SMCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "26800565"
        },
        {
          "offsetInBeginSection": 588,
          "offsetInEndSection": 754,
          "text": "The results recapitulated in this commentary emphasize the involvement of DDR1 in the pro-inflammatory and pro-fibrotic processes which drives the development of CKD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "29455614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "WHAT IS KNOWN AND OBJECTIVE: Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase involved in the pathological processes of several diseases, such as keloid formation, renal fibrosis, atherosclerosis, tumours, and inflammatory processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "35665520"
        },
        {
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1774,
          "text": "Moreover, the EP300 inhibitor SGC-CBP30 displayed synergistic effects with DDR1 inhibitors in pathogenic scores, airway goblet cell counts in bronchoalveolar lavage fluid (BALF), IL-4, IFN-γ, FN1COL1 A1 secretion and α-SMA, a marker of myofibroblast.CONCLUSIONS: The EP300 siRNA and inhibitors sensitized DDR1 inhibitors in our pulmonary fibrosis models in vitro and in vivo, implicating a combined inhibition of DDR1 with EP300 as potential therapies for IPF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30119248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "OBJECTIVES: Pulmonary fibrosis is strongly correlated with inflammation factors, cytokine, and collagen secretion, whereby discoidin domain receptor 1 (DDR1) signaling plays an important role.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30119248"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 717,
          "text": "The results suggested the discoidin domain receptor 1 (DDR1) and downstream c-Jun N-terminal kinases (JNK) pathway may play important roles in the progression of IPF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "26956955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Discoidin domain receptors (DDR) are categorized under tyrosine kinase receptors (RTKs) and play a crucial role in various etiological conditions such as cancer, fibrosis, atherosclerosis, osteoarthritis, and inflammatory diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39883387"
        },
        {
          "offsetInBeginSection": 853,
          "offsetInEndSection": 1037,
          "text": "Further studies demonstrated that both periostin and DDR1 are involved in the regulation of inflammation and fibrosis, two major processes implicated in the development of renal diseas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28536691"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 363,
          "text": "Dysregulated DDR function is associated with progression of various human diseases, including fibrosis, arthritis, and cance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "24725424"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 510,
          "text": "Discoidin domain receptor (DDR)-1 has a crucial role in regulating vital processes, including cell differentiation, proliferation, adhesion, migration, invasion, and matrix remodeling. Overexpression or activation of DDR1 in various pathological scenarios makes it a potential therapeutic target for the treatment of cancer, fibrosis, atherosclerosis, and neuropsychiatric, psychiatric, and neurodegenerative disorders. In this review, we summarize current therapeutic approaches targeting DDR1 from a medicina",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38580164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Discoidin domain receptor1 (DDR1) is a collagen activated receptor tyrosine kinase and an attractive anti-fibrotic target. Its expression is mainly limited to epithelial cells located in several organs including skin, kidney, liver and lung. DDR1\u0027s biology is elusive, with unknown downstream activation pathways; however, it may act as a mediator of the stromal-epithelial interaction, potentially controlling the activation state of the resident quiescent fibroblasts. Increased expression of DDR1 has bee",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30954571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 503,
          "text": "Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase with important functions in organogenesis and tissue homeostasis. Aberrant DDR1 activity contributes to the progression of human diseases, including fibrosis and cancer. How DDR1 activity is regulated is poorly understood. We investigated the function of the long intracellular juxtamembrane (JM) region of human DDR1 and found that the kinase-proximal segment, JM4, is an important regulator of kinase activity. Crysta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "32839343"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "BACKGROUND: The discoidin domain receptor 1 (DDR1) is activated by collagens, upregulated in injured and fibrotic kidneys, and contributes to fibrosis by regulating extracellular matrix production, but how DDR1 controls fibrosis is poorly understood. DDR1 is a receptor tyrosine kinase (RTK). RTKs can translocate t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31383731"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "Discoidin domain receptors (DDRs) are a family of 2 non-integrin collagen receptors, DDR1 and DDR2, which display a tyrosine kinase activity. They are mainly expressed during embryonic development and their role during adulthood is very limited. DDR1 has been widely studied in several types of cancers, in atherosclerosis and fibrosis, but also in chronic kidney disease (CKD). This review focuses on the role of DDR1 in chronic nephropathies and on the effect of its deletion in the pathological processe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "28743124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 486,
          "text": "Discoidin domain receptor (DDR) 1, a collagen binding receptor kinase, is an intensively researched therapeutic target for cancer, fibrosis and other diseases. The majority of early known DDR1 inhibitors targeted the ATP binding pocket of this enzyme that shares structural similarities with other kinase pockets across the biological system. This structural similarity of DDR1 kinase with other protein kinases often leads to \"off target \"toxicity issues. Understanding of uniqueness i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36698236"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 510,
          "text": "Discoidin domain receptors (DDR) play crucial roles in cell proliferation and differentiation. When DDRs are overexpressed, it has been associated with various diseases such as cancers, fibrotic disorders, and inflammation. This study aimed to expand on previous research by using a structure-based drug design approach to develop a series of new indole-urea derivatives as potent inhibitors of DDR1. Through biochemical analyses, it was found that these compounds effectively inhibited DDR1/2, with compound 7",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38171149"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-02-05T13:41:22.779Z",
        "round": 10
      },
      "id": "6772c2d4592fa48873000005",
      "ideal_answer": [
        "Yes, Discoidin domain receptor 1 (DDR1) is indeed associated with fibrosis. It is involved in the pathogenesis of fibrotic disorders by regulating extracellular matrix production, and its overexpression or dysregulation is linked to increased fibrosis in various tissues.",
        "Yes, DDR1 is associated with fibrosis. It is involved in the pathogenesis of fibrotic disorders and interacts with pathways that regulate fibrosis, such as the TGF-β pathway.",
        "Yes, discoidin domain receptor 1 (DDR1) is associated with fibrosis. It contributes to fibrosis by linking to collagen compaction in lesions, interacting with pathways such as TGF-β, and influencing fibroblast activity and extracellular matrix production.",
        "Yes, Discoidin domain receptor (DDR)-1 is associated with fibrosis. It interacts with pathways such as TGF-β to restrict fibrosis, and its involvement in fibrotic processes is mediated through extracellular matrix regulation. Inhibition of DDR1 has been shown to reduce fibrosis in various pathological conditions.",
        "Yes, DDR1 is associated with fibrosis and plays a crucial role by mediating processes like inflammation, collagen secretion, and matrix remodeling. This involvement makes it a potential therapeutic target for fibrotic conditions.",
        "Discoidin domain receptor 1 (DDR1) is indeed associated with fibrosis, contributing to the regulation of extracellular matrix production and playing a role in the pathogenesis of fibrotic disorders in various tissues, including the kidneys, liver, and others.",
        "Yes, Discoidin domain receptor 1 (DDR1) is indeed associated with fibrosis, contributing to the pathogenesis of fibrotic disorders by regulating extracellular matrix production and playing a role in various stages of fibrosis in different tissues and organs."
      ],
      "exact_answer": "yes"
    },
    {
      "answerReady": true,
      "body": "Is Asundexian superior to Apixaban for Atrial Fibrillation?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1743,
          "offsetInEndSection": 2011,
          "text": "ilar in the two groups.CONCLUSIONS: Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period bef",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "39225267"
        }
      ],
      "type": "yesno",
      "answerReady_on": {
        "date": "2025-01-22T10:48:02.119Z",
        "round": 9
      },
      "id": "677e83f0592fa4887300001f",
      "ideal_answer": [],
      "exact_answer": "no"
    },
    {
      "answerReady": true,
      "body": "When should children diagnosed with attention deficit hyperactivity disorder (ADHD) be offered pharmacological treatment?",
      "documents": [],
      "snippets": [],
      "type": "summary",
      "answerReady_on": {
        "date": "2025-02-20T13:39:59.613Z",
        "round": 11
      },
      "id": "6777b80b592fa4887300000e",
      "ideal_answer": [
        "Children diagnosed with ADHD should be offered pharmacological treatment when behavioral therapy alone does not lead to improvement, especially if the symptoms are severe and cause significant impairment. In children aged 6 to 12, medications such as atomoxetine can provide continuous symptom relief. European guidelines suggest considering pharmacological treatment in cases of severe symptoms or co-occurring disorders like Oppositional Defiant Disorder, Conduct Disorder, or Learning Disorders."
      ]
    },
    {
      "answerReady": true,
      "body": "Which new treatments are investigated for cerebral palsy?",
      "documents": [
        "17846067"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 489,
          "text": "OBJECTIVE: To explore patients\u0027 experiences of a self-administered electrotherapy treatment for muscle spasticity in cerebral palsy and stroke; the Exopulse Mollii Suit®.DESIGN: Qualitative design with an inductive approach Subjects: Fifteen patients with spasticity due to stroke or cerebral palsy, participating in a previous randomized controlled trial evaluating the treatment concept.METHODS: Information letters were sent to all potential participants (n \u003d 27) in the previous study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34935050"
        },
        {
          "offsetInBeginSection": 719,
          "offsetInEndSection": 1134,
          "text": "For the transplantation group, a total of 30 cerebral palsy patients received an autologous NSC-like cells transplantation (1-2 × 107 cells into the subarachnoid cavity) and rehabilitation treatments whereas 30 patients in the control group only received rehabilitation treatment.RESULTS: We recorded the gross motor function measurement scores, language quotients, and adverse events up to 6 months post-treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "23351389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 601,
          "text": "BACKGROUND: Spasticity is common in cerebral palsy and can result in pain and diminished health-related quality of life.OBJECTIVE: To evaluate the safety and efficacy of onabotulinumtoxinA for lower limb spasticity treatment in children with cerebral palsy.METHODS: In this registrational phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT01603628), children (2-\u003c 17 years) with cerebral palsy and ankle spasticity (Modified Ashworth Scale-Bohannon [MAS] score≥2) were randomized 1 : 1 : 1 to standardized physical therapy and onabotulinumtoxinA (4 or 8 U/kg), or placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "34957954"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "BACKGROUND: Constraint-induced movement therapy (CIMT) is emerging as a treatment approach for children with hemiplegic cerebral palsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "17846067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Various therapeutic interventions have been used in the management of children with cerebral palsy. Traditional physiotherapy and occupational therapy are widely used interventions and have been shown to be of benefit in the treatment of cerebral palsy. Evidence in support of the effectiveness of the neurodevelopmental treatment is equivocal at best. There is evidence to support the use and effectiveness of neuromuscular electrical stimulation in children with cerebral palsy. The effectiveness of many othe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "16391455"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 503,
          "text": "Cerebral palsy is a nonprogressive heterogeneous group of neurological disorders with a growing rate of prevalence. Recently, cellular therapy is emerging as a potential novel treatment strategy for cerebral palsy. The various mechanisms by which cellular therapy works include neuroprotection, immunomodulation, neurorestoration, and neurogenesis. We conducted an open label, nonrandomized study on 40 cases of cerebral palsy with an aim of evaluating the benefit of cellular therapy in combination wit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "25788947"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-03-04T13:15:26.949Z",
        "round": 8
      },
      "id": "6593e5c206a2ea257c000020",
      "ideal_answer": [
        "New treatments investigated for cerebral palsy include stem cell therapy, which shows promise in treating motor disabilities. Bone marrow derived mononuclear cells (MNCs) have been shown to be safe and effective for motor deficits. Botulinum toxin type A (BTX-A) is being used for spasticity management in children, while Intrathecal Baclofen Therapy (ITB) is also being developed. Additionally, there is encouraging evidence that Selective Serotonin Reuptake Inhibitors (SSRIs) might improve motor function in patients with cerebral palsy.",
        "Recent advances in the treatment of cerebral palsy have led to the investigation of newer modalities such as constraint-induced movement therapy and robotic interventions, which show promise for achieving both short- and long-term functional gains. These innovative approaches aim to capitalize on neuroplasticity, offering potential benefits for individuals affected by cerebral palsy. As research continues to evolve, it is crucial for physicians, healthcare teams, and families managing cerebral palsy to stay informed about these emerging therapies, which hold great potential for improving outcomes in this population.",
        "Recent investigations into new treatments for cerebral palsy include botulinum toxin type A for reducing muscle spasticity, robotic-assisted gait training devices to help improve mobility, and Rosiglitazone for activating specific biological pathways beneficial in CP. AiWalker-K devices are being utilized for rehabilitation, while allogeneic cord blood and erythropoietin therapies are being studied for their potential benefits in treating CP. Intrathecal baclofen and cellular therapies are also explored for their capacities to ameliorate symptoms and enhance life quality. Furthermore, social assistive robots are being tested as a novel intervention to engage and motivate children in therapy."
      ],
      "exact_answer": [
        [
          "Stem cell therapy Mesenchymal stem cells (MSCs) Allogeneic mesenchymal stem cells NSC-like cells Bone marrow derived mononuclear cells (MNCs) Botulinum toxin type A (BTX-A) Intrathecal Baclofen Therapy (ITB) Selective Serotonin Reuptake Inhibitors (SSRIs) Intrathecal baclofen infusion Advancements in genetic research for precision medicine. Mesenchymal stem cell therapy (MSCT) using umbilical cord-derived MSCs. Surgical interventions such as tendon transfers and muscle lengthening.",
          "intravenous infusions of allogeneic AB0/Rh-identical UCB cells",
          "UPper Limb Children Action Observation Training (UPCAT)"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "Which metabolic pathways are related with neonatal sepsis?",
      "documents": [],
      "snippets": [],
      "type": "list",
      "id": "677ed79d592fa4887300002a",
      "ideal_answer": [],
      "exact_answer": []
    },
    {
      "answerReady": true,
      "body": "Causes of borderline personality disorder.",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 526,
          "offsetInEndSection": 718,
          "text": "Some cases of BPD are linked genetically to and are in the \"border\" of bipolar disorder. But the condition can also arise from adverse post-natal factors: parental cruelty or neglect, or inces",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "30840560"
        },
        {
          "offsetInBeginSection": 917,
          "offsetInEndSection": 1287,
          "text": "One probable pathway is identified that leads to borderline personality disorder; it begins with early vulnerability, expressed initially as impulsivity and followed by heightened emotional sensitivity. These vulnerabilities are potentiated across development by environmental risk factors that give rise to more extreme emotional, behavioral, and cognitive dysregulatio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "19379027"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2025-02-06T11:01:08.985Z",
        "round": 10
      },
      "id": "6777bebf592fa48873000015",
      "ideal_answer": [
        "Borderline personality disorder (BPD) is attributed to a combination of genetic predisposition and early traumatic experiences including emotional, physical, and sexual abuse. An invalidating environment during development plays a significant role in the disorder. Additionally, brain dysfunctions, particularly in the orbitofrontal cortex, and cognitive inhibition impairments contribute to impulsivity and other symptoms associated with BPD.",
        "Borderline Personality Disorder (BPD) can be caused by an interplay of genetic and environmental factors. Key causes include childhood trauma, such as emotional, physical, and sexual abuse, and emotional neglect. Other contributing factors include adverse family environments, negative parental behaviors like cruelty or incest, and an emotionally vulnerable temperament exacerbated by an invalidating environment. Genetic predispositions, especially those linking BPD to bipolar disorder, may also be involved.",
        "The exact causes of borderline personality disorder (BPD) are still not fully understood, but research suggests that it is a complex interplay of genetic, environmental, and neurobiological factors. Childhood trauma, particularly emotional abuse and neglect, is a significant risk factor for developing BPD. Individuals with BPD often have difficulty regulating their emotions, which can lead to intense mood swings and impulsive behaviors. Additionally, studies have shown that BPD is associated with abnormalities in brain regions involved in emotional regulation, such as the amygdala and prefrontal cortex. Furthermore, research has identified a link between BPD and difficulties in mentalization, which refers to the ability to understand and interpret the thoughts, feelings, and behaviors of oneself and others. Other potential risk factors for BPD include genetic predisposition, family dynamics, and social learning. However, it is essential to note that BPD is a heterogeneous disorder, and each individual\u0027s experience may be unique."
      ],
      "exact_answer": [
        [
          "childhood trauma",
          "genetic factors",
          "emotionally vulnerable temperament",
          "risk genes for bipolar disorder",
          "maladaptive parenting",
          "neurobiological abnormalities",
          "Environmental influences"
        ]
      ]
    },
    {
      "answerReady": true,
      "body": "What are the uses for faecal microbiota transplantation (FMT) in children under 19 years of age?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 1133,
          "offsetInEndSection": 1429,
          "text": "FMT also reduced Childhood Autism Rating Scale (CARS) scores (WMD \u003d -6.95; 95% CI, -8.76 to -5.14; P \u003c 0.001; I 2 \u003d 28.1%).Conclusion: Our results indicate that FMT can benefit children with autism by reducing ABC and CARS scores, but more high-quality studies are needed to verify these results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36818228"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 366,
          "text": "FMT is a safe and effective treatment for recurrent CDI in immunocompetent children and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "31617299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children and adults. Although complications of FMT have been reported, it is generally believed to be a safe procedure. Novel indications for FMT are being studied, with the hope that ultimately it may be useful for ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "36580630"
        }
      ],
      "type": "list",
      "answerReady_on": {
        "date": "2024-03-04T10:12:26.467Z",
        "round": 8
      },
      "id": "6593d1b806a2ea257c000017",
      "ideal_answer": [
        "Faecal microbiota transplantation (FMT) is primarily used in children under 19 years of age to treat recurrent Clostridioides difficile infection, where it is considered safe and effective. Additionally, it is being explored as a potential alternative treatment for adolescents with refractory irritable bowel syndrome (IBS). Further studies are needed to evaluate its efficacy in other conditions.",
        "Faecal microbiota transplantation (FMT) is used in children under 19 years of age primarily for treating recurrent Clostridium difficile infection (RCDI) and has potential benefits for treating inflammatory bowel diseases such as IBD and ulcerative colitis. It is considered effective in restoring gut eubiosis and can provide a short-term response in managing these conditions.",
        "Faecal microbiota transplantation (FMT) is primarily used in children under 19 years of age to treat recurrent Clostridium difficile infection (RCDI) and has been explored for its potential in managing pediatric inflammatory bowel diseases like ulcerative colitis. While its role is still being researched, FMT shows promise in these areas due to its ability to restore healthy gut microbiota.",
        "Faecal microbiota transplantation (FMT) is utilized in children under 19 years of age primarily for the treatment of recurrent Clostridium difficile infection. It is also applied to manage symptoms associated with Autism Spectrum Disorder (ASD), functional gastrointestinal disorders (FGIDs), ulcerative colitis, and cytomegalovirus (CMV) colitis. FMT is appreciated for its ability to modulate the gut microbiome towards a healthier state, thereby alleviating gastrointestinal and behavioral symptoms linked to these conditions.",
        "Studies suggest that faecal microbiota transplantation (FMT) is an effective and safe treatment option for various gastrointestinal disorders in children under 19 years of age. FMT has been shown to be beneficial in treating recurrent Clostridium difficile infection (rCDI), inflammatory bowel disease (IBD), functional gastrointestinal disorders (FGIDs), and even childhood autism. The procedure, which involves infusing donor fecal matter into the patient\u0027s digestive system via a nasogastric tube or endoscope, has been found to modulate the gut microbiome and metabolome towards a healthy state in children with these conditions. Additionally, FMT has been used successfully in pediatric patients with ulcerative colitis (UC) and can be considered as a feasible option for treatment of refractory CDI in pediatric oncology patients.",
        "Faecal microbiota transplantation (FMT) has been found to be a safe and effective treatment for various conditions in children under 19 years of age. Studies have shown that FMT is efficacious in treating recurrent Clostridium difficile infection, ulcerative colitis, and refractory diarrhea in pediatric patients. Additionally, FMT has been used to treat pseudomembranous enteritis, and has been found to modulate the fecal microbiome and metabolome towards a healthy state in children with functional gastrointestinal disorders (FGIDs). Furthermore, FMT has been shown to reduce symptoms of autism, including Childhood Autism Rating Scale (CARS) scores and Aberrant Behavior Checklist (ABC) scores. Overall, FMT appears to be a well-tolerated and effective treatment option for a range of conditions in children, with high rates of symptom resolution and no serious adverse effects reported."
      ],
      "exact_answer": [
        [
          "Recurrent Clostridioides difficile infection Refractory Irritable Bowel Syndrome (IBS) recurrent Clostridioides difficile infection refractory IBS refractory irritable bowel syndrome decolonisation of multi-drug resistant organisms Treatment of recurrent Clostridioides difficile infections (CDI). Restoration of gut microbiota after conventional therapies fail.",
          "refractory IBS in adolescents",
          "Inflammatory Bowel Disease (IBD)"
        ]
      ]
    },
    {
      "answerReady": false,
      "body": "How can we define severity in paediatric sepsis?",
      "documents": [],
      "snippets": [
        {
          "offsetInBeginSection": 2147,
          "offsetInEndSection": 2317,
          "text": "A ten-gene disease severity signature achieved an AUC of 82·2% (95% CI 76·3-88·1) in predicting organ dysfunction within 24 h of sampling in the RAPIDS validation cohort.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "38513681"
        }
      ],
      "type": "summary",
      "id": "65844e3506a2ea257c000003",
      "ideal_answer": []
    }
  ]
}